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  Summary 
 
I  
Summary 
The present study investigates the diversity and function of the T cell repertoire specific for the 
immediate-early 1 (IE-1) antigen of HCMV and analyzes the viral countermeasures to recogni-
tion of this antigen, with an aim to improve antiviral immunotherapy. Among HCMV antigens, 
IE-1 is a dominant target of CD8+ T cells. Superior protective function of IE-1-specific CD8+ T 
cells is expected because T cells recognizing immediate-early infection can destroy infected 
cells before these produce new virus. CD8+ and CD4+ T cells specific for IE-1 could be ex-
panded in vitro from all healthy HCMV carriers by stimulation of peripheral blood cells with 
autologous IE-1-expressing activated B cell lines (mini-LCLs). Specific T cell clones were 
established from expanded T cells by limiting dilution and used to define epitope specificities 
and the impact of viral immunoevasion on T cells with different specificities.  
CD4+ T cells against IE-1 were a quantitatively small but customary component of the HCMV-
specific T cell repertoire. In each donor, 3–7 IE-1 epitopes were identified (27 in total) and pre-
sented by HLA-DR, DQ or DP allotypes, and some epitopes were shared between donors. 
CD4+ epitopes were distributed over the entire IE-1 sequence. All IE-1-specific CD4+ T cell 
clones produced Th1 cytokines (IL-2, IFN-γ, TNF-α), some of them also Th2 cytokines (IL-4), 
and only few were cytotoxic. CD4+ T cell clones had distinct reactivity against HCMV-infected 
dendritic cells (DCs), which was especially strong for HLA-DP-restricted clones, indicating that 
IE-1 presentation by different class II allotypes may be differentially regulated.  
The CD8+ T cell response to IE-1 was found to be extremely large and focused on 1 or 2 
epitopes per donor, often shared between donors. Unexpectedly, newly identified CD8+ T cells 
restricted through a very frequent HLA-C allotype, C*0702, dominated the T cell response to IE-
1 in carriers of this allele, and recognized HCMV-infected cells much more efficiently than HLA-
A and B-restricted T cells. Detailed analyses using HCMV strains deleted for all four or three of 
the HLA class I-specific immunoevasins US2/3/6/11 revealed allotype-specific patterns of 
interference with T cell recognition by each of US2, US3 and US11. A concerted action of se-
veral immunoevasins already at the immediate-early phase of infection was necessary to block 
antigen presentation by most HLA-A and B allotypes. HLA-C*0702 was selectively excluded 
from viral immunoevasion, and CD8+ T cell recognition through HLA-C*0702 but not HLA-A or -
B allotypes was specifically preserved. Conversely, killing of infected cells by NK cells carrying 
an HLA-C-specific inhibitory receptor was specifically inhibited. Thus, HCMV immunoevasion 
strikes a balance between excessive recognition by CD8+ T cells and by NK cells. As a conse-
quence, HLA-C-restricted antigen presentation is selectively preserved and HLA-C-restricted T 
cells may be superior effectors of HCMV-specific vaccines and cellular immunotherapies. 
  
 
Zusammenfassung 
 
III 
Zusammenfassung 
Diese Arbeit untersucht die Diversität und Funktion des spezifischen T-Zellrepertoires gegen 
das Antigen immediate-early 1 (IE-1) von HCMV und die viralen Maßnahmen gegen seine 
Erkennung. Ziel ist die Verbesserung der antiviralen Immuntherapie. IE-1 ist ein dominantes 
Zielantigen HCMV-spezifischer CD8+-T-Zellen. Eine protektive Wirkung gerade IE-1-spezifi-
scher T-Zellen wird erwartet, da T-Zellen gegen Antigene der IE-Phase infizierte Zellen zerstö-
ren können, bevor neues Virus gebildet wird. Spezifische CD8+- und CD4+-T-Zellen gegen IE-
1 konnten in vitro aus Blut jedes gesunden HCMV-Trägers durch Stimulation mit autologen IE-
1-exprimierenden B-Zelllinien (mini-LCLs) expandiert werden. Spezifische T-Zellklone wurden 
hergestellt, um die Zielepitope der T-Zellen zu ermitteln und die virale Immunevasion gegen-
über T-Zellen verschiedener Spezifitäten zu untersuchen.  
CD4+ T-Zellen gegen IE-1 waren in HCMV-Trägern zwar in geringer Zahl, jedoch regelmäßig 
vorhanden. Je Spender wurden 3–7 IE-1-Epitope identifiziert (27 insgesamt), die durch HLA-
DR, DQ oder DP präsentiert wurden, manche dieser Epitope in mehreren Spendern. Die CD4+- 
T-Zellepitope waren über den Großteil der IE-1-Sequenz verteilt. IE-1-spezifische T-Zellklone 
sezernierten Th1-Zytokine (IL-2, IFN-γ, TNF-α), manche auch Th2-Zytokine (IL-4), nur wenige 
waren zytotoxisch. Alle CD4+-T-Zellklone waren ausgeprägt reaktiv gegen HCMV-infizierte 
dendritische Zellen (DCs), am stärksten HLA-DP-restringierte Klone, ein Hinweis auf eine 
differentielle Antigenpräsentation durch verschiedene Klasse-II-Allotypen.  
Die CD8+-T-Zellantwort gegen IE-1 erwies sich als sehr stark. Sie richtete sich gegen 1 bis 2 
Epitope pro Spender, bei verschiedenen Spendern oft dieselben. Unerwartet dominierten bisher 
unbekannte HLA-C-restringierte CD8+-T-Zellen die Immunantwort gegen IE-1, restringiert durch 
den häufigen Allotyp HLA-C*0702. Solche T-Zellen erkannten die HCMV-Infektion weit effizien-
ter als HLA-A- und HLA-B-restringierte T-Zellen. Untersuchungen mit HCMV-Rekombinanten, in 
denen alle vier oder drei der vier HLA-Klasse-I-spezifischen Immunevasine US2/3/6/11 deletiert 
waren, ergaben distinkte Allotyp-spezifische Muster der Inhibition der T-Zellerkennung durch 
US2, US3 und US11. Bei den meisten HLA-A- und HLA-B-Allotypen war die Kooperation meh-
rerer Moleküle der US2/3/6/11-Gruppe in der IE-Phase der Infektion notwendig, um die 
Antigenpräsentation zu unterbinden. HLA-C*0702 war von der viralen Immunevasion 
ausgenommen, und die Erkennung durch HLA-C*0702-restringierte T-Zellen, nicht aber HLA-
A/B-restringierte T-Zellen, war selektiv bewahrt. Umgekehrt war die Zytolyse von infizierten 
Zellen durch NK-Zellen, die einen inhibitorischen Rezeptor für HLA-C trugen, spezifisch 
inhibiert. Die Immunevasion durch HCMV scheint so ausbalanciert zu sein, dass eine exzessive 
Erkennung einerseits durch CD8+ T-Zellen, andererseits durch NK-Zellen vermieden wird. 
Infolgedessen wird die HLA-C-restringierte Antigenpräsentation selektiv bewahrt. Daher könn-
ten HLA-C-restringierte T-Zellen besonders geeignete Effektoren einer HCMV-spezifischen 
Impfung oder zellulären Immuntherapie sein. 
  
Table of contents 
 
V 
Table of contents 
Summary ...................................................................................................................................................... I 
Zusammenfassung .................................................................................................................................... III 
Table of contents ....................................................................................................................................... V 
1 Introduction .......................................................................................................................................... 1 
1.1 Cellular immune response mechanisms .................................................................................... 1 
1.1.1 Antigen presentation in the human system ............................................................................. 2 
1.1.2 T lymphocytes ......................................................................................................................... 7 
1.1.3 Natural killer cells .................................................................................................................... 9 
1.2 Human cytomegalovirus ............................................................................................................ 12 
1.2.1 HCMV infection and diseases ............................................................................................... 12 
1.2.2 Biology of HCMV ................................................................................................................... 14 
1.2.3 Effectors of the antiviral immune response ........................................................................... 16 
1.2.4 Viral immune evasion strategies ........................................................................................... 18 
1.2.5 Immunotherapy ..................................................................................................................... 21 
1.3 Aims of the study ....................................................................................................................... 24 
2 Materials ............................................................................................................................................. 25 
2.1 Bacteria ....................................................................................................................................... 25 
2.2 Eukaryotic cells .......................................................................................................................... 25 
2.2.1 Primary cells .......................................................................................................................... 25 
2.2.2 Cell lines ................................................................................................................................ 27 
2.3 Viruses ......................................................................................................................................... 28 
2.4 Plasmids ...................................................................................................................................... 29 
2.5 Oligonucleotides ........................................................................................................................ 30 
2.6 Peptides ....................................................................................................................................... 30 
2.7 Antibodies ................................................................................................................................... 33 
2.8 Peptide/HLA multimers .............................................................................................................. 33 
2.9 Cell culture media and additives ............................................................................................... 33 
2.10 Commercial kits ........................................................................................................................ 35 
2.11 Enzymes .................................................................................................................................... 35 
2.12 Chemicals, reagents and buffers ............................................................................................ 35 
2.13 Consumables ............................................................................................................................ 36 
2.14 Laboratory equipment and devices ........................................................................................ 36 
2.15 Databases and software .......................................................................................................... 37 
2.16 Services ..................................................................................................................................... 38 
3 Methods .............................................................................................................................................. 39 
3.1 Microbiological methods ........................................................................................................... 39 
3.1.1 Cultivation and storage of bacteria ........................................................................................ 39 
3.1.2 Transformation of bacteria .................................................................................................... 39 
3.2 Molecular biology methods ....................................................................................................... 39 
3.2.1 General DNA techniques ...................................................................................................... 39 
3.2.1.1 Plasmid DNA purification from E.coli ............................................................................. 39 
3.2.1.2 Restriction enzyme digest, dephosphorylation, ligation ................................................. 40 
3.2.1.3 Agarose gel electrophoresis .......................................................................................... 40 
3.2.2 Analysis of B cell lines for the presence of EBV-specific sequences .................................... 41 
3.2.3 Cloning of chimeric MHC class I molecules .......................................................................... 42 
3.3 Cell culture methods .................................................................................................................. 42 
3.3.1 Cell culture conditions ........................................................................................................... 42 
3.3.2 Cryopreservation of cells ....................................................................................................... 43 
3.3.3 Transfection of cells with plasmid DNA ................................................................................. 44 
3.3.4 Isolation of peripheral blood mononuclear cells .................................................................... 44 
3.3.5 Establishment of permanent B cell lines ............................................................................... 45 
3.3.5.1 CD40-stimulated B cell lines .......................................................................................... 45 
3.3.5.2 EBV-transformed mini-lymphoblastoid cell lines ............................................................ 46 
3.3.6 Establishment and maintenance of T cell cultures ................................................................ 46 
3.3.6.1 Generation of HCMV-specific polyclonal T cell lines ..................................................... 46 
Table of contents 
 
VI 
3.3.6.2 Generation of HCMV-specific monoclonal T cell lines ................................................... 47 
3.3.7 Generation of monocyte-derived dendritic cells .................................................................... 47 
3.3.8 Isolation and cultivation of primary NK cells .......................................................................... 48 
3.3.9 Cytotoxicity analysis .............................................................................................................. 48 
3.3.10 Regression assay ................................................................................................................ 49 
3.3.11 MTT assay .......................................................................................................................... 49 
3.4 Immunological methods ............................................................................................................ 50 
3.4.1 Immunomagnetic separation of cell populations ................................................................... 50 
3.4.2 Phenotypic analysis of cells by flow cytometry ...................................................................... 51 
3.4.2.1 Staining of cell surface antigens .................................................................................... 51 
3.4.2.2 Peptide/HLA class I multimer staining ............................................................................ 52 
3.4.3 HLA class I- and KIR-blocking studies with NK cells ............................................................. 53 
3.4.4 ELISA for quantification of cytokine-release .......................................................................... 53 
3.4.5 ELISpot for quantification of IFN-γ-secreting cells ................................................................ 54 
3.5 Virus-based methods ................................................................................................................. 55 
3.5.1 Epstein-Barr virus .................................................................................................................. 55 
3.5.2 Modified vaccinia virus Ankara .............................................................................................. 55 
3.5.3 Human cytomegalovirus ........................................................................................................ 56 
4 Results ................................................................................................................................................ 57 
4.1 Generation and analysis of IE-1-specific polyclonal T cell lines ........................................... 57 
4.1.1 Generation of mini-lymphoblastoid cell lines ......................................................................... 58 
4.1.2 Generation of polyclonal T cell lines by mLCL-stimulation .................................................... 59 
4.1.3 Characterization of polyclonal T cell lines ............................................................................. 61 
4.2 IE-1-specific CD4+ T cell repertoire .......................................................................................... 64 
4.2.1 Analysis of the CD4+ fraction of the polyclonal T cell lines ................................................... 65 
4.2.2 Generation of T cell clones and screening for IE-1 recognition ............................................. 67 
4.2.3 Definition of IE-1 CD4+ T cell epitopes ................................................................................. 68 
4.2.4 Analysis of effector functions of IE-1-specific CD4+ T cells .................................................. 75 
4.2.5 T cell recognition of HCMV-infected target cells ................................................................... 80 
4.3 IE-1-specific CD8+ T cell repertoire .......................................................................................... 81 
4.3.1 Analysis of the CD8+ fraction of the polyclonal T cell lines ................................................... 82 
4.3.2 Identification of a dominant HLA-C-restricted T cell species ................................................. 87 
4.3.3 Frequency of HLA-C*0702-specific T cells in PBMCs of HCMV carriers .............................. 90 
4.4 T cell recognition of IE-1 in context of an HCMV infection ..................................................... 93 
4.4.1 Time course of IE-1 recognition on HCMV-infected fibroblasts by specific CD8+  
 T cell clones .......................................................................................................................... 93 
4.4.2 Influence of pp65 on T cell recognition of IE-1 ...................................................................... 95 
4.4.3 Influence of HCMV immunoevasins on T cell recognition of IE-1 ......................................... 97 
4.5 Allotype-specific action of HCMV immunoevasins ................................................................. 99 
4.5.1 Glycoproteins US2 and US11 ............................................................................................. 100 
4.5.2 Function of domains of HLA class I molecules in immunoevasion ...................................... 103 
4.5.3 Time course of interference with IE-1 and pp65 epitope presentation ................................ 104 
4.5.4 Immunoevasion of T cell recognition under immediate-early conditions ............................. 110 
4.6 The role of HLA-C*0702 in context of NK cell recognition of HCMV infection ................... 112 
4.6.1 Generation and analysis of HLA-C*0702-specific NK cell lines .......................................... 112 
4.6.2 Analysis of NK cell recognition of HCMV-infected fibroblasts ............................................. 114 
4.6.3 Analysis of the capability of HLA-C*0702 to interfere with NK cell killing ............................ 116 
5 Discussion ........................................................................................................................................ 119 
5.1 The CD4+ T cell repertoire against the IE-1 antigen .............................................................. 121 
5.2 The CD8+ T cell repertoire against the IE-1 antigen .............................................................. 129 
5.3 Differential resistance of CD8+ T cells to HCMV immunoevasion ....................................... 134 
5.4 The relationship between HLA-C, CD8+ T cells and NK cells .............................................. 139 
References .............................................................................................................................................. 143 
Abbreviations ......................................................................................................................................... 161 
Danksagung ............................................................................................................................................ 163 
Introduction 
 
1 
1 Introduction 
The human body provides an ideal living environment for infectious organisms such as para-
sites, fungi, bacteria and viruses. However, the microorganisms encountered daily in the life of a 
healthy individual cause disease only sporadically. This is due to the evolvement of a complex 
network of cells, tissues, and organs, positioned throughout the body - the immune system -, 
which provides a broad variety of host defense mechanisms. To selectively attack "foreign" in-
vaders and not cells of the host organism, the immune system has the ability to distinguish be-
tween "self" and "non-self". Also malignant cells with "altered self" can be recognized and elimi-
nated which plays a major role in tumor surveillance. 
 
If a pathogen penetrates the physical barriers of the body, it is immediately confronted with the 
unspecific defense strategies of the innate immune system, which is constitutively present and 
ready to be mobilized upon infection. In addition, vertebrates have evolved a more specific se-
cond line of defense, the adaptive immune system, which is effective with a delay of 4–7 days 
and is initiated by components of the innate immune response. During initial exposure to a 
pathogen the adaptive immunity develops an immunological memory, which leads to an en-
hanced response to subsequent encounters with the same pathogen and is the basis for 
vaccination. The defense strategies of both the innate and the adaptive immune response com-
prise humoral (secretory molecules) as well as cellular components. (Janeway et al., 2006) 
 
1.1 Cellular immune response mechanisms 
All immune cells originate from hematopoietic stem cells in the bone marrow which give rise to 
myeloid cells (including neutrophils, monocytes, macrophages, dendritic cells (DCs)) and lym-
phoid cells (B cells, T cells, natural killer (NK) cells). During an immune response, these cells 
exhibit complex interrelationships that allow them to fine-tune reactions to almost any pathogen. 
Neutrophils, monocytes, macrophages, DCs and NK cells are important mediators of the innate 
immune response. They possess pattern recognition receptors (PRRs) like Toll-like receptors 
(TLRs), which recognize broad molecular patterns (PAMPs = pathogen associated molecular 
patterns) present in a number of different pathogens but not in host cells. In this way, innate 
immune mechanisms can act efficiently to a variety of different pathogens. Neutrophils and tis-
sue macrophages are the first to arrive in large numbers at a site of infection. Monocytes, which 
differentiate into macrophages, and immature DCs are recruited later. These cells are primarily 
phagocytic cells that engulf microorganisms and digest them intracellularly. They possess a 
variety of cell surface receptors through which they can bind infectious agents. For example, as 
a result of the activation of a catalytic cascade of serum proteins, bacteria are coated with 
complement factors and can be targeted by phagocytes via complement receptors. Recognition 
of pathogens by PRRs also activates phagocytes to secrete a range of cytokines (chemokines, 
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interleukins, TNF-α) that have important local and systemic effects contributing to both innate 
and adaptive immunity. For example, IL-8, MCP-1 and RANTES are chemoattractants that func-
tion in recruiting leukocytes, monocytes, and other effector cells from the bloodstream to sites of 
infection. NK cells are cytotoxic lymphocytes involved in non-specific immune responses to 
intracellular infections with bacteria and viruses, and further function in tumor surveillance. 
Circulating NK cells can be activated in response to cytokines and recognize changes in the 
expression of cell-surface proteins induced by infection or growth transformation. 
 
B and T lymphocytes are the major players of the adaptive immune system. The specificity of 
the adaptive immune response resides in the receptors of T and B cells, the TCR and BCR, 
respectively, which recognize discrete antigens of a particular pathogen. The actual portions or 
fragments of an antigen that react with lymphocyte receptors are termed epitopes. To induce 
specific immune responses, mature DCs and macrophages stimulated during the initial immune 
response act as antigen-presenting cells (APCs) to T and B lymphocytes. After exposure to an 
antigen, B cells differentiate into plasma cells that produce and release specific antibodies (a 
soluble form of their BCRs) into the bloodstream. By binding to the surface of extracellular 
pathogens, antibodies enable phagocytosis of the pathogens via Fc receptors. T cells contribute 
to immune responses in two different ways: helper T cells coordinate the entire immune re-
sponse by secretion of cytokines (including interleukins, growth factors, interferons), while cyto-
toxic T cells directly contact infected cells and destroy them. (Janeway et al., 2006) 
 
1.1.1 Antigen presentation in the human system 
As key players of the adaptive immune response, T lymphocytes continuously examine the 
intracellular and extracellular milieu for signs of infection, which become manifested as anti-
genic peptides presented on the surface of infected cells, phagocytes, or other cells that have 
taken up microbial material. The scaffolds for the presentation of these peptides are highly 
polymorphic glycoproteins, which are encoded in the major histocompatibility complex (MHC). 
In the human system, the MHC proteins are also called human leukocyte antigens (HLAs) as 
they were first discovered through antigenic differences between white blood cells from different 
individuals. There are two classes of MHC molecules, MHC class I and MHC class II, which 
show distinct protein structures (Fig. 1.1), expression patterns on host cells, and peptide loading 
mechanisms, and are targeted by different T cell subsets. 
  
MHC class I molecules consist of two polypeptide chains, an α chain (heavy chain, 44 kDa) and 
a smaller β chain (light chain, 12 kDa), the β2-microglobulin (β2m). The heavy chain comprises 
three extracellular α domains (α1–α3), a transmembrane domain and a cytosolic tail. The two 
polypeptide chains are noncovalently associated by interaction of β2m and α3 domain, which 
both have an immunoglobulin-like structure. The α1 and α2 domains form a groove on the sur-
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face of the MHC molecule, which is the site of peptide binding. The groove is bounded by an 
eight-stranded beta-pleated sheet on the bottom and two alpha helices on the sides and can 
accommodate peptides of approximately 8–10 amino acids in length. Whether a particular pep-
tide can bind to a particular MHC molecule depends on the amino acid residues that line the 
groove and make contact with the peptide. These are the residues that are the most polymor-
phic in the MHC molecule. MHC class II molecules are heterodimers of an α and a β chain, 
which show approximately equal size (30 kDa) and are both anchored in the cell membrane. 
Each polypeptide chain, α and β, consists of two domains, α1/α2 and β1/β2, respectively, a 
transmembrane domain and a cytosolic tail. The peptide-binding groove is formed by the α1 and 
β1 domains and shows similar structure than for MHC class I molecules. However, the peptide 
binding groove is more open in MHC class II molecules compared to MHC class I molecules, so 
that the ends of peptides bound to MHC class II molecules are not buried within the groove. 
Consequently, MHC class II molecules can accommodate longer peptides of approximately 13–
25 amino acids. (Germain, 1994) 
 
Fig. 1.1: Structure of MHC class I and 
II molecules. MHC class I molecules 
consist of an α chain subdivided into α1–
α3 domains, transmembrane region and 
cytosolic tail, and a non-covalently 
associated β2-microglobulin. The pep-
tide binding groove is formed by the α1 
and α2 domains and can accommodate 
peptides of approximately 8–10 amino 
acids. MHC class II molecules are 
heterodimers of an α and a β chain. 
Each chain consists of two extracellular 
domains, α1/α2 and β1/β2, a transmem-
brane and a cytosolic region. The pep-
tide-binding groove is formed by the α1 
and β1 domains and can bind peptides 
of 13–25 amino acids. The transmem-
brane and cytosolic regions have not 
been part of the structural analysis and 
are not shown. Modified according to 
(Liu and Gao, 2011). 
 
The genes encoding the MHC class I α chain and the MHC class II α and β chains are located 
in the MHC. In humans this gene cluster is also termed HLA complex and is located on the 
short arm of chromosome 6 (Fig. 1.2). The gene for β2-microglobulin is located on chromosome 
15. The MHC is polygenic, i.e. it contains several different MHC class I and MHC class II genes, 
and it is highly polymorphic, i.e. there exist multiple allelic variants of each gene within the 
population. Alleles of an MHC gene are codominantly expressed, and both gene products are 
able to present antigens to T cells. The HLA protein encoded by an allele is termed the 
allomorph. The particular combination of HLA alleles found on a single chromosome is termed 
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the HLA haplotype. The combination of HLA class I and II allotypes expressed by a person is 
termed the HLA type.  
 
The HLA complex spans approximately 4 Mb and comprises class I, II and III regions. The class 
III region encodes a variety of different proteins including complement factors (e.g. C2, C4), the 
heat shock protein HSP70, and TNF-α and -β. In the class I region are six genes which encode 
HLA class I heavy chains and give rise to six class I isoforms, the highly polymorphic HLA-A, -B 
and -C molecules (classical MHC class I molecules), and the less polymorphic HLA-E, -F and -
G molecules (non-classical MHC class I molecules). The products of class II genes also form 
three major isoforms of MHC class II molecules termed HLA-DR, -DQ and -DP. However, each 
of DR, DQ and DP is assembled by an α and a β chain, which are encoded by separate genes 
in the HLA class II region designated as A and B, respectively (e.g. HLA-DQA1 and HLA-
DQB1). The part of the HLA class II region that encodes HLA-DR molecules is more complex 
than those encoding the other class II isotypes, because there are several functional β-chain 
genes (DRB1, DRB3, DRB4, DRB5) and their number varies between different haplotypes with 
only DRB1 being always present. The β-chain products of all the expressed DRB genes 
associate with the α chain encoded by HLA-DRA, which is non-polymorphic. In contrast to DRA, 
DQA and DPA are polymorphic. Therefore, the number of different MHC molecules is further 
increased by the combinations of DQ and DP α and β allotypes encoded by different 
chromosomes. The exact number of different MHC class II molecules expressed in one indi-
viduum depends on how many genes and which alleles are present on each chromosome. The 
MHC class II region also encodes proteins with other important immunological functions, for 
example tapasin, the TAP1:TAP2 peptide transporter, and immunoproteasome subunits (LMP2, 
LMP7). (Marsh, 2000) 
 
 
 
 
Fig. 1.2: Organization of the human major histocompatibility complex (HLA complex). HLA class I 
heavy chain genes are located in the class I region of the HLA complex and encode classical HLA class I 
molecules HLA-A, -B and -C, as well as non-classical HLA molecules HLA-E, -F, -G. HLA class II 
molecules involved in antigen presentation are HLA-DR, -DQ and -DP. These molecules are 
heterodimers of an α and a β chain, both which are encoded in the HLA class II region of the HLA 
complex. According to (Trowsdale, 2002). 
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As individuals carry different sets of HLA molecules, these surface glycoproteins themselves 
can become foreign antigens when organs or cells are transplanted. The T lymphocytes of an 
immunocompetent transplant recipient trigger an alloreactive immune response to the "foreign" 
HLA molecules on grafted cells. This situation is termed host versus graft (HVG) reaction, can 
result in transplant rejection and is repressed by immunosuppressive drug administration. 
However, after transplantation into an immunocompromised host, the immunocompetent T 
lymphocytes within the graft recognize the HLA molecules on the recipient's cells as alloanti-
gens and respond with proliferation and host tissue damage. This situation is known as graft 
versus host disease (GVHD) and includes clinical manifestations like diarrhea, erythema, fever, 
pain and ultimately death. Matching of donor's and recipient's HLA type increases the success 
rate of grafts. However, genetic differences at other loci encoding minor histocompatibility anti-
gens may still trigger GVHD or graft failure. 
  
Loading of MHC class I and II molecules with peptides requires the processing of antigens into 
smaller fragments. Cytosolic proteins from a variety of sources including viruses are degraded 
by the proteasome and cytosolic proteases. The resulting peptides are then transported through 
the transporter associated with antigen processing (TAP) complex into the endoplasmic reticu-
lum (ER) where they are further trimmed by ER aminopeptidases (ERAPs) to produce peptides 
of usually 8–10 aa for presentation on MHC class I molecules (Serwold et al., 2002). Very 
hydrophobic peptides and peptides generated in the ER or Golgi compartment can also reach 
the MHC class I pathway in a TAP-independent manner (Lautscham et al., 2003). MHC class I 
heavy chains are translocated during their synthesis into the lumen of the ER and assembled 
with β2m. The loading of MHC class I heterodimers with the short peptides is coordinated by the 
peptide-loading complex, which consists of the TAP components TAP1 and TAP2, the ER-resi-
dent chaperone-like proteins ERp57, calreticulin, tapasin, and protein disulfide isomerase (PDI) 
(Park et al., 2006). This complex also has a function in peptide editing to select for the presenta-
tion of stable peptide-MHC class I complexes (Wright et al., 2004). MHC class I/peptide-com-
plexes leave the endoplasmic reticulum and are transported through the Golgi compartment to 
the cell surface where they present the peptides to CD8+ T cells. MHC class I molecules typi-
cally present peptides derived from proteins synthesized in the same cell. However, exogenous 
proteins internalized by DCs and macrophages can be fed into the MHC class I pathway by 
retrotranslocation into the cytosol or by processing with endosomal proteases and loading onto 
MHC class I in the endocytic compartment itself. This phenomenon is referred to as cross-
presentation (Cresswell et al., 2005). 
 
MHC class II molecules are loaded with antigenic peptides in endosomal or lysosomal vesicles 
termed the MHC class II compartment (MIIC). Exogenous proteins access the MIIC through 
phagocytosis and endocytosis, endogenous cellular or viral proteins by a process involving 
autophagy (Crotzer and Blum, 2010). Antigenic peptides of an appropriate length for binding to 
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MHC class II molecules are generated by lysosomal proteases. The biosynthetic pathway for 
MHC class II-dependent peptide presentation starts with the ER assembly of MHC class II di-
mers in complex with the invariant chain (Ii). Ii blocks the peptide-binding groove of MHC II 
molecules, thus preventing peptide occupation in pre-lysosomal compartments. This complex 
traffics to the acidic MIIC, where Ii is subjected to sequential proteolysis. The final cleavage 
product, class II-associated Ii peptide (CLIP), can be replaced with high-affinity antigenic pep-
tides, an exchange reaction that is catalyzed by the chaperone-like molecule HLA-DM. After 
transport to the cell surface, MHC class II/peptide-complexes are presented to CD4+ T cells. 
(Neefjes et al., 2011) 
  
MHC class I molecules are expressed on almost all nucleated body cells, thus allowing the di-
rect recognition and elimination of virus-infected or malignant cells by cytotoxic T cells. By con-
trast, constitutive expression of MHC class II molecules is restricted to specialized cells includ-
ing thymic epithelial cells and professional APCs (DCs, macrophages, B cells) (Jensen, 2007). 
However, during an immune response MHC class II gene expression can be induced in other 
cells by IFN-γ, which is predominantly made by activated T cells and NK cells. IFN-γ also 
upregulates MHC class I surface levels by increasing expression of MHC class I α chain, β2-
microglobulin, tapasin, and TAP components (Schroder et al., 2004). Furthermore, IFN-γ 
induces the expression of the immunoproteasome, which is normally also restricted to 
professional APCs. In the immunoproteasome, the three catalytically active β subunits of the 
constitutive 26S-proteasome are replaced by the IFN-γ inducible subunits LMP2 (β1i), LMP7 
(β5i) and MECL-1 (β2i) (Groettrup et al., 2001). These exchanges together with the IFN-γ-
induced proteasome-associated activator PA28 alter the cleavage specificity of the proteasome, 
thus extending the range of antigenic peptides for MHC presentation (Schroder et al., 2004).  
  
Several APCs are also used in vitro for antigen processing and presentation on MHC class I 
and II molecules. DCs are considered to be the most potent APCs due to their unique ability to 
prime antigen-inexperienced (naive) T cells and their enhanced capacity to reactivate memory T 
cells. Monocyte-derived DCs are already used in the clinic as vaccines to induce therapeutic 
anti-tumor T cell responses (Chiang et al., 2011). Unfortunately, the application of DCs is limited 
due to their rareness in the peripheral blood and difficulty to expand them ex vivo (von Bergwelt-
Baildon et al., 2002). Another important group of APCs are B cells. However, resting B cells 
have found to be inactive or tolerogenic as APCs to T cells due to a lack of costimulatory 
molecule expression (Matzinger, 1994). Infection of primary B cells with the B-tropic Epstein-
Barr virus transforms the B cells into long-term proliferating lymphoblastoid cell lines (LCLs), 
which display an activated phenotype characterized by high-level expression of MHC class I 
and II molecules, as well as costimulatory molecules (B7.1, B7.2, ICAM-1 and LFA-3) (Kilger et 
al., 1999). Deletion of EBV genes essential for lytic replication gives rise to so-called mini-EBV 
vectors that do not support release of progeny virus from infected cells (Kempkes et al., 1995). 
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Mini-EBVs can accommodate additional genes, which are then expressed in the mini-(m)LCLs 
and presented to CD8+ and CD4+ T cells (Kilger et al., 1999; Moosmann et al., 2002). A 
frequently used EBV-free alternative to activate B cells in vitro is the cocultivation of B cells with 
CD40-ligand (Wiesner et al., 2008). Also this method has shown to efficiently reactivate antigen-
specific T cells in vitro (Schultze et al., 1997). 
 
1.1.2 T lymphocytes 
During T cell development, the precursor T cells migrate from the bone marrow into the thymus 
where they undergo differentiation into several T cell subsets, which have been defined accord-
ing to their expressed surface markers, functional properties and secreted effector molecules. 
Two distinct T cell lineages, α:β and γ:δ T cells, can be further distinguished based on the 
polypeptide chains (α, β  vs. γ, δ) that make up the main constituents of their antigen-specific 
receptors (TCRs). The majority of T cells in the blood and secondary lymphoid organs ex-
presses an α:β TCR that recognizes antigenic peptides in the context of HLA molecules. The 
smaller population of γ:δ T cells predominate in the mucosal epithelium and recognizes a 
heterogenous class of TCR ligands (peptidic and non-peptidic, e.g. phospholipids) usually in an 
HLA-independent manner, for example in context of the non-polymorphic MHC-Ib protein CD1 
(Champagne, 2011). Expression of either an α:β or γ:δ TCR requires the successive rearrange-
ment of the germline gene segments V, (D), J, which encode the two TCR chains. Due to allelic 
exclusion, each T cell bears a TCR of only one specificity at its surface. As a result of random 
V(D)J rearrangements, TCRs of many specificities are generated, including some that do not 
recognize self MHC or are reactive to self antigens. It is the role of the thymus to ensure that T 
cells that go to the periphery are self-MHC-restricted, but are unable to react with self antigens. 
During a process known as positive selection, only T cells survive that are able to bind to self 
MHC molecules expressed by cortical thymic epithelial cells. T cells bearing a TCR that recog-
nizes self MHC molecules associated with self peptides expressed by thymic epithelial cells, 
DCs and macrophages are deleted in a process called negative selection. (Starr et al., 2003) 
 
The peptide binding specificity of the TCR is determined by the variable (V) regions of the two 
receptor chains, which have immunoglobulin-like structure. Accessory molecules also called co-
receptors expressed on T cells stabilize the interaction between TCR and MHC/peptide com-
plex. Mature α:β T cells generally express one of the coreceptors CD8 or CD4. CD8 molecules 
interact with the α3 domain of MHC class I proteins, whereas CD4 molecules target the β2 do-
main of MHC class II proteins. Following antigen interaction, activation signals are transduced 
to the cell by the CD3 complex, which is closely associated with the two TCR chains. The CD3 
complex is composed of one γ, one δ, two ε and 2 ξ chains, which interact with second messen-
gers (e.g. the ζ chain-associated protein kinase ZAP70) that forward the activation signal to the 
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nucleus. The molecules of the CD3 complex are all invariant and do not contribute to the TCR 
binding specificity. (Rudolph et al., 2006) 
 
Activation of naive CD8+ and CD4+ T cells, a process which is termed T cell priming and takes 
place in the lymph nodes, requires the simultaneous delivery of a costimulatory signal in addi-
tion to the interaction of the TCR with the antigenic peptide and self MHC. This second signal 
comes from the engagement of costimulatory cell surface molecules (e.g. CD28 on T cells) with 
their ligands (e.g. CD80), which are only expressed by professional APCs, usually DCs. There-
fore, only these professional APCs are able to initiate the clonal expansion of naive T cells and 
their differentiation into armed effector cells. Once a naive T cell has been primed, subsequent 
recognition of its specific antigen leads to an immune attack without the need for costimulation.  
  
CD8+ and CD4+ T cells make up the majority of effector T lymphocytes. CD8+ T cells are 
primarily cytotoxic and can directly kill infected target cells. Depending on the cytokine milieu, 
antigen concentration, type of APCs and costimulatory molecules, naive CD4+ T cells can 
differentiate into three main effector subsets termed T helper (Th) 1, Th2 and Th17, which are 
characterized by the production of distinct cytokines and effector functions. To combat 
intracellular pathogens, Th1 cells (producing IL-2, IFN-γ, TNF-α and TNF-β) can mobilize the 
cellular arm of the immune system by activating macrophages and stimulating cytotoxic CD8+ T 
cell proliferation. For elimination of extracellular pathogens, Th2 cells (producing IL-4, IL-5, IL-6, 
IL-10, IL-13 and IL-25) promote humoral immune responses by stimulating B cells to secrete 
antibodies of particular isotypes. Th17 cells (IL-17, IL-21, IL-22) are highly pro-inflammatory and 
play a role in protection against certain extracellular pathogens, but also in inflammation and 
autoimmunity (Bettelli et al., 2007). A subpopulation of CD4+ T cells referred to as regulatory T 
cells (Treg, CD25+, Foxp3+) suppresses immune functions to prevent excessive reactions and to 
maintain tolerance to self antigens. Treg are released from the thymus as a distinct lineage 
called natural Treg. However, Treg can also be induced in the peripheral lymphoid organs after 
antigen priming by expression of transcription factors including Foxp3. (Luckheeram et al., 
2012) 
 
After elimination of the invading pathogen, a fraction of effector T lymphocytes persists as 
circulating memory cells in the absence of antigenic stimulation and has the capacity to expand 
rapidly upon secondary antigen challenge. Memory T cells can be distinguished from naive T 
cells according to the surface expression of CD45RA and the lymph node homing receptors 
CCR7 and CD62L (L-selectin) (Willinger et al., 2005). Naive T cells express all of these pro-
teins. Among the memory T cells, three subsets are defined: effector memory T cells (TEM: 
CCR7-, CD62L-, CD45RA-) express chemokine receptors (e.g., CXCR3) for migration to in-
flamed tissues and display immediate effector function; central memory T cells (TCM: CCR7+, 
CD62L+, CD45RA-) express lymph node homing receptors and lack immediate effector func-
Introduction 
 
9 
tion, but efficiently stimulate dendritic cells and differentiate into CCR7- effector cells upon 
secondary stimulation (Sallusto et al., 1999); effector memory T cells reexpressing CD45RA 
(TEMRA: CCR7-, CD62L-, CD45RA+) are considered to be late differentiated cells, with limited 
proliferative but high functional capacity (D'Asaro et al., 2006). Recent data even suggest the 
existence of a stem cell-like memory T cell population (CCR7+, CD62L+, CD45RA+) with en-
hanced self-renewal capacity and the ability to differentiate to central memory, effector memory 
and effector T cells (Gattinoni et al., 2011). Antigen-specific memory T cells can be reactivated 
and expanded in vitro from peripheral blood mononuclear cells (PBMCs) with autologous (from 
the same donor) APCs like monocyte-derived DCs or activated B cells (CD40-stimulated or 
EBV-transformed) that are transduced or loaded with the antigenic peptide (described in 1.1.1). 
 
1.1.3 Natural killer cells 
NK cells are an early component of the innate immune defense and continuously survey the 
host cells for altered expression of surface molecules caused by intracellular pathogens or tu-
mor transformation. Following cell-to-cell contact, they can induce apoptosis in target cells by 
either of two mechanisms: release of cytoplasmic granules containing membrane-disrupting 
perforin and serin proteases granzymes or engagement of target-cell death receptors 
(e.g.Fas/CD95) with their cognate ligands (e.g. FasL) expressed on the NK cell membrane 
(Trapani and Smyth, 2002). NK cells can further shape adaptive immune responses through 
release of immunoregulatory cytokines or direct interaction with DCs (Vivier et al., 2011).  
 
NK cells comprise 5-10% of peripheral blood lymphocytes and are phenotypically characterized 
by lack of CD3 (T cell marker) and presence of CD56 (NCAM). Two subsets with distinct roles 
during the immune response can be distinguished according to their CD56 surface density 
(Cooper et al., 2001). CD56dim cells (low density), the majority of circulating NK cells in the 
blood, are primarily cytolytic and have only little ability to produce cytokines in response to 
activation. By contrast, CD56bright cells (high density) constitute only 10% of total NK cells in the 
blood but are the dominant NK cell population in secondary lymphoid tissues. They have only 
low lytic activity but instead are potent producers of immunoregulatory cytokines (IFN-γ, TNF-α, 
GM-CSF). IFN-γ is considered the prototypic NK cell cytokine, which enhances MHC expres-
sion, promotes Th1 differentiation and has broad antiviral and growth-inhibitory effects (Caligi-
uri, 2008). 
 
To distinguish healthy cells from infected or transformed cells, NK cells are equipped with an 
array of germline-encoded activating and inhibitory surface receptors. The net income of posi-
tive and negative signaling events triggers cytolytic programs, as well as cytokine or chemokine 
secretion (Vivier et al., 2004). NK cell activating receptors selectively detect molecules that are 
only present upon infection or cellular transformation. Important members of the broad panel of 
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structurally distinct activating receptors are the natural cytotoxicity receptors (NCR), CD16 
(FcγRIIIA) and the C-type lectin-like receptor NKG2D. NCRs (e.g. NKp46) play a role in NK cell-
mediated cytotoxicity against tumor cells (Moretta et al., 2001), but can also bind viral compo-
nents like hemagglutinins from influenza virus (Mandelboim et al., 2001). CD16 (FcγRIIIA), the 
low-affinity receptor for immunogloblin G (IgG), is abundantly expressed on CD56dim cells and 
can bind to and destroy IgG-coated cells in a process termed antibody-dependent cellular 
cytotoxicity (ADCC) (Cooper et al., 2001). NKG2D, which is among the best characterized NK 
cell receptors, is expressed on all NK cells as a homodimer. It can induce both a cytotoxic and a 
cytokine-mediated response upon engagement with stress-inducible ligands including the MHC 
class I chain-related (MIC) A and B molecules and the UL16-binding proteins 1, 2, 3 and 4 
(ULBP1–4) (Sutherland et al., 2001).  
  
NK cells use inhibitory receptors to monitor the absence of constitutively expressed self mole-
cules ("missing self") on target cells. Upon engagement with its self ligand, the inhibitory recep-
tor sends a signal to the cell that antagonizes activating signaling pathways, thus preventing 
cytolysis of normal cells and limiting the production of inflammatory cytokines (Vivier et al., 
2004). The panel of inhibitory receptors is divided into two main groups according to their 
specificity for MHC class I molecules or non-MHC ligands. An example for the less diverse 
group of receptors targeting non-MHC molecules is the killer cell lectin-like receptor G1 
(KLRG1), which is expressed on a subset of NK cells and binds to classical cadherins (E, N, R). 
For example, E-cadherin is expressed in healthy tissues but is downregulated in metastasizing 
epithelial tumors (Ito et al., 2006). The more diverse group of HLA class I-specific inhibitory 
receptors comprises three main classes which all display variegated expression patterns in 
peripheral blood NK cells: killer-cell immunoglobulin-like receptors (KIRs), killer-cell lectin-like 
receptors (KLRs, e.g. CD94-NKG2A) and the leukocyte immunoglobulin-like receptor 1 
(LILRB1/ILT-2/CD85j) (Fig. 1.3). LILRB1 appears to play only a minor role compared to KIRs 
and NKG2A and binds with low affinity to a conserved amino acid stretch in the α3 domain of 
MHC class I molecules (Chapman et al., 1999a). The ligand for CD94-NKG2A is the non-classi-
cal MHC class I molecule HLA-E, which presents peptides derived from leader sequences of 
other HLA class I molecules, thus allowing NK cells to indirectly monitor the total MHC class I 
expression on target cells (Borrego et al., 1998). The KIR receptors specifically bind HLA-A, -B 
and -C in a peptide-dependent manner and can thereby discriminate between different peptides 
bound to the same HLA allotype (Hansasuta et al., 2004). KIRs are type I transmembrane 
glycoproteins with two (KIR2) or three (KIR3) Ig-like domains in the extracellular region and pos-
sess either a short (S) or long (L) cytoplasmic tail (Pegram et al., 2011). KIRs with short 
cytoplasmic tails probably arose by gene duplication and mediate activation instead of inhibition. 
However, under normal circumstances, activating KIRs have lower affinity for their respective 
ligands than their inhibitory counterparts, which allows the inhibitory signal to dominate and to 
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minimize the risk of autoimmunity (Lanier, 2005). Conservation of activating KIRs through evolu-
tion may result from selective pressure imposed by pathogens (Arase et al., 2002). 
 
KIRs are encoded by a diverse and polymorphic gene family consisting of 15 genes and 2 
pseudogenes that are closely linked on chromosome 19. Two groups of KIR haplotypes, desig-
nated A and B (Fig. 1.3), with different gene content and allelic polymorphism have been identi-
fied within the population (Uhrberg, 2005). KIR subfamilies recognize polymorphisms of HLA 
class I molecules. A dimorphism at position 80 of the α1 domain divides HLA-C molecules into 
two groups of KIR2DL ligands, with the C1 group (Asn80) being recognized by KIR2DL2 and 3, 
and the C2 group (Lys80) being recognized by KIR2DL1. Similarly, there is a dimorphism in the 
C-terminal region of the α1 domain (aa 77–83) of HLA-B molecules that correlates well with the 
serological classification of HLA-B (and certain HLA-A) molecules into Bw4 and Bw6 groups. 
Only members of the Bw4 group have been identified as KIR ligands, namely for KIR3DL1 
(Parham, 2005). Finally, a few HLA-A allotypes (A03, A11) have been shown to engage 
KIR3DL2 (Lanier, 2005).   
 
  
 
Fig. 1.3 Organization of the human KIR locus and HLA class I-specific receptors. Left: Numerous 
KIR haplotypes with different gene content and allelic variants are found in the human population. The 
shortest (haplotype A) and the longest (from the group of haplotypes B) KIR haplotypes are aligned. 
Grey=conserved genes; green=genes that can be present in haplotype A and B; blue=genes/alleles spe-
cific for haplotype B. The number of confirmed allelic variants is indicated below the name of each gene. 
According to (Parham, 2005) Right: NK cell inhibitory receptors specific for HLA class I molecules. Modi-
fied according to (Lanier, 2005). 
 
The NK cells of an individual express variable numbers and combinations of the genome-en-
coded KIRs, giving rise to many NK cell subsets regulated by different self HLA ligands 
(Valiante et al., 1997). The decision of which KIRs are to be expressed on each NK cell seems 
to be primarily random, but is fixed by the methylation of KIR gene loci (Chan et al., 2003). How-
ever, there is evidence for modulation of the KIR repertoire by the host HLA haplotype 
(Schonberg et al., 2011). Interestingly, NK cells that do not express a self HLA-specific inhibi-
tory KIR nontheless remain non-reactive to self-tissue. There are some mechanisms postulated 
which might ensure this self-tolerance (Orr and Lanier, 2010). The "licensing" hypothesis pro-
poses that NK cells are initially unresponsive and that engagement of their inhibitory receptors 
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with host MHC class I molecules during development licenses or "arms" them to become potent 
effectors against MHC class I-deficient target cells (Kim et al., 2005). In accordance with this 
hypothesis, NK cells that do not express KIRs for self-MHC molecules are not armed and there-
fore not responsive. 
 
1.2 Human cytomegalovirus 
Human cytomegalovirus (HCMV), also called human herpesvirus 5, belongs to the β-subgroup 
of the herpesvirus family (Davison, 2007b). Like other herpesviruses, including herpes simplex 
virus type 1 and 2 (HSV-1, -2), varicella-zoster virus, HHV-6, HHV-7, Epstein-Barr virus (EBV) 
and Kaposi’s sarcoma-associated herpesvirus (KSHV), HCMV is a widespread pathogen that 
commonly infects humans. In human populations, HCMV has a seroprevalence between 50 and 
90%, depending on the geographic and socioeconomic conditions as well as ethnic back-
grounds (Cannon et al., 2010). A remarkable biological property of HCMV with high clinical im-
portance, and a feature common to all members of the herpesvirus family, is its ability to estab-
lish lifelong persistence within the host following initial infection. 
 
1.2.1 HCMV infection and diseases 
HCMV is commonly acquired by direct contact with an infected person who excretes actively 
replicating virus with body fluids like urine, saliva and breast milk. Furthermore, HCMV can be 
transmitted by blood transfusion or organ and bone marrow grafts (Boppana and Fowler, 2007). 
The majority of primary infections of healthy individuals are asymptomatic. In some cases, pri-
mary infection can result in a mononucleosis-like syndrome, which is clinically indistinguishable 
from primary EBV infection, with symptoms including sore throat, fever, fatigue, myalgia, 
lymphadenopathy and mild hepatitis (Sissons and Carmichael, 2002). After primary infection, 
HCMV persists lifelong in a disguised state called "viral latency", but undergoes periodic 
asymptomatic reactivation with shedding of infectious virus. Primary infection as well as 
reactivation from latency is hold in check by effective defense mechanisms of the host's im-
mune system. As a consequence, HCMV disease is restricted to the immunocompromised or 
immunologically immature host. HCMV disease can affect various tissue types (Vancikova and 
Dvorak, 2001). Disease symptoms like organ dysfunction results from both direct cytopathic 
effects of the virus and indirect damage caused by antiviral immune defense mechanisms (Britt, 
2007b). 
 
Actively replicating HCMV present during pregnancy, whether from primary maternal infection or 
from reactivation, is congenitally transmitted to the fetus in 40% of cases and can confer harm 
to the immunologically immature host (Revello and Gerna, 2002). The earlier the mother ac-
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quires the infection, the more severe are the damages, even including intrauterine death 
(Vancikova and Dvorak, 2001). Approximately 10–15% of the transplacentally infected babies 
have severe symptoms at birth including liver disease, encephalitis or pneumonitis. Their peri-
natal mortality rate is approximately 10%. Among the surviving babies, 70–80% suffer perma-
nent neurological sequelae like mental retardation, visual impairment or hearing loss (Boppana 
et al., 1992). HCMV can further be transmitted from the mother to the newborn through the 
genital tract at delivery or postnatally through breast feeding and can thereby cause CMV-
associated symptoms, especially pneumonitis and hepatitis (Hamprecht et al., 2005). 
 
Serious HCMV disease is further caused by opportunistic infection of immunocompromised pa-
tients whose cellular immunity, the principal host defense against HCMV, is impaired. High risk 
for HCMV disease is consistently associated with transplantation and acquired immunodefi-
ciency syndrome (AIDS) through HIV infection. In HIV patients, CMV disease occurs with ad-
vanced immunosuppression (CD4+ T cell count <100 cells/µL, high viral load) and is usually 
caused by reactivation of latent virus rather than primary infection. The most common clinical 
manifestation is retinitis, followed by gastrointestinal disease and encephalitis. With introduction 
of highly active anti-retroviral therapy (HAART) in 1995–1996 to enable persistent immune 
reconstitution, the incidence of CMV disease has significantly declined but still remains an im-
portant issue in persons who are not receiving HAART or who failed to respond (Boeckh and 
Geballe, 2011). HCMV infection or reactivation after transplantation is a consequence of 
immunosuppressive medication applied to avoid graft rejection. The risk of CMV disease clearly 
depends on the type and intensity of the immunosuppressive regimen used. For example, the 
administration of anti-lymphocyte antibodies such as OKT3 results in the release of large 
amounts of proinflammatory cytokines, which may promote HCMV reactivation from latency 
(Fietze et al., 1994). In solid organ transplantation (SOT), the combination of a seronegative 
patient and a seropositive donor bears the highest risk for HCMV infection by virus reactivation 
from the graft. Reactivation of endogenous HCMV in seropositive recipients is less common. In 
the SOT recipient, HCMV can cause a febrile illness with fever and leukopenia, as well as tis-
sue-invasive disease, which manifests as hepatitis, pneumonitis, pancreatitis, colitis or myo-
carditis (Crough and Khanna, 2009). Furthermore, HCMV has been implicated in rejection of the 
transplanted organ (Evans et al., 2000). In contrast to the SOT setting, HCMV infections follow-
ing allogeneic hematopoietic stem cell transplantation (HSCT) are more frequently caused by 
reactivation of latent virus present in the seropositive recipient. In HSCT, pneumonitis is the 
most serious CMV-associated complication, causing high mortality rates even with antiviral 
treatment (Sissons and Carmichael, 2002). 
 
Today, antiviral prophylaxis and preemptive therapy strategies are widely used in SOT/HSCT 
and have led to a reduction of CMV disease during the time they are applied (typically the first 3 
months). However, late CMV disease (>100 days post transplantation) continues to be a clinical 
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problem. The currently approved drugs are ganciclovir (GCV), foscarnet (FOS) and cidofovir 
(CDV). Several side effects including nephrotoxicity and myelotoxicity limit their application. 
Furthermore, resistance to all three drugs resulting from mutations in the drug target, the viral 
DNA polymerase, has been described (Lurain and Chou, 2010). To improve safety and to over-
come resistance, several new anti-HCMV compounds with other modes of action are continu-
ously investigated in clinical trials (Boeckh and Geballe, 2011). 
 
1.2.2 Biology of HCMV 
Among the human herpesviruses, HCMV has the largest genome, with a size of ~235 kb 
comprising up to 250 protein-coding open reading frames (ORFs) (Murphy et al., 2003). The 
double-stranded linear DNA genome is divided into two segments that contain unique long (UL) 
or unique short (US) sequences and are bounded by internal and terminal repeats (Davison, 
2007a). Viral genes are named with the prefix of the segment in which they are located, fol-
lowed by a sequential number. Genomes of commonly used laboratory strains like AD169 and 
Towne have multiple mutations, deletions, and rearrangements compared to fresh clinical iso-
lates (Bradley et al., 2009). This is due to extensive laboratory passage in fibroblasts which se-
lects for mutations adapted to the cell culture growth and can cause differences in virulence and 
tissue tropism, for example loss of the ability to replicate in endothelial cells (Cha et al., 1996; 
Prichard et al., 2001).  
  
The viral genome is enclosed in an icosahedral nucleocapsid, which is surrounded by a dense 
protein-containing matrix termed the tegument and a lipid-bilayered envelope extensively spiked 
with glycoproteins (e.g. gB, gH, gL, gM, gN, gO) (Liu and Hong Zhou, 2007). The tegument con-
tains the majority of the virion proteins, with the most abundant tegument protein being the 
lower matrix phosphoprotein 65 (pp65, UL83 gene product). Other major tegument proteins are 
the core virion maturation protein pp150 (large matrix phosphoprotein; UL32), the virion 
transactivator pp71 (upper matrix protein, UL82), the membrane-associated myristylated 
phosphoprotein pp28 (UL99), and the high molecular weight tegument protein (UL48). Some 
tegument proteins play a structural role for the assembly of virions, but also for disassembly 
upon cell entry. Other tegument proteins fulfill diverse functions at different stages of the virus 
life cycle including viral entry, modulation of host cell response and DNA replication (Kalejta, 
2008). Virions also contain cellular components including lipids and structural proteins, which 
may play an important role in stabilizing infectious particles, as well as cellular and viral RNAs 
(Liu and Hong Zhou, 2007). Viral mRNAs appear to be packaged selectively into virions and 
have been proposed to facilitate initiation of viral infection upon cell entry (Bresnahan and 
Shenk, 2000). HCMV-infected cells in culture produce two other types of particles in addition to 
infectious virions: noninfectious enveloped particles (NIEPs) and dense bodies. NIEPs contain 
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an identical assortment of envelope, tegument, and capsid proteins than infectious virions but 
lack viral genomes. Dense bodies are enveloped tegument proteins that lack nucleocapsids and 
are primarily composed of the viral pp65 protein (Varnum et al., 2004). 
 
HCMV enters human fibroblast cells through direct fusion with the cell membrane (Compton et 
al., 1992). Envelope glycoproteins mediate both the attachment to cell surface receptors (e.g. 
heparan sulfate proteoglycans, integrins, platelet-derived growth factor receptor) and the 
membrane fusion event leading to the release of nucleocapsids and tegument into the 
cytoplasm (Compton and Feire, 2007). In epithelial and endothelial cells, HCMV enters through 
low-pH-dependent endocytosis mediated by additional viral envelope glycoproteins (Ryckman 
et al., 2006). After translocation of the nucleocapsids into the cell nucleus, viral DNA is released 
and viral genes are expressed in a temporal cascade comprising immediate-early (IE), early (E) 
and late (L) phase (Stinski, 1978). IE proteins are mainly transcriptional regulators required for 
initiation of the lytic replication program. IE-1/ IE-2 transcription factors induce the expression of 
E proteins, which are mainly involved in viral DNA replication. Finally, late genes encoding 
structural components of the virion or assembly proteins are expressed from the replicated 
genomes and permit the formation of new virions. After encapsidation of viral DNA, mature 
nucleocapsids traverse the nuclear membrane undergoing a process of envelopment and de-
envelopment and acquire their tegument in perinuclear compartments. Virions further gain their 
lipid membrane and envelope glycoproteins by budding into Golgi-derived cytoplasmic 
compartments (Britt, 2007a). Finally mature virus particles exit the cell using the exocytotic 
pathway, thus completing one cycle of lytic replication approximately 72–96 hours post infection 
(Loewendorf and Benedict, 2010). 
  
As demonstrated by the variety of tissue-specific diseases in vivo, HCMV shows a broad cellu-
lar tropism for lytic replication, including differentiated cells of the endoderm, mesoderm, and 
ectoderm, for example fibroblasts, endothelial cells, epithelial cells, smooth muscle cells, stro-
mal cells, macrophages, dendritic cells, neuronal cells, glial cells, hepatocytes, and trophoblasts 
(Prosch et al., 1995; Compton and Feire, 2007). By contrast, the virus fails to replicate in poorly 
differentiated cells such as progenitor cells of the myeloid lineage, which are considered to be 
the main reservoir for latent HCMV (Sinclair and Sissons, 2006). In these cells, HCMV is main-
tained in a nearly silent state with only very low levels of gene expression (Sinclair and Sissons, 
2006). The critical event for transition to productive infection is the expression of IE transcription 
factors IE-1/IE-2. IE-1/IE-2 expression is controlled by the major IE promoter/enhancer (MIEP), 
which is regulated by changes in chromatinization but also viral (pp71) and cellular factors like 
NF-κB and cyclic AMP (cAMP) (Stinski and Isomura, 2008). Differentiation of myeloid progeni-
tors to macrophages and DCs results in specific chromatin remodelling of the MIEP to an open, 
transcriptionally active chromatin structure allowing IE gene expression (Reeves et al., 2005). 
HCMV reactivation further occurs in response to inflammation or stress via induction of cellular 
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factors (Crough and Khanna, 2009). Proinflammatory cytokines are released during allogeneic 
transplantation, AIDS or sepsis. Among them, TNF-α is considered to be a key mediator of 
HCMV reactivation via NF-κB induction in latently infected cells (Prosch et al., 1995). Similarly, 
stress-induced catecholamines and proinflammatory prostaglandins promote HCMV reactivation 
through the cAMP pathway (Prosch et al., 1995; Kline et al., 1998). 
 
1.2.3 Effectors of the antiviral immune response 
The host defense against HCMV begins very early after infection with non-specific innate im-
mune mechanisms that mediate direct elimination of HCMV-infected cells but also priming of 
the subsequent adaptive immune response. HCMV is detected by Toll-like receptors (TLRs) at 
the very earliest stages of viral life cycle, upon initial virus-cell contact. The interaction of viral 
structural proteins including gB/gH with TLR2 triggers the secretion of inflammatory cytokines 
that activate and recrute cells of the innate immune system, for example DCs, macrophages 
and NK cells (Compton et al., 2003). HCMV particles are also robust inducers of interferons and 
interferon-stimulated genes (ISGs) encoding, for example, various cytokines, thus establishing 
an antiviral state in the infected host cell (Boehme et al., 2004).  
 
As integral part of the innate immunity, NK cells have an important role in the early control of 
viral infections. However, direct evidence for the role of NK cells in immunity to HCMV is limited. 
Patients with rare NK cell defects or deficiency are susceptible to life-threatening HCMV infec-
tions (Biron et al., 1989; Gazit et al., 2004). Furthermore, recovery of NK cell activity following 
HSCT has also been associated with survival of patients with CMV-related disease (Quinnan et 
al., 1982a). In addition, the murine (M)CMV model system provides evidence for a protective 
role of NK cells, as NK cell depletion in mice resulted in higher MCMV tissue titers and in-
creased mortality (Scalzo and Yokoyama, 2008). However, a number of in vitro systems have 
shown that HCMV-infected cells are relatively resistant to NK cell-mediated lysis, suggesting 
that HCMV has evolved mechanisms to evade NK cell recognition (Wills et al., 2007). Indeed, a 
great variety of HCMV-encoded NK cell evasion proteins were identified the past years, thus 
providing indirect evidence for the importance of these cells in the innate response to HCMV. 
 
HCMV is also a potent immunogen that triggers strong responses from both arms, humoral and 
cellular, of the adaptive immune system. However, the humoral, antibody-mediated immune 
response is not essential for the resolution of primary CMV infection and rather plays a role in 
restriction of viral dissemination and limiting the severity of the disease (Jonjic et al., 1994; Bop-
pana and Britt, 1995). HCMV primary infection elicits antibodies specific for numerous HCMV 
proteins including structural proteins (e.g. pp65 and pp150), envelope glycoproteins (predomi-
nantly gB and gH) as well as non-structural proteins such as IE1 (Jackson et al., 2011). Virus-
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neutralizing activity is predominantly mediated by gB-specific antibodies, which comprise at 
least 50% of the neutralizing antibodies in HCMV-infected individuals (Britt et al., 1990).  
 
The restriction of HCMV disease almost exclusively to individuals with cellular immunodefi-
ciency implicates that adaptive T cell responses are the predominant mechanism of HCMV con-
trol. This is supported by the observation that reconstitution of HCMV-specific T cell immunity 
and adoptive T cell transfer in immunocompromised patients correlates with protection from 
HCMV disease (Jackson et al., 2011). In seropositive humans, HCMV is targeted by an 
enormously high fraction of circulating T cells in the peripheral blood, comprising on average 
10% of both the CD4+ and CD8+ T cell memory compartments (Sylwester et al., 2005). This 
fraction tends to increase with age ("memory inflation"), which may support the hypothesis that 
HCMV contributes to immune system exhaustion and dysfunction in the elderly (Moss, 2010). A 
protective role against HCMV is also described for a subset of gamma delta (γδ) T cells (Vδ2-) 
which expands following HCMV reactivation in kidney and stem cell transplant recipients and 
has the ability to kill HCMV-infected target cells in vitro (Halary et al., 2005; Knight et al., 2010). 
However, the target structures of the γδ T cells on the surface of HCMV-infected cells are not 
known so far. 
 
A loss of HCMV control was primarily associated with the lack of HCMV-specific cytotoxic CD8+ 
T cells (CTLs) (Quinnan et al., 1982b; Reusser et al., 1991), which can directly kill HCMV-in-
fected cells. HCMV-specific CD8+ T cell responses can target various viral antigens expressed 
at different stages during viral replication cycle and associated with diverse functions including 
structural proteins (pp150, pp50, pp28, gB, gH), transcription factors (IE-1, IE-2) and even 
immunomodulatory proteins (gpUS2–11) (Elkington et al., 2003; Sylwester et al., 2005). How-
ever, only a small number of these antigens, including the 72-kDa IE-1 protein and the tegu-
ment protein pp65, is prevalently recognized in a majority of healthy carriers, thus being consid-
ered as immunodominant (Khan et al., 2005; Sylwester et al., 2005). The reasons underlying 
this immunodominance are largely unresolved. As the most abundant structural protein, pp65 is 
introduced into host cells upon virus entry and is therefore able to sensitize HCMV-infected cells 
for pp65-specific CTLs already before de novo expression of viral proteins including 
immunoevasive proteins which interfere with MHC class I antigen presentation (Riddell et al., 
1991; McLaughlin-Taylor et al., 1994). Over the past years, intensive studies on pp65-specific T 
cell responses led to the identification of various CD8+ T cell epitopes (Wills et al., 1996; Kondo 
et al., 2004). However, an even more important role as a T cell target has to be assumed for IE-
1, as IE-1-specific CD8+ T cells, but not pp65-specific T cells, are associated with protection 
from viral disease in solid organ transplant patients (Bunde et al., 2005). Furthermore, a delay in 
IE-1-specific CD8+ T cell reconstitution correlated with HCMV disease after stem cell 
transplantation (Sacre et al., 2008). The IE-1 transcription factor is among the first proteins to be 
expressed in HCMV-infected cells during lytic infection (Stinski et al., 1983), thereby enabling 
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CTL interference at a very early stage of the viral life cycle. More importantly, virus reactivation 
from latency is initiated with the expression of IE proteins (Sinclair and Sissons, 2006). There-
fore, IE-1-specific T cells and not T cells directed against structural or late expressed proteins 
are expected to efficiently control viral reactivation from latency before release of progeny virus. 
Indeed, there is direct evidence for an involvement of IE-1 epitope-specific CTLs in the immune 
surveillance of MCMV pulmonary latency by sensing of reactivated IE-1 gene expression 
(Simon et al., 2006). IE-1 therefore appears to be a preferable target of HCMV-specific 
immunotherapy, the more so since a variety of IE-1 epitopes restricted through different MHC 
class I allotypes have been identified (Kern et al., 1999; Khan et al., 2002; Elkington et al., 
2003). 
  
The role of CD4+ T cells in the control of HCMV is not as obvious as for CD8+ T cells. However, 
there is increasing evidence that CD4+ T cells are also an essential part of the immunity to 
HCMV. Analysis of the CD4+ T cell response to the entire HCMV proteome has also shown a 
very broad response, with an individual recognizing a median of 12 ORFs and with five ORFs 
(encoding gB, pp65, major capsid protein, pp28, IE-2) being recognized by more than half of the 
donors tested (Sylwester et al., 2005). So far, individual peptide epitopes have been identified in 
pp65, IE-1, gB and gH (Davignon et al., 1996; Kern et al., 2002; Elkington et al., 2004). HCMV-
specific CD4+ T cells have been associated with helper function as maintenance of adoptively 
transferred HCMV-specific CD8+ T cells in HSCT patients was clearly dependent on the pres-
ence of the CD4+ T cells (Walter et al., 1995). This is further supported by the finding, that 
HCMV-specific CD4+ T cells primarily secrete the Th1 cytokines IFN-γ and TNF-α but rarely the 
Th2 cytokine IL-4 (Rentenaar et al., 2000; van Leeuwen et al., 2006). However, there is 
accumulating evidence that HCMV-specific CD4+ T cell subsets can also directly act upon in-
fected cells, a feature that was thought to be restricted to cytotoxic CD8+ T cells (van Leeuwen 
et al., 2004). Cytotoxic CD4+ T cells have been identified against a number of HCMV antigens, 
including pp65, gB and gH (Hopkins et al., 1996; Elkington et al., 2004; Weekes et al., 2004). 
 
1.2.4 Viral immune evasion strategies 
During millions of years of coevolution with hominoids, HCMV has evolved a multitude of im-
mune evasion proteins designed to silence the host's immune response, thus allowing the virus 
to survive in a hostile environment. The simplest way to avoid recognition by the immune sys-
tem is to reduce viral antigen expression, which HCMV successfully employs during latency 
(Sinclair and Sissons, 2006). Latent HCMV might also avoid elimination by the immune system 
by expression of the viral IL-10 homolog cmvIL-10 (Slobedman et al., 2009), which is a potent 
immunosuppressor that downregulates inflammatory cytokine synthesis and interferes with 
MHC class II expression on antigen-presenting cells (Moore et al., 2001). During productive 
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infection, HCMV also modulates both arms of the immune response, innate and adaptive, by 
the expression of several homologues of cytokine receptors (UL144=TNFR), chemokines 
(pUL146/vCXC-1 and pUL147/vCXC-2) and chemokine receptors (e.g. pUS28/CCR1), as well 
as chemokine binding proteins (p21.5). HCMV further encodes two Fcγ receptor homologues, 
gp34 and gp68, which might bind HCMV-specific antibodies, thus protecting infected cells from 
phagocytosis, NK cell-mediated ADCC and complement activation. In addition, the three HCMV 
proteins IE-1, IE-2 and pp65 interfere with components of the type I IFN signaling pathway as 
well as ISG activation. (reviewed in (Miller-Kittrell and Sparer, 2009)) 
  
One central immune escape mechanism is the inhibition of NK cells, which are the key players 
of the antiviral innate immunity. Some HCMV-encoded proteins alter the surface expression of 
activating NK cell receptor ligands. The HCMV UL16-encoded glycoprotein binds the natural 
stress-induced ligands ULBP1, ULBP2 and MICB, thus disrupting their interaction with the 
activating NK cell receptor NKG2D (Dunn et al., 2003). Similarly, the HCMV-encoded micro-
RNA miR-UL112 selectively targets MICB for downregulation in infected cells (Stern-Ginossar 
et al., 2007). Furthermore, the glycoprotein UL142 was found to downregulate the cell surface 
expression of another NKG2D ligand, MICA (Chalupny et al., 2006). The protein encoded by 
UL141 specifically targets and prevents the expression of the cell surface glycoproteins CD155 
and CD112, which both function as ligands for the activating NK cell receptor DNAM-1 
(Tomasec et al., 2005; Prod'homme et al., 2010). Finally, the structural protein pp65 was de-
scribed to interfere with NK cell-mediated killing of HCMV-infected cells by interacting with the 
activating NK receptor NKp30 (Arnon et al., 2005). HCMV has also developed mechanisms to 
compensate for virus-mediated downregulation of MHC class I molecules, which, according to 
the "missing self"-hypothesis, renders infected cells sensitive for NK cell lysis. Viral glycoprotein 
UL18 binds the inhibitory receptor ILT-2 as a surrogate of endogenous MHC class I molecules 
(Chapman et al., 1999b). However, the function of gpUL18 has not been clearly defined as it 
was found to inhibit but also to activate NK cells in vitro (Prod'homme et al., 2007). Furthermore, 
HCMV-encoded UL40 protein can promote surface expression of HLA-E, the ligand for the 
inhibitory C-type lectin CD94/NKG2A, by providing UL40-derived TAP-independent peptides 
that bind to HLA-E (Tomasec et al., 2000). However, conflicting reports have found that UL40 
either inhibited or had no effect on NK cell lysis of HCMV-infected cells (Falk et al., 2002; Wang 
et al., 2002). 
  
A major focus of HCMV immune evasion lies on the inhibition of antigen processing and 
presentation in order to evade T cell recognition, which is the main HCMV defense mechanism. 
A pp65-associated kinase activity, probably from interaction with Polo-like kinase 1 (Gallina et 
al., 1999), was found to selectively block presentation of IE-1 protein-derived peptides (Gilbert 
et al., 1996). Early work observed that HCMV downregulated MHC class I molecules from the 
surface of infected cells (Barnes and Grundy, 1992; del Val et al., 1992). The genomic region 
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implicated in this phenomenon was US2–US11 (Jones et al., 1995) encoding the viral 
glycoproteins US2, US3, US6, US10, and US11, which have subsequently been found to 
modulate MHC class I (and II) antigen presentation (Fig. 1.4). GpUS3 is expressed during the 
IE period of the viral replication cycle and retains fully assembled MHC class I complexes in the 
ER by direct binding to the ER-resident chaperone tapasin (Zhao and Biegalke, 2003). Tapasin 
is essential for optimal peptide loading and surface expression of some MHC class I allotypes. 
Hence, susceptibility of MHC class I allotypes to US3 retention correlates with their tapasin 
dependence (Park et al., 2004). Additionally, gpUS3 reduces MHC class II antigen presentation 
by binding of newly synthesized MHC class II α/β heterodimers, thereby preventing their 
association with the invariant chain (Hegde et al., 2002). The early phase proteins gpUS2 and 
gpUS11 mediate the dislocation of MHC class I heavy chains from the ER to the cytosol for 
subsequent proteasomal degradation. Despite the similar outcome of their action, gpUS2 and 
gpUS11 use different molecular mechanisms involving diverse cellular factors of the ER-
associated protein degradation (ERAD) pathway to mediate MHC class I destruction (Noriega et 
al., 2012). For example, gpUS2-mediated MHC degradation depends on the chaperones 
calnexin, BiP, and calreticulin, whereas gpUS11 action requires Derlin-1, a protein described to 
be involved in the removal of misfolded proteins (Miller-Kittrell and Sparer, 2009). Like gpUS3, 
gpUS2 and gpUS11 target MHC class I heavy chains in an allele-specific manner. Amino acid 
residues near the border between α2 and α3 domains are involved in the interaction with gpUS2 
(Gewurz et al., 2001; Barel et al., 2006). By contrast, gpUS11 discriminates between HLA allelic 
variants based on their cytosolic tail residues. Furthermore, residues in the α1 and α2 domains 
may modulate gpUS11 targeting (Barel et al., 2003). In addition to its interference with MHC 
class I presentation, gpUS2 also inhibits MHC class II presentation by inducing the degradation 
of HLA-DR and -DM α chains (Tomazin et al., 1999). The HCMV early/late protein gpUS6 
inhibits the translocation of antigenic peptides by the TAP complex, by preventing the binding of 
ATP to TAP1 (Ahn et al., 1997). Finally, gpUS10 binds free MHC class I heavy chains and 
delays their egress from the ER. GpUS10 is specific for HLA-G molecules (Park et al., 2010), 
whereas it does not block classical MHC class I maturation or surface expression (Jones et al., 
1995). In addition to the immunoevasins encoded within the US2–11 region, the HCMV-
encoded miRNA US4-1 plays a role in inhibiting antigen presentation to CTLs (Kim et al., 2011). 
US4-1 specifically targets the mRNA of ER aminopeptidase ERAP1, thus preventing ERAP1 
translation and, consequently, the trimming of TAP-translocated precursors of MHC class I 
peptides (Saric et al., 2002). 
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Fig. 1.4: HCMV-endoded glycopro-
teins and miRNA interfere with 
MHC class I antigen processing 
and presentation. Glycoprotein US3 
retains fully-assembled MHC/peptide 
complexes in the ER. GpUS10 delays 
MHC egress from the ER. GpUS2 and 
gpUS11 individually mediate the 
retrograde translocation of MHC class 
I heavy chains from the ER to the 
cytosol and subsequent degradation 
at the proteasome. GpUS6 interacts 
with the TAP complex, thereby 
interfering with peptide transport from 
the cytosol into the ER and subse-
quent MHC loading. Micro-RNA US4-
1 specifically targets the mRNA of 
ER-aminopeptidase ERAP1 and pre-
vents its translation and, conse-
quently, the trimming of TAP-translo-
cated precursors of MHC class I pep-
tides. 
 
 
 
1.2.5 Immunotherapy 
After transplantation, the reconstitution of B and T cell immunity is delayed due to 
immunosuppressive drug administration for prevention of GVHD, and this delay puts the patient 
at high risk of infectious complications, especially HCMV disease. Current antiviral drugs are 
limited by toxicities and lack of efficacy in established HCMV disease. Therefore, the design of 
adoptive immunotherapeutic strategies to correct antibody and T cell immunodeficiencies may 
be an attractive alternative. Passive administration of immunoglobulin preparations containing 
HCMV-specific antibodies has only provided limited success in the transplant setting. Despite 
some reports about improved disease outcome and survival (Falagas et al., 1997), there was no 
clear evidence that prophylactic immunoglobulin treatment lowered the incidence of HCMV dis-
ease (Ringden et al., 1987; Munoz et al., 2001). By contrast, in pregnant women, HCMV-spe-
cific immunoglobulin transfer significantly reduced the risk of congenital HCMV disease (Nigro 
et al., 2005).  
 
Due to a strong correlation between recovery of HCMV-specific T cell immunity and protection 
from HCMV disease (Quinnan et al., 1982a; Reusser et al., 1991; Li et al., 1994), adoptive T 
cell transfer appears to be a more promising strategy for immunosuppressed patients. Indeed, 
patients who have received ex vivo expanded HCMV-specific T cells were protected from both 
primary and reactivating HCMV infection (Riddell et al., 1992; Peggs et al., 2003). Protective 
immunity could be successfully transferred to patients by the infusion of either HCMV-specific 
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CD8+ cytotoxic T cell clones or polyclonal T cell lines (Einsele et al., 2008). However, the 
maintenance of a protective CD8+ T cell immunity was depending on the presence of CD4+ 
helper T cell function (Walter et al., 1995; Einsele et al., 2002), suggesting that immunotherapy 
should not focus on CD8+ T cells alone. Over the last three decades, a number of strategies to 
isolate and expand HCMV-specific T cells for adoptive T cell therapy have been explored. Pio-
neer work on adoptive T cell transfer was done using HCMV-infected autologous fibroblasts for 
in vitro expansion of CD8+ T cell clones (Riddell et al., 1992; Walter et al., 1995). Other T cell 
expansion techniques use EBV-infected B cells or APCs retrovirally transduced with genes of 
interest as stimulator cells. Although being very effective approaches for T cell stimulation, 
these methods rise biosafety concerns due to the presence of live viruses and may therefore 
not be applicable to current good manufacturing practice (GMP) standards (Rauser et al., 
2004). Other effective strategies for the generation of HCMV-specific T cells use DCs pulsed 
with specific antigens (Peggs et al., 2001) or synthetic peptides (Kleihauer et al., 2001). How-
ever, these methods are very labor and cost intensive and require several weeks for the 
generation of a clinical product. In an alternative approach, HCMV-specific T cells can be di-
rectly isolated from the peripheral blood of seropositive donors using HLA/peptide multimeric 
complexes (Cobbold et al., 2005). A new kind of multimeric HLA complexes called streptamers 
bind reversibly to the T cell receptor, thus offering the opportunity to transfer nearly "untouched" 
antigen-specific T cells (Knabel et al., 2002). A clinical study employing this principle in HCMV 
therapy after HSCT is ongoing (Schmitt et al., 2011). Furthermore, virus-specific T cells can be 
isolated within 36 hours by stimulation of PBMCs with synthetic peptides or antigen followed by 
IFN-γ capture-based isolation (Moosmann et al., 2010). The transfer of HCMV-specific T cells 
prepared with this procedure significantly reduced HCMV reactivation and disease in HSCT 
patients (Feuchtinger et al., 2010). These two methods allow rapid isolation of specific T cells 
without time-consuming in vitro expansion, thus avoiding T cell senescence, reducing the poten-
tial risk for contamination of the T cell preparation, and reducing the cost and complexity of 
production under clinical conditions. 
 
Congenital HCMV infection is the leading infectious cause of mental retardation in children. In 
addition, HCMV seroprevalence is linked to an immune-risk phenotype in the very elderly that 
may predispose to early death (Pawelec and Derhovanessian, 2011). It appears that this cannot 
be resolved by other means than active immune prophylaxis. Therefore, HCMV is considered to 
be a prime candidate for eradication from the human population through vaccination. A 
successful vaccine strategy should stimulate both protective humoral and cell-mediated immun-
ity. Therefore, more than 30 years ago, live-attenuated HCMV strains like AD169 and Towne 
were studied as vaccine candidates. Especially strain Towne was intensively investigated in 
seronegative volunteers and transplant recipients. Although most candidates developed hu-
moral and T cell responses following vaccination, these were not protective against infection 
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with natural HCMV (Plotkin et al., 1991; Adler et al., 1995). Meanwhile, several other ap-
proaches for HCMV vaccine development have been attempted, for example recombinant virus 
vaccines (e.g. based on VSV, MVA or AdV), subunit vaccines, peptide vaccines and DNA vac-
cines (Schleiss, 2008). However, there is no licensed HCMV vaccine currently available, and 
the reasons for this are complex. For example, most efforts of HCMV vaccine development 
have focused on the antibody target gB and the T cell targets pp65 and IE1. However, during 
evaluation of the T cell responses in HCMV-seropositive individuals several HCMV proteins in 
addition to pp65 and IE-1 were identified as T cell targets (Sylwester et al., 2005) and their 
significance for mediation of protective immunity is not yet clear. Furthermore, it became obvi-
ous that neutralizing antibodies against gB are not able to prevent HCMV entry in epithelial and 
endothelial cells as this process does not involve gB but instead a complex of the glycoproteins 
gH/gL/UL128/130/131 (Revello and Gerna, 2010). Nevertheless, there are promising HCMV 
vaccine candidates, whose implementation could impact significantly on HCMV disease. The 
principle barrier to licensure of an HCMV vaccine is probably the lack of public awareness of the 
threat posed by congenital HCMV infection and the severe disabilities it produces in children 
(Schleiss, 2008). 
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1.3 Aims of the study 
The IE-1 antigen of HCMV is a preferred target for antiviral immunotherapy. Its kinetics of 
expression, and studies in the mouse model, make it likely that IE-1-specific T cells protect from 
infection. However, many questions on IE-1-specific T cells were unanswered at the outset of 
the present study. IE-1-specific CD4+ T cells had been described, although some studies could 
not detect them in healthy donors. Furthermore, it was known that IE-1-specific CD8+ T cells 
are often dominant in healthy carriers, but most studies described that they do not recognize 
infected cells in the presence of viral immunoevasive proteins. Therefore, the aim of the present 
study was to address the following questions:  
 
I. Can CD8+ and CD4+ T cells specific for the IE-1 protein be reliably expanded in vitro from 
the peripheral blood cells of healthy HCMV carriers by stimulation with mini-lymphoblas-
toid cell lines? Can specific CD8+ and CD4+ T cell clones be established?  
 
II. Can new target epitopes of IE-1-specific CD8+ and CD4+ T cells be identified that will be 
of use in antiviral immunotherapy? How diverse are responses in healthy virus carriers, 
how many different epitopes are targeted, and which ones are recognized by dominant T 
cell populations? 
 
III. What are the effector functions of IE-1-specific CD8+ and CD4+ T cells?  
 
IV. Do IE-1-specific CD8+ and CD4+ T cells recognize infected cells, and which cell types? Is 
there a specialization for particular cell types, is there a preferential recognition of tissue 
cells (e.g. fibroblasts) or hematopoietic cells (e.g. dendritic cells)? What are the conditions 
for recognition?  
 
V. Can it be confirmed that recognition of infected cells by IE-1-specific CD8+ T cells is inhib-
ited by viral immunoevasins? Is this true for all IE-1 epitope specificities and HLA re-
strictions, or are there systematic differences? What is the role of individual viral 
immunoevasins in such a suppression? Can CD8+ T cell specificities be identified that 
control infection particularly well?  
 
VI. Can IE-1 be used as a model antigen to obtain a better understanding of MHC class I 
immunoevasion by HCMV?  
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2 Materials 
2.1 Bacteria 
For preparation of plasmid DNA and cloning purposes, the chemically competent E.coli strains 
DH5α and DH10B (Invitrogen, Karlsruhe, Germany) were used: 
 
genotype DH5α: F-, ϕ80dlacZ∆M15, ∆(lacZYA-argF), U169, deoR, recA1, endA1,  
   hsdR17(rk-, mk-), supE44, thi-I, gyrA96, relA1, λ-. 
genotype DH10B: F-, mcrA, ∆(mrr-hsdRMS-mcrBC), ϕ80dlacZ∆M15, ∆lacX74, deoR, recA1,  
   endA1, araD139, ∆(ara, leu)7697, galU, galK, λ-, rpsL, nupG. 
 
2.2 Eukaryotic cells 
2.2.1 Primary cells 
Peripheral blood mononuclear cells (PBMCs) were obtained from standard blood donations of 
healthy adult donors or from buffy coats received from the Institute for Transfusion Medicine, 
University of Ulm, Germany. All blood donors contributing to this work were anonymized. The 
institutional review board (Ethikkommission, Klinikum der Universität München, Marchioninistr. 
25, 81377 Munich, Germany) approved the study. All work was conducted according to the 
principles expressed in the Helsinki Declaration. High- or low-resolution HLA types and virus 
carrier status of the PBMC donors are listed in Table 2.1. 
 
Table 2.1: HLA types of donors and virus carrier status (n.d. = not determined) 
 
Donor HLA-A HLA-B HLA-C HLA-DRB1 HLA-DR (B3/4/5) 
HLA-DQ 
(A1/B1) 
HLA-DP 
(A1/B1) 
HCMV 
status 
EBV 
status 
AAJ *0201 *0301 
*3801 
*4403 
*0402 
*1203 
*0701 
*1301 
B3*0101 
-- 
B4*0101 
-- 
n.d. n.d. neg neg 
ABF *02 *03 
*35 
*4001 
*03 
*15 n.d. n.d. n.d. n.d. pos pos 
ACR *0301 *6801 
*0702 
*3501 
*0401 
*0702 
*0101 
*1501 n.d. n.d. n.d. neg pos 
AEA *0101 *2402 
*0801 
*1402 
*0701 
*0802 
*0301 
*1502 n.d. n.d. n.d. pos pos 
AES *2602 -- 
*3501 
*4801 
*0401 
*0803 
*1101 
*1501 
B3*0202 
-- 
B5*0101 
-- 
B1*0301 
B1*0602 
B1*0201 
B1*0402 pos neg 
AJJ *0201 -- 
*0702 
*3503 
*0401 
*0702 
*03 
*14 n.d. n.d. n.d. pos pos 
AJG *0201 -- 
*3503 
*5701 
*04 
*06 
*07 
*11 n.d. 
B1*03 
B1*03 n.d. pos pos 
AJU *0201 *24 
*07 
*40 
*0304 
*0702 
*07 
*13 
B3*0202 
-- 
B4*0101 
-- 
A1*0103 
A1*0201 
B1*0202 
B1*0603 
A1*0103 
-- 
B1*0401 
B1*2001 
pos pos 
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Donor HLA-A HLA-B HLA-C HLA-DRB1 HLA-DR (B3/4/5) 
HLA-DQ 
(A1/B1) 
HLA-DP 
(A1/B1) 
HCMV 
status 
EBV 
status 
ALT *0201 -- 
*0702 
*4002 
*0202 
*0702 
*0401 
*1501 
B4*0103 
B5*0101 
B1*0301 
B1*0602 
B1*0401 
B1*1101 pos pos 
AMD *01 *11 
*08 
*1501 
*0303 
*0701 
*03 
*11 
B3*0101 
B3*0202 
B1*02 
B1*03 n.d. pos pos 
ARZ *0201 *2902 
*4402 
*4501 
*0602 
-- 
*04 
*15 
B4*0103 
B5*0101 
B1*03 
B1*06 
A1*0103 
-- 
B1*0201 
B1*0301 
pos pos 
ASG *0101 *2902 
*0801 
*4403 
*0701 
*1601 
*13 
*15 
B3*0101 
B5*0101 
B1*0602 
B1*0603 n.d. pos pos 
ASI *0201 -- 
*44 
*51 
*02 
*05 
*08 
*11 n.d. 
B1*03 
B1*04 n.d. neg pos 
ASM *03 *33 
*07 
*14 
*0702 
*0802 
*01 
*15 n.d. n.d. n.d. neg n.d. 
ATH *02 *24 
*44 
*51 
*02 
*05 n.d. n.d. n.d. n.d. pos pos 
AYH *0207 *0301 
*2704 
*4402 
*0501 
*1202 n.d. n.d. n.d. n.d. pos pos 
F43 *01 *24 
*07 
*57 
*0602 
*0702 
*07 
*15 
B4 
B5 
B1*03 
B1*06 n.d. pos n.d. 
F45 *01 *68 
*08 
*14 
*07 
*08 
*13 
*15 
B3 
B5 
B1*03 
B1*06 n.d. pos pos 
F46 *03 *11 
*07 
*3501 
*0401 
*0702 
*13 
*15 
B3 
B5 
B1*06 
-- 
B1*0401 
B1*0402 pos pos 
F59 *02 *68 
*18 
*4001 
*0701 
-- 
*11 
*13 B3 
B1*03 
B1*06 n.d. pos n.d. 
F60 *02 *26 
*07 
*38 
*0702 
*1203 
*0201 
*0401 B3 
B1*03 
B1*06 n.d. pos pos 
F61 *02 *34 
*14 
*44 
*0401 
*0802 
*01 
*07 B4 
A1*0101 
A1*0201 
B1*02 
B1*05 
A1*0103 
A1*0201 
B1*0402 
B1*1401 
pos pos 
F62 *03 -- 
*3501 
*5201 
*0401 
*1202 
*0101 
*1502 B5*0102 
B1*05 
B1*06 n.d. pos pos 
F63 *03 *24 
*18 
*4001 
*0401 
*1504 
*01 
*08 -- 
B1*03 
B1*05 
B1*0401 
-- pos n.d. 
F64 *02 *29 
*1501 
*44 
*0304 
*0701 
*07 
*13 
B3 
B4 
A1*0103 
A1*0201 
B1*0202 
B1*0603 
A1*0103 
A1*0201 
B1*0201 
B1*1101 
pos pos 
F65 *24 *68 
*35 
*44 
*0303 
*1601 
*14 
*15 
B3*0202 
B5*0101 
B1*05 
B1*06 
B1*0201 
B1*0301 pos n.d. 
LM02 *03 *24 
*07 
*18 
*0701 
*0702 n.d. n.d. n.d. n.d. pos pos 
LM16 *0301 *3101 
*0702 
*0801 
*0701 
*0702 n.d. n.d. n.d. n.d. pos n.d. 
LM20 *0201 *2402 
*0702 
*3901 
*0702 
*1203 n.d. n.d. n.d. n.d. pos n.d. 
LT12 *11 *11 
*07 
*55 
*0102 
*0702 n.d. n.d. n.d. n.d. pos n.d. 
SA01 *0301 *6801 
*0702 
*5101 
*0702 
*1502 
*0701 
*1501 n.d. n.d. n.d. pos pos 
SA03 *0101 *0301 
*0702 
*5701 
*0602 
*0702 
*0701 
*1501 n.d. n.d. n.d. pos pos 
SA04 *0102 *0201 
*0702 
*4901 
*0701 
*0702 
*1401 
*1501 n.d. n.d. n.d. pos pos 
SA05 *2301 *3001 
*0705 
*4901 
*0701 
*1505 
*1301 
*1501 n.d. n.d. n.d. pos pos 
SA12 *01 *03 
*07 
*35 
*0401 
*0702 n.d. n.d. n.d. n.d. pos pos 
SA13 *03 -- 
*07 
*52 
*0702 
*1202 n.d. n.d. n.d. n.d. pos pos 
Materials 
 
27 
Primary NK cell lines used in this study were all established from PBMCs of donor AJU with the 
following KIR genotype:  
 
positive for genes encoding KIRs:  2DL1, 2DL3, 2DL4, 2DS4, 3DL1, 3DL2, 3DL3 
negative for genes encoding KIRs:  2DL2, 2DL5, 2DS1, 2DS2, 2DS3, 2DS5, 3DS1 
 
This genotype suggests AJU to be homozygous for KIR haplotype A (Uhrberg et al., 1997; 
Parham, 2005). 
 
2.2.2 Cell lines 
TR-2/293  EBV-packaging cell line based on the human embryonic kidney 293 cell 
   line (Delecluse et al., 1999) (available in the Department of Gene Vectors,  
   Helmholtz Zentrum München) 
 
BHK-21  baby hamster kidney cells, derived from kidney of Syrian golden hamster 
   (MACPHERSON and STOKER, 1962) (CCL-10TM, purchased from ATCC) 
 
Daudi   B lymphoblastoid cell line, MHC class I-deficient (Klein et al., 1968)  
   (purchased from ATCC) 
 
K562   immortalized human chronic myelogenous leukemia cell line, MHC class  
   I-deficient (Lozzio and Lozzio, 1975) (purchased from ATCC) 
  
L721.221  B lymphoblastoid cell line, MHC class I-deficient  
   (Shimizu and DeMars, 1989) 
    (kindly provided by Elfriede Nößner, Helmholtz Zentrum München) 
  
L721.221 C*0602 L721.221 stably transfected with the HLA-C*0602 gene (Falk et al., 1995)  
   (kindly provided by Elfriede Nößner, Helmholtz Zentrum München) 
  
L721.221 C*0702 L721.221 stably transfected with the HLA-C*0702 gene (Falk et al., 1995)  
   (kindly provided by Elfriede Nößner, Helmholtz Zentrum München) 
  
LL8   murine fibroblast L929 cell line stably transfected with the human CD40  
   ligand-encoding gene (L. Schirrmann and A. Moosmann, unpublished) 
 
 
Mini-lymphoblastoid cell lines (mLCLs) and CD40-stimulated B cell lines were established 
within this work from PBMCs of the blood donors listed in Table 2.1. 
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T cell clones specific for pp65- and IE-1 were established within this work from PBMCs of the 
blood donors listed in Table 2.1. Systematic nomenclature includes a three-letter abbreviation 
for the anonymized donor (XYZ), P or M to indicate the target antigen (pp65 or IE-1, respec-
tively), the number of the T cell clone, and a three-letter abbreviation for the recognized peptide. 
  
XYZP#1 NLV  T cell clone number 1 of donor XYZ that recognizes NLV peptide of pp65 
XYZM#1 CRV  T cell clone number 1 of donor XYZ that recognizes CRV peptide of IE-1 
 
Human fibroblast cell lines used in this work: 
 
 
2.3 Viruses 
Modified vaccinia virus Ankara (MVA) wild-type strain and recombinants were kindly provided 
by Naem Khan, Birmingham, UK (Khan et al., 2005). 
MVA-wt  MVA wild-type strain 
MVA-pp65  MVA recombinant with expression cassette for HCMV pp65 antigen 
MVA-IE-1  MVA recombinant with expression cassette for HCMV IE-1 antigen 
 
The following recombinant, modified mini-Epstein-Barr virus (mini-EBV) strains and correspond-
ing viral plasmids were used in this study: 
mini-EBV  plasmid 1495.A, no foreign antigen encoded 
mini-EBV-pp65 plasmid 4014, pp65-expression cassette 
mini-EBV-IE-1  plasmid 3457, IE-1-expression cassette 
 
The mini-EBV plasmid 1495.A (Kempkes et al., 1995) contains all viral genes and elements 
necessary for transformation of primary B cells. Mini-EBVs coding for pp65 or IE-1 were 
constructed from 1495.A by Andreas Moosmann, Helmholtz Zentrum München, Germany 
(Moosmann et al., 2002) or Martina Wiesner, Helmholtz Zentrum München, Germany (Wiesner, 
2005), respectively. Thereby, an expression cassette carrying the transgene's cDNA sequence 
under the SV40 promoter derived from the expression plasmid pSG-5 (Stratagene) was 
introduced into 1495.A by homologous recombination. 
cell line description source HLA-A HLA-B HLA-C 
BFF2 primary human foreskin fibroblast cell line from an adult donor 
department of gene 
vectors 
*02 
*03 
*35 
*4001 
*03 
*15 
CZF primary human foreskin fibroblast cell line from an adult donor 
department of gene 
vectors 
*02 
*02 
*18 
*60 
*03 
*05 
MRC-5 human fetal lung fibroblast cell line European collection of cell cultures 
*0201 
*2902 
*0702 
*4402 
*0501 
*0702 
WI-38 human fetal lung fibroblast cell line European collection of cell cultures  
*0205 
*6801 
*0801 
*5801 
*0701 
*0701 
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HCMV strain AD169 was kindly provided by Martin Messerle (Hannover, Germany). 
 
Recombinant HCMV strains lacking three or all four HCMV-encoded immunoevasive proteins 
gpUS2, 3, 6 and 11 were kindly provided by Bodo Plachter, Mainz, Germany, and are listed 
below. These HCMV mutants were generated via BAC mutagenesis, by successive deletion of 
the individual sequences coding for US2, 3, 6 and 11 from the US gene locus as described in 
Besold et al., 2009. 
  
virus strain original name immunoevasin encoded reference 
CMV-∆all RV-KB6 - Besold et al., 2009 
CMV-US2 RV-KB13 gpUS2 Besold et al., 2009 
CMV-US3 RV-KB7 gpUS3 Noriega et al., 2012 
CMV-US6 RV-KB5 gpUS6 unpublished 
CMV-US11 RV-KB9 gpUS11 Besold et al., 2009 
  
 
2.4 Plasmids 
p2670    expression plasmid encoding the EBV glycoprotein BALF4/gp110 
    (Neuhierl et al., 2002) 
 
p509    expression plasmid encoding the EBV lytic transactivator BZLF1 
    (Delecluse et al., 1999) 
  
pCMV-HLA-A*0201  expression plasmid encoding recombinant HLA-A*0201 (kindly  
    provided by Josef Mautner, Helmholtz Zentrum München) 
 
pCMV-HLA-B*0702  expression plasmid encoding recombinant HLA-B*0702 (kindly  
    provided by Josef Mautner, Helmholtz Zentrum München) 
  
pCMV-HLA-C*0702  expression plasmid encoding recombinant HLA-C*0702 (kindly  
    provided by Josef Mautner, Helmholtz Zentrum München) 
  
pEGFP-C1   expression plasmid for enhanced green fluorescent protein  
    (EGFP) (purchased from Clontech, Mountain View, USA) 
 
Plasmids coding for chimeric HLA molecules were constructed within this study: 
 
pCMV-HLA-A2/C7  expression plasmid encoding HLA-chimera HLA-A2/C7 (aa -24 to  
    175 of HLA-A*0201 and 176 to 342 of HLA-C*0702) 
  
pCMV-HLA-C7/A2  expression plasmid encoding HLA-chimera HLA-C7/A2 (aa -24 to  
    175 of HLA-C*0702 and 176 to 341 of HLA-A*0201) 
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2.5 Oligonucleotides 
Oligonucleotides used in this work were synthesized by Metabion (Munich, Germany) and are 
listed as follows in 5'→3' direction. 
 
Cell lines were screened for the presence of a mini-EBV genome with primers recognizing mini-
EBV-encoded chloramphenicol-acetyltransferase gene: 
cam-up:  TTC TGC CGA CAT GGA AGC CAT C 
cam-down:  GGA GTG AAT ACC ACG ACG ATT TCC 
 
Cell lines were screened for the presence of a wild-type EBV genome with primers recognizing 
BXLF1 gene encoding gp85: 
gp85c:   TGG TCA GCA GCA GAT AGT GAA CG 
gp85d:   TGT GGA TGG GTT TCT TGG GC 
 
Primers for detection of the gene encoding GAPDH (used as PCR amplification control; kindly 
provided by Stephanie Medele, Helmholtz Zentrum München, Germany): 
GAPDH-F3:  GAC ATC AAG AAG GTG GTG AAG CAG 
GAPDH-B4:  AAG TGG TCG TTG AGG GCA ATG 
 
2.6 Peptides 
All peptides used in this study were synthesized to >70% purity by JPT (Berlin, Germany), 
resuspended in 100% dimethyl sulfoxide (DMSO) and stored at -20°C. In the T cell effector 
assays, the DMSO concentration was kept below 0.1% (vol/vol).  
 
Peptides derived from HCMV pp65 and IE-1 proteins used in this work are listed in Table 2.2. 
For published epitopes and epitopes identified within this work, the three letter abbreviation and 
HLA restriction are denoted. All peptides were stored at 5 mg/mL and diluted to a final 
concentration of 5 µg/mL in the assay mixtures. 
 
Table 2.2: Peptides derived from HCMV pp65 and IE-1 proteins. 
source/ 
description antigen 
peptide 
sequence 
abbreviation 
for epitopes aa position 
HLA-
restriction 
AD169 IE-1 ATTFLQTMLR ATT 32–41 A*6801 
AD169 IE-1 CRVLCCYV  309-316  
AD169 IE-1 CRVLCCYVL CRV 309–317 C*0702 
CRV variant (Toledo, 
TB40E, Davis) IE-1 CRVLCCYIL  309–317 C*0702 
AD169 IE-1 DEEEAIVAY  379–387 B*1801 
AD169 IE-1 EFCRVLCCY  307–315  
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source/ 
description antigen 
peptide 
sequence 
abbreviation 
for epitopes aa position 
HLA-
restriction 
AD169 IE-1 EFFTKNSAFPK  213–223  
AD169 IE-1 EFFTKNSAFPKT  213–224  
AD169 IE-1 EFFTKNSAFPKTT EFF 213–225 DRB1*1501/ DRB5*0101 
AD169 IE-1 EFFTKNSAFPKTTN  213–226  
AD169 IE-1 ELRRKMMYM ELR 199–207 B*0801 B*1801 
AD169 IE-1 FCRVLCCYV  308–316  
AD169 IE-1 FTKNSAFPKT  215–224  
AD169 IE-1 FTKNSAFPKTTN  215–225  
AD169 IE-1 FTKNSAFPKTTNG  215–226  
AD169 IE-1 FFTKNSAFPKT  214–224  
AD169 IE-1 FFTKNSAFPKTT  214–225  
AD169 IE-1 FFTKNSAFPKTTN  214–226  
AD169 IE-1 FFTKNSAFPKTTNG  214–227  
AD169 IE-1 IEFFTKNSAFPK  212–223  
AD169 IE-1 IEFFTKNSAFPKT  212–224  
AD169 IE-1 IEFFTKNSAFPKTT  212–225  
AD169 IE-1 KEVNSQLSL KEV 42–50 B*4001 
AD169 IE-1 NIEFFTKNSAF  211–221  
AD169 IE-1 QIKVRVDMV QIK 88–96 B*0801 
AD169 IE-1 RHRIKEHMLK RHR 97–106 A*0301 
AD169 IE-1 RVLCCYVL  310–317  
AD169 IE-1 RVLCCYVLE  310–318  
AD169 IE-1 TKNSAFPKTTN  216–226  
AD169 IE-1 TKNSAFPKTTNG  216–227  
AD169 IE-1 VLCCYVLEE  311–319  
AD169 IE-1 VLEETSVML VLE 316–324 A*0201 
phospho-VLE IE-1 VLEE-pT-SVML  316–324 A*0201 
phospho-VLE IE-1 VLEET-pS-VML  316–324 A*0201 
AD169 pp65 IPSINVHHY IPS 123–131 B*3501 
AD169 pp65 NLVPMVATV NLV 495–503 A*0201 
AD169 pp65 RPHERNGFTV RPH 265–274 B*0702 
AD169 pp65 TPRVTGGGAM TPR 417–426 B*0702 
 
Frequency and specificity of IE-1-specific T cells were analyzed by using a library of 120 pep-
tides, each 15 amino acids in length, spanning the entire IE-1 sequence of HCMV strain AD169, 
with subsequent peptides overlapping in 11 amino acids (Table 2.3). Nine additional peptides 
containing sequence variants present in the HCMV strains Toledo and TB40E were included in 
the study (peptides #121-129).  
  
IE-1 peptides were ordered from JPT as  
  
IE-1 mix   "PepMix HCMVA IE-1"; mix of peptides #1-120; final concentration of 0.5  
   µg/ml/peptide in the assay mixtures 
individual peptides peptides #1-129; final concentration of 5 µg/mL in the assay mixtures 
  
For mapping of IE-1 epitopes, the 129 peptides were subpooled in a cross-matrix fashion (Kern 
et al., 1999), such that every single peptide was contained in one "vertical" subpool (#1–12) and 
one "horizontal" subpool (#13–23) (Fig. 2.1). 
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Table 2.3: IE-1 peptide library 
1 MESSAKRKMDPDNPD 34 LDKVHEPFEEMKCIG 67 LTHIDHIFMDILTTC 100 SDSLVSPPESPVPAT 
2 AKRKMDPDNPDEGPS 35 HEPFEEMKCIGLTMQ 68 DHIFMDILTTCVETM 101 VSPPESPVPATIPLS 
3 MDPDNPDEGPSSKVP 36 EEMKCIGLTMQSMYE 69 MDILTTCVETMCNEY 102 ESPVPATIPLSSVIV 
4 NPDEGPSSKVPRPET 37 CIGLTMQSMYENYIV 70 TTCVETMCNEYKVTS 103 PATIPLSSVIVAENS 
5 GPSSKVPRPETPVTK 38 TMQSMYENYIVPEDK 71 ETMCNEYKVTSDACM 104 PLSSVIVAENSDQEE 
6 KVPRPETPVTKATTF 39 MYENYIVPEDKREMW 72 NEYKVTSDACMMTMY 105 VIVAENSDQEESEQS 
7 PETPVTKATTFLQTM 40 YIVPEDKREMWMACI 73 VTSDACMMTMYGGIS 106 ENSDQEESEQSDEEE 
8 VTKATTFLQTMLRKE 41 EDKREMWMACIKELH 74 ACMMTMYGGISLLSE 107 QEESEQSDEEEEEGA 
9 TTFLQTMLRKEVNSQ 42 EMWMACIKELHDVSK 75 TMYGGISLLSEFCRV 108 EQSDEEEEEGAQEER 
10 QTMLRKEVNSQLSLG 43 ACIKELHDVSKGAAN 76 GISLLSEFCRVLCCY 109 EEEEEGAQEEREDTV 
11 RKEVNSQLSLGDPLF 44 ELHDVSKGAANKLGG 77 LSEFCRVLCCYVLEE 110 EGAQEEREDTVSVKS 
12 NSQLSLGDPLFPELA 45 VSKGAANKLGGALQA 78 CRVLCCYVLEETSVM 111 EEREDTVSVKSEPVS 
13 SLGDPLFPELAEESL 46 AANKLGGALQAKARA 79 CCYVLEETSVMLAKR 112 DTVSVKSEPVSEIEE 
14 PLFPELAEESLKTFE 47 LGGALQAKARAKKDE 80 LEETSVMLAKRPLIT 113 VKSEPVSEIEEVAPE 
15 ELAEESLKTFEQVTE 48 LQAKARAKKDELRRK 81 SVMLAKRPLITKPEV 114 PVSEIEEVAPEEEED 
16 ESLKTFEQVTEDCNE 49 ARAKKDELRRKMMYM 82 AKRPLITKPEVISVM 115 IEEVAPEEEEDGAEE 
17 TFEQVTEDCNENPEK 50 KDELRRKMMYMCYRN 83 LITKPEVISVMKRRI 116 APEEEEDGAEEPTAS 
18 VTEDCNENPEKDVLA 51 RRKMMYMCYRNIEFF 84 PEVISVMKRRIEEIC 117 EEDGAEEPTASGGKS 
19 CNENPEKDVLAELVK 52 MYMCYRNIEFFTKNS 85 SVMKRRIEEICMKVF 118 AEEPTASGGKSTHPM 
20 PEKDVLAELVKQIKV 53 YRNIEFFTKNSAFPK 86 RRIEEICMKVFAQYI 119 TASGGKSTHPMVTRS 
21 VLAELVKQIKVRVDM 54 EFFTKNSAFPKTTNG 87 EICMKVFAQYILGAD 120 GKSTHPMVTRSKADQ 
22 LVKQIKVRVDMVRHR 55 KNSAFPKTTNGCSQA 88 KVFAQYILGADPLRV 121 LKAKARAKKDELKRK 
23 IKVRVDMVRHRIKEH 56 FPKTTNGCSQAMAAL 89 QYILGADPLRVCSPS 122 ARAKKDELKRKMIYM 
24 VDMVRHRIKEHMLKK 57 TNGCSQAMAALQNLP 90 GADPLRVCSPSVDDL 123 KDELKRKMIYMCYRN 
25 RHRIKEHMLKKYTQT 58 SQAMAALQNLPQCSP 91 LRVCSPSVDDLRAIA 124 KRKMIYMCYRNVEFF 
26 KEHMLKKYTQTEEKF 59 AALQNLPQCSPDEIM 92 SPSVDDLRAIAEESD 125 LTEFCRVLCCYILEE 
27 LKKYTQTEEKFTGAF 60 NLPQCSPDEIMAYAQ 93 DDLRAIAEESDEEEA 126 CRVLCCYILEETSVL 
28 TQTEEKFTGAFNMMG 61 CSPDEIMAYAQKIFK 94 AIAEESDEEEAIVAY 127 CCYILEETSVLLAKR 
29 EKFTGAFNMMGGCLQ 62 EIMAYAQKIFKILDE 95 ESDEEEAIVAYTLAT 128 LEETSVLLAKRPLIT 
30 GAFNMMGGCLQNALD 63 YAQKIFKILDEERDK 96 EEAIVAYTLATAGVS 129 ESDEEDAIAAYTLAT 
31 MMGGCLQNALDILDK 64 IFKILDEERDKVLTH 97 VAYTLATAGVSSSDS   
32 CLQNALDILDKVHEP 65 LDEERDKVLTHIDHI 98 LATAGVSSSDSLVSP   
33 ALDILDKVHEPFEEM 66 RDKVLTHIDHIFMDI 99 GVSSSDSLVSPPESP   
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
13 1 2 3 4 5 6 7 8 9 10 11 12 
14 13 14 15 16 17 18 19 20 21 22 23 24 
15 25 26 27 28 29 30 31 32 33 34 35 36 
16 37 38 39 40 41 42 43 44 45 46 47 48 
17 49 50 51 52 53 54 55 56 57 58 59 60 
18 61 62 63 64 65 66 67 68 69 70 71 72 
19 73 74 75 76 77 78 79 80 81 82 83 84 
20 85 86 87 88 89 90 91 92 93 94 95 96 
21 97 98 99 100 101 102 103 104 105 106 107 108 
22 109 110 111 112 113 114 115 116 117 118 119 120 
23 121 122 123 124 125 126 127 128 129    
 
Fig. 2.1: Cross-matrix orientation of 23 IE-1 peptide subpools containing 120 peptides of AD169 
(#1–120) and 9 sequence variants present in the HCMV strains Toledo and TB40E (#121–129). 
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2.7 Antibodies 
All antibodies used in this study were made in mouse and are listed as follows. 
 
specificity clone isotype conjugate company 
CD3 HIT3a IgG2a PE-Cy5 BioLegend, San Diego, USA 
CD4 RPA-T4 IgG1 FITC BD Biosciences, Heidelberg, Germany 
CD8α RPA-T8 IgG1 APC BioLegend, San Diego, USA 
CD56 HCD56 IgG1 PE-Cy5 BioLegend, San Diego, USA 
HLA-A2 BB7.2 IgG2b PE BioLegend, San Diego, USA 
HLA-A2 BB7.2 IgG2b unlabeled BioLegend, San Diego, USA 
HLA-ABC W6/32 IgG2a PE BioLegend, San Diego, USA 
HLA-ABC W6/32 IgG2a unlabeled BioLegend, San Diego, USA 
HLA-B7 BB7.1 IgG1 PE Millipore, Billerica, USA 
HLA-DR L234 IgG2a unlabeled BioLegend, San Diego, USA 
HLA-DQ SPV-L3 IgG2a unlabeled AbD Serotec, Kidlington, UK 
HLA-DP B7/21 IgG3 unlabeled Abcam, Cambridge, UK 
KIR2DL1 
(CD158a) 
HP-3E4 IgM FITC BD Biosciences, Heidelberg, Germany 
KIR2DL2/3 
(CD158b) 
CH-L IgG2b PE BD Biosciences, Heidelberg, Germany 
KIR2DL2/3 
(CD158b) 
DX27 IgG2a unlabeled BioLegend, San Diego, USA 
KIR3DL1 DX9 IgG1 FITC BioLegend, San Diego, USA 
NKG2A 
(CD159a) 
Z199.1 IgG2b APC Beckman Coulter, Krefeld, Germany 
isotype control MOPC-21 IgG1 PE BioLegend, San Diego, USA 
isotype control MOPC-173 IgG2a PE BioLegend, San Diego, USA 
isotype control MPC-11 IgG2b PE BioLegend, San Diego, USA 
 
The following antibody-coupled beads were used for immunomagnetic separation: 
MACS® CD3 MicroBeads, human  Miltenyi Biotec, Bergisch Gladbach, Germany 
MACS® CD4 MicroBeads, human  Miltenyi Biotec, Bergisch Gladbach, Germany 
MACS® PE MicroBeads   Miltenyi Biotec, Bergisch Gladbach, Germany 
 
2.8 Peptide/HLA multimers 
A PE-conjugated CRV/HLA-C*0702 streptamer was generated within a collaboration by Fabian 
Schlott (group of Michael Neuenhahn/Dirk Busch; Institute for Medical Microbiology, Immunol-
ogy and Hygiene, Technische Universität München) and kindly provided for staining of CRV-
specific CD8+ T cells. An unlabeled TPR/HLA-B*0702-Pentamer was ordered from (Proim-
mune, Oxford, England). Pentamer-positive cells were counterstained with Pro5 Fluorotag R-PE 
(Proimmune, Oxford, England). 
 
2.9 Cell culture media and additives 
E.coli were cultivated in LB (Luria Bertani) medium or on solid LB agar plates. 
Luria Broth Base    Gibco Invitrogen, Karlsruhe, Germany 
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Select Agar     Gibco Invitrogen, Karlsruhe, Germany 
 
The following antibiotics were used for selection purposes: 
ampicillin sodium salt    Carl Roth GmbH, Karlsruhe, Germany 
chloramphenicol    Sigma-Aldrich, St. Louis, USA 
kanamycin sulfate salt   Sigma-Aldrich, St. Louis, USA 
  
 
Eukaryotic cell culture 
 
The following media and additives were used for cultivation of eukaryotic cells. 
 
name application/function source 
RPMI 1640 standard cell culture medium Gibco Invitrogen, 
Karlsruhe, Germany 
DMEM cell culture medium for adherent cells 
(fibroblasts, BHK-21, TR-2/293) 
Gibco Invitrogen, 
Karlsruhe, Germany 
Opti-MEM cell culture medium for transfection Gibco Invitrogen, 
Karlsruhe, Germany 
fetal calf serum (FCS) nutritive substance Biochrom, Berlin, 
Germany 
penicillin/streptomycin antibiotics, inhibition of bacteria growth Gibco Invitrogen, 
Karlsruhe, Germany 
sodium selenite supplies an essential element (additive for 
RPMI 1640 and DMEM) 
ICN Biochemicals, 
Aurora, USA 
0.05% Trypsin-EDTA detachment of adherent cells Gibco Invitrogen, 
Karlsruhe, Germany 
Cyclosporin A immunosuppressant, inhibits T and NK cell 
growth during establishment of B cell lines 
Novartis, Nürnberg, 
Germany 
Geneticine G-418 sulphate antibiotic for selection of eukaryotic cells Gibco Invitrogen, 
Karlsruhe, Germany 
Hygromycin B antibiotic for selection of eukaryotic cells Invitrogen, Karlsruhe, 
Germany 
 
 
The following cytokines were used for cultivation of specific cell types. 
 
name application source 
recombinant human IL-2 
("Proleukin S") 
cultivation of T cells, NK cells Novartis, Nürnberg, 
Germany 
recombinant human IL-1β establishment of DCs Biochrom, Berlin, Germany 
recombinant human IL-4 cultivation of CD40-stimulated B cells, 
establishment of DCs 
R&D Systems, Minneapolis, 
USA 
recombinant human IL-6 establishment of DCs Biochrom, Berlin, Germany 
recombinant human IFN-γ cultivation of fibroblasts (enhancement 
of MHC expression) 
PAN Biotech, Aidenbach, 
Germany 
recombinant human GM-CSF establishment of DCs Genzyme, Neu-Isenburg, 
Germany 
Prostaglandin E2 (PGE2) establishment of DCs Sigma, St. Louis, USA 
recombinant human TNF-α establishment of DCs Biochrom, Berlin, Germany 
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2.10 Commercial kits 
AP Conjugate Substrate Kit   Bio-Rad, München, Germany 
Endofree® Plasmid Maxi Kit   Qiagen, Hilden, Germany 
QIAprep® Spin Miniprep Kit   Qiagen, Hilden, Germany 
Human IFN-γ ELISA Kit (ALP)  Mabtech, Nacka Strand, Sweden 
Human GM-CSF ELISA Kit (ALP)  Mabtech, Nacka Strand, Sweden 
Human TNF-α ELISA Kit (ALP)  Mabtech, Nacka Strand, Sweden 
Human IL-2 ELISA Kit (ALP)   Mabtech, Nacka Strand, Sweden 
Human IL-4 ELISA Kit (ALP)   Mabtech, Nacka Strand, Sweden 
Human IL-10 ELISA Kit (ALP)  Mabtech, Nacka Strand, Sweden 
Human IFN-γ ELISpot Kit (ALP)  Mabtech, Nacka Strand, Sweden 
MACS® IFN-γ secretion assay  Miltenyi Biotec, Bergisch Gladbach, Germany 
Nucleofector® Kit R    Lonza, Basel, Switzerland 
 
2.11 Enzymes 
restriction enzymes EcoRI, Esp3I, PvuII Fermentas, St. Leon-Rot, Germany 
Shrimp Alkaline Phosphatase (SAP) Fermentas, St. Leon-Rot, Germany 
T4 DNA ligase    Fermentas, St. Leon-Rot, Germany 
Taq-DNA polymerase   Fermentas, St. Leon-Rot, Germany 
 
2.12 Chemicals, reagents and buffers 
actinomycin D  (ActD)    Sigma-Aldrich, St. Louis, USA 
Biocoll Separating Solution   Biochrom, Berlin, Germany 
calcein acetoxymethylester (AM)  Invitrogen, Karlsruhe, Germany 
cover oil     Biotest AG, Dreieich, Germany 
cycloheximide (CHX)    Sigma-Aldrich, St. Louis, USA 
dimethyl sulfoxide (DMSO)   Carl Roth GmbH, Karlsruhe, Germany 
diethanolamine (DEA)   Carl Roth GmbH, Karlsruhe, Germany 
DNA agarose     Biozym, Hessisch Oldendorf, Germany 
DNA loading dye (6x)    Fermentas, St. Leon-Rot, Germany  
ethidium bromide    Carl Roth GmbH, Karlsruhe, Germany 
FACS Flow/Clean/Rinse   BD Biosciences, Heidelberg, Germany 
GeneRulerTM DNA Ladder Mix  Fermentas, St. Leon-Rot, Germany 
GeneRulerTM 100 bp DNA Ladder  Fermentas, St. Leon-Rot, Germany 
Heparin-Natrium 25,000   Braun, Melsungen, Germany 
human serum type AB   Cambrex, East Rutherford, USA 
ionomycin calcium salt   Tocris Bioscience, Bristol, UK 
magnesium sulfate heptahydrate  Carl Roth GmbH, Karlsruhe, Germany  
NaOH (50 mM)    Carl Roth GmbH, Karlsruhe, Germany 
para-nitrophenyl phosphate (pNPP)  Carl Roth GmbH, Karlsruhe, Germany 
PBS Dulbecco (w/o Mg2+)   Biochrom, Berlin, Germany 
PCR reagents (MgCl2, 2 mM dNTPs) Fermentas, St. Leon-Rot, Germany 
polyethyleneimine (PEI) MW≈25 000 g/mol Aldrich, St. Louis, USA 
sodium dodecyl sulphate (SDS)  Carl Roth, GmbH, Karlsruhe, Germany 
TAE (Tris, acetate, EDTA)   Carl Roth, GmbH, Karlsruhe, Germany 
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tetradecanoylphorbol acetate (TPA)  Sigma-Aldrich, St. Louis, USA 
thiazolyl blue tetrazolium bromide (MTT) Sigma-Aldrich, St. Louis, USA 
Tris/HCl (1 M)     Carl Roth, GmbH, Karlsruhe, Germany 
TritonTM X-100    Carl Roth GmbH, Karlsruhe, Germany 
trypan blue     Merck, Darmstadt, Germany 
TÜRK's solution    Merck, Darmstadt, Germany  
Tween® 20     Carl Roth GmbH, Karlsruhe, Germany 
 
2.13 Consumables 
6-/12-/24-/48-/96-well flat-bottom plates BD Biosciences, Heidelberg, Germany 
96-well MultiScreen HTC Filter plates Millipore, Billerica, USA 
96-well round-bottom plates   Nunc A/S, Roskilde, Denmark 
96-well V-bottom plates   Hartenstein, Würzburg, Germany 
BD FalconTM cell strainer 100 µm  BD Biosciences, Heidelberg, Germany 
BD FalconTM conical tubes 15 mL, 50 mL BD Biosciences, Heidelberg, Germany 
BD FalconTM Polystyrene Round-Bottom  
Tubes (5 mL)     BD Biosciences, Heidelberg, Germany 
cell culture flasks (25/80/175 cm2)  Nunc A/S, Roskilde, Denmark 
cell scrapers     Nunc A/S, Roskilde, Denmark 
cryo tube vials 1.8 mL   Nunc A/S, Roskilde, Denmark 
Immunoplates MaxiSorp® 96-w flat-bottom Nunc A/S, Roskilde, Denmark 
Infuject® 50 mL syringes and needles Dispomed Witt oHG, Gelnhausen, Germany 
PCR reaction tubes    Abgene, Hamburg, Germany 
plastic pipettes  
(2 mL; 5 mL; 10 mL; 25 mL)   Greiner Bio-One, Kremsmünster, Österreich 
polypropylene tubes 1.3 mL   Greiner Bio-One, Kremsmünster, Österreich 
pipette tips (Diamond® TowerPackTM)    
(0.110µL; 10100µL; 1001000µL)  Gilson Inc., Middleton, USA 
reaction tubes 0.5 mL ; 1.5 mL; 2 mL Eppendorf, Hamburg, Germany 
Reagent Reservoir Costar® 50 mL  Corning Inc., Corning, USA 
single use pasteur pipettes 3.2 mL  Carl Roth GmbH, Karlsruhe, Germany  
syringe filter Minisart® 0.2 µm  Sartorius AG, Göttingen, Germany    
syringe filter NalgeneTM 0.8 µm  Nalge Company, Rochester, USA 
 
2.14 Laboratory equipment and devices 
bacteria incubator/shaker innovaTM 4400 New Brunswick Scientific, Enfield, USA 
"Centrifuge 5415 R"    Eppendorf, Hamburg, Germany 
centrifuge "Avanti® J-26 XP"   Beckman Coulter, Krefeld, Germany 
centrifuge "Multifuge 3 L-R"   Heraeus Holding, Hanau, Germany 
centrifuge "Rotanta 46 RSC"   Hettich AG, Bäch, Switzerland 
"FACS Calibur" cytofluorometer  Becton Dickinson, Heidelberg, Germany 
Fluorescence microscope Axiovert 200M Zeiss, Jena, Germany 
forceps     Hartenstein, Würzburg, Germany 
freezer -20°C     Liebherr, Bilberach an der Riss, Germany 
freezer -80°C "Hera freeze"   Heraeus Holding, Hanau, Germany 
fridge      Bosch, Gerlingen-Schillerhöhe, Germany 
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gel documentation system   Peqlab Biotechnologie, Erlangen, Germany 
gel electrophoresis chambers  Peqlab Biotechnologie, Erlangen, Germany 
glass ware     SCHOTT AG, Mainz, Germany 
HP Scanjet G4050    Hewlett Packard, Böblingen, Germany 
irradiation device Gammacell 40 (Cs-137) Atomic Energy of Canada Limited, Ottawa, Kanada 
HERAEUS PICO 21 centrifuge  Thermo Fisher Scientific, Waltham, USA 
ice machine AF 200    Scotsman, Milan, Italy 
incubator CO2-AUTO-ZERO   Heraeus Holding, Hanau, Germany 
incubator CO2-Unitherm 170   UniEquip, Planegg, Germany 
inverted microscope Axiovert 25  Zeiss, Jena, Germany  
laminar flow hoods    BDK, Sonnenbühl-Genkingen, Germany 
magnetic stirrer  "IKAMag REO"  IKA®-Werke GmbH, Staufen, Germany 
microwave "compact microwave oven" Reston Lloyd, Sterling, USA  
Nanodrop ND-1000 spectrophotometer Peqlab Biotechnologie, Erlangen, Germany 
Neubauer counting chamber   Paul Marienfeld, Lauda-Königshofen, Germany 
Nucleofector I Device    Lonza, Basel, Switzerland 
PCR-machine "Mastercycler Personal" Eppendorf, Hamburg, Germany 
pH Tester (HI98108, pHep®)   Hanna® Instruments, Smithfield, USA 
Pipetboy acu     INTEGRA Biosciences, Fernwald, Germany 
plasticware     Brand, Wertheim, Germany 
PowerPac 200 power supply   Bio-Rad, München, Germany 
precision balance "SPB 55"   Scaltec Instruments, Göttingen, Germany 
Reference® pipettes  
(0.510 µL; 10100 µL; 1001000 µL)  Eppendorf, Hamburg, Germany 
Thermomixer compact   Eppendorf, Hamburg, Germany 
Transferpette® (20200 µL)   Brand, Wertheim, Germany 
tumble roller mixer TRM-50   IDL GmbH, Nidderau, Germany 
ultra pure water device "Aquintus"  membraPure, Hennigsdorf, Germany 
Universal Microplate Reader EL-800 BIO-TEK Instruments, Winooski, USA 
vacuum pump     Fröbel Labortechnik, Lindau, Germany 
Vortex mixer VM-300    NeoLab, Heidelberg, Germany 
Wallac Victor2 1420 Multilabel-Counter PerkinElmer, Waltham, USA 
water baths     GFL, Burgwedel, Germany 
 
2.15 Databases and software 
The following databases and bioinformatic tools were used within this study: 
 
IMGT/HLA database  supply of HLA sequences (www.ebi.ac.uk/imgt/hla/) 
SYFPEITHI   epitope prediction (www.syfpeithi.de/) 
BIMAS    epitope prediction (www-bimas.cit.nih.gov) 
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Software used within this study for design of experiments, data analysis and data illustration is 
listed as follows. 
 
name application source 
Adobe® Illustrator® CS5 illustration and graphic design Adobe Systems Inc., San José, USA 
Bookends 11.2.7. reference management Sonny Software, Chevy Chase, USA 
CellQuestTM Pro FACS analysis BD Biosciences, Heidelberg, Germany 
FlowJo 9.4.11 FACS analysis TreeStar Inc., Ashland, USA 
GraphPad Prism5 data illustration GraphPad Software, La Jolla, USA 
KC4 ELISA measurement, calculation  of standard curves TreeStar Inc., Ashland, USA 
MacVector 12.0.6. nucleotide and protein sequence analysis and alignment MacVector Inc., Cary, USA 
Microsoft® Word 2011 word processing  Microsoft, Redmond, USA 
Microsoft® Excel 2011 data analysis and illustration  Microsoft, Redmond, USA 
 
2.16 Services 
The HCMV and EBV IgG serostatus of the blood donors was determined by the Max von 
Pettenkofer-Institute, München, Germany. 
 
High or low resolution HLA typing of blood donors was performed on PBMCs or cell lines from 
the donors using PCR-based methods by IMGM, Martinsried, Germany. 
  
KIR typing of donor AJU was performed on PBMCs of this donor using PCR-based methods by 
IMGM, Martinsried, Germany.  
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3 Methods 
3.1 Microbiological methods 
3.1.1 Cultivation and storage of bacteria 
Escherichia coli (E. coli) strain DH5α (Invitrogen) was used for propagation of the low size, high 
copy plasmids listed in 2.4. and for cloning purposes. E. coli strain DH10B (Invitrogen) was 
used for preparation of mini-EBV vector DNA listed in 2.3.  
 
Bacteria from cryo-cultures were directly plated on LB agar plates and incubated overnight at 
37°C. Resulting single cell colonies were used for inoculation of suspension cultures grown in 
LB medium at 37°C under constant agitation at 200 rpm. Plasmid-carrying bacteria were 
cultivated in presence of antibiotics (100 µg/mL ampicillin, 30 µg/mL chloramphenicol, 30 µg/mL 
kanamycin) to select for resistance genes. 
  
For long-term storage, dense overnight cultures of E. coli were supplemented with 7% DMSO, 
transferred to cryovials and frozen at -80°C. 
 
3.1.2 Transformation of bacteria 
Transformation of bacteria with purified plasmid DNA or ligated DNA fragments was performed 
with chemically competent E. coli DH5α cells (Invitrogen) following the manufacturer's instruc-
tions. Up to 1 µg of plasmid DNA or 2–5 µL of ligation mixture was added to 50 µL of E. coli 
cells. After transformation, bacteria were plated on LB agar plates with the respective antibiotics 
and incubated overnight at 37°C. 
 
3.2 Molecular biology methods 
3.2.1 General DNA techniques 
3.2.1.1 Plasmid DNA purification from E.coli 
Small scale purification of low and high copy plasmid DNA for restriction enzyme analyses was 
performed by using the QIAprep® Spin Miniprep Kit (Qiagen). E. coli colonies were picked with 
pipette tips from the LB agar plates and incubated in 4 mL LB medium overnight under constant 
agitation (200 rpm). Approximately 2 mL of dense bacteria culture were used for plasmid 
preparation according to the manufacturer's protocol. 
  
Large scale purification of low and high copy plasmid DNA for transfection of eukaryotic cells 
was performed by using the Endofree® Plasmid Maxi Kit (Qiagen) according to the manufactur-
er's protocol. For high copy plasmids (all plasmids listed in 2.4), 400 mL of saturated overnight 
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bacteria culture was used for purification (yield ≤ 1 mg DNA). For low copy plasmids (mini-EBV 
plasmids listed in 2.3), 2x 400 mL of dense overnight bacteria culture were necessary to isolate 
sufficient vector DNA for mini-EBV production (yield ≤ 100 µg). 
  
The nucleic acid concentration of plasmid preparations was determined by absorbency readings 
at 260 nm with the Nanodrop ND-1000 spectrophotometer (Peqlab Biotechnologie). Samples 
with an absorbance ratio 260 nm/280 nm between 1.8 and 2.0 were considered as appropriately 
pure. 
 
3.2.1.2 Restriction enzyme digest, dephosphorylation, ligation 
Restriction endonuclease digests of DNA were performed with enzymes from the manufacturer 
Fermentas. Using 10 units of the chosen enzyme for each µg of DNA, reaction mixtures were 
incubated in the recommended reaction buffer for 1 h at 37°C (recommended temperature for 
the selected enzymes Esp3I, EcoRI and PvuII). 
  
After restriction enzyme digest, Shrimp Alkaline Phosphatase (SAP, Fermentas) was used 
according to the manufacturer's instructions to remove 5' phosphates from free DNA ends in 
order to avoid spontaneous religation of vector DNA. 
  
Ligations of digested vector DNA and insert DNA were performed using the T4 DNA Ligase 
(Fermentas) according to the manufacturer's protocol. In general, 50 ng of vector DNA were 
mixed with the appropriate amount of insert DNA at a vector/insert ratio between 1:2 and 1:10. 
 
3.2.1.3 Agarose gel electrophoresis 
DNA fragments from restriction enzyme digests and PCR products were separated according to 
their size by agarose gel electrophoresis. 1.0–2.0% agarose gels were prepared in 1x TAE 
buffer. For visualization, ethidium bromide was added in a final concentration of 0.1 µg/mL. The 
nucleic acid was mixed with 6x loading dye (Fermentas) prior to loading onto the agarose gel. 
The molecular weight markers GeneRulerTM DNA Ladder Mix and GeneRulerTM 100 bp DNA 
Ladder (Fermentas) were used to determine DNA fragment size. 1x TAE served as running 
buffer. Gels were documented by ultraviolet (UV) light irradiation (gel documentation system, 
Peqlab Biotechnologie). 
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3.2.2 Analysis of B cell lines for the presence of EBV-specific sequences 
Each mini-EBV-transformed lymphoblastoid cell line (mLCL) established within this study was 
checked by polymerase chain reaction (PCR) for the presence of a mini-EBV-specific sequence 
(chloramphenicol acetyltransferase, cam) using primers cam-up and cam-down (product size: 
294 bp).  
 
EBV-free CD40-stimulated B cell lines and mLCLs were checked for contamination with 
lymphoblastoid cells transformed by endogenous wild-type EBV of seropositive donors. Primers 
gp85c and gp85d (product size: 461 bp) were specific for the gene BXLF1, encoding viral 
glycoprotein gp85, which is present in wild-type EBV strains and laboratory EBV strain B95.8, 
but not in recombinant mini-EBV vectors. B95.8-transformed LCLs were used as a PCR-control 
for detection of wild-type EBV-specific sequence. In PCR reactions of CD40-stimulated B cells, 
primers specific for GAPDH (GAPDH-F3 and -B4) were used as a control for genomic DNA 
amplification for the case that wild-type EBV sequence could not be detected. 
  
For PCR, crude DNA was isolated from mLCLs, LCLs and CD40-stimulated B cells by alkaline 
lysis. 1 mL of dense cell culture containing approximately 1x 106 cells was harvested by 
centrifugation in a 1.5 mL reaction tube. After complete removal of the supernatant, the cell pel-
let was resuspended in 25 µL 50 mM NaOH, covered with oil and incubated at 95°C for 10 
minutes. The lysate was cooled on ice, neutralized with 4 µL 1 M Tris/HCl (pH 7) and centri-
fuged at maximum speed for 1 minute. 1 µL of supernatant (below the cover oil) containing the 
genomic DNA was used in the PCR reaction mixture. 
  
For mLCLs, the primer pairs cam-up/cam-down and gp85c/gp85d, and for CD40-stimulated B 
cells, the primer pairs gp85c/gp85d and GAPDH-F3/GAPDH-B4 were added into the same 
reaction mixture at a ratio of 1:1. The PCR reaction mixture is listed as follows: 
 
     [µL] 
 
DNA      1.00 
Taq-buffer     5.00 
Taq DNA polymerase    1.25 
primers each     2.50 
dNTPs (2 mM)    5.00 
MgCl2 (25 mM)    5.00 
H2O    22.75 
 
total    50.00 
 
 
The PCR protocol comprised 30 cycles of amplification, with 45 seconds each of denaturation at 
96°C, primer annealing at 59°C, and elongation at 72°C. 
Methods 
 
42 
3.2.3 Cloning of chimeric MHC class I molecules 
Plasmids carrying cDNAs of full-length class I heavy chains, pCMV-HLA-A*0201 and pCMV-
HLA-C*0702, were used for the construction of the HLA-chimera HLA-A2/C7 (aa -24 to 175 of 
HLA-A*0201 and 176 to 342 of HLA-C*0702) and its counterpart HLA-C7/A2 (aa -24 to 175 of 
HLA-C*0702 and 176 to 341 of HLA-A*0201).  
  
These switched chimeras were constructed using an EcoRI restriction site within the vector 
backbone and an Esp3I restriction site that was located within an entirely conserved sequence 
near the C-terminal end of the α2-domain. Each template was sequentially digested with the two 
restriction enzymes. To minimize spontaneous religation of the corresponding sticky ends, one 
of the two plasmids, pCMV-HLA-A*0201 or pCMV-HLA-C*0702, was dephosphorylated with 
Shrimp Alkaline Phosphatase (SAP, Fermentas). Fragments of both templates, dephosphory-
lated and not dephosphorylated, were mixed, religated with T4 DNA Ligase (Fermentas) and 
transformed into DH5α (Invitrogen). When analyzing the resulting plasmids with restriction en-
zyme PvuII (Fermentas), all 4 possible HLA constructs were obtained: the two chimeras HLA-
A2/C7 and -C7/A2 as well as religated HLA-A*0201 and -C*0702. 
 
3.3 Cell culture methods 
3.3.1 Cell culture conditions 
All eukaryotic cells used in this study were cultivated in an incubator with humidified atmosphere 
at 37°C and 5% CO2. Handling of cells was carried out in laminar flow hoods. 
  
Standard cell culture medium for LCLs, mLCLs, K562 cells, Daudi cells, LL8 cells, CD40-stimu-
lated B cells, and TR-2/293 cells was RPMI-1640 supplemented with 10% fetal calf serum 
(FCS), penicillin/streptomycin (100 U/mL/100 µg/mL) and 100 nM sodium selenite.  
  
LCLs, mLCLs, K562 cells, and Daudi cells were cultivated in suspension and, depending on 
their proliferation rate, were expanded one or two times per week 25-fold each time. For the 
HLA-C*0602- or -C*0702-expressing derivatives of the MHC class I-deficient LCL L721.221, hy-
gromycin B (0.5 mg/mL) was added to the cell culture medium to avoid loss of the transfected 
HLA-encoding construct. 
 
Murine LL8 fibroblasts stably expressing CD40 ligand (CD40L) were cultivated adherently. 
Confluent cells were split once per week by washing with PBS and incubation with 0.5% Tryp-
sin/EDTA for 5 minutes at 37°C. Detached cells were pelleted by centrifugation and expanded 
approximately 40-fold in fresh standard cell culture medium. 
  
CD40-stimulated B cell lines were cultivated in flat-bottom 12-well plates on a layer of irradiated 
(180 Gy) CD40L-expressing LL8 cells (1x 106 cells/plate). Standard cell culture medium was 
Methods 
 
43 
supplemented with recombinant human (rhu)IL-4 (2 ng/mL). CD40-stimulated B cell lines were 
replated two times per week on fresh irradiated LL8 feeder cells and thereby expanded 2- to 6-
fold depending on their proliferation rate. 
 
The EBV-packaging TR-2/293 cell line was cultivated adherently in presence of hygromycin B 
(100 µg/mL) in order to preserve the stably transfected maxi-EBV plasmid. Confluent cells were 
passaged two times per week by tapping the flask until all cells were detached. Cells were pel-
leted by centrifugation and expanded 5-10-fold in fresh standard cell culture medium. 
 
BHK-21 cells and human fibroblast cell lines were cultivated in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco/Invitrogen) with the same supplements as described for the standard 
cell culture medium. Both cell lines were passaged twice a week by trypsinization (0.05% Tryp-
sin/EDTA for 1–2 minutes). Fibroblast cell lines were split at around 80% confluency approxi-
mately 24-fold. BHK-21 cells were grown until reaching 100% confluency and expanded 10-fold. 
  
In general, cells were pelleted by centrifugation for 10 minutes at 300 x g and at room tempera-
ture. 
 
Cell count was determined using a Neubauer counting chamber. Before counting, cell suspen-
sions were diluted 2–10-fold with a 0.5% trypan blue solution in order to visualize dead cells. 
Negatively charged trypan blue cannot be absorbed by viable cells with intact cell membranes. 
By contrast, dead cells with damaged cell membranes do not exclude this dye and appear in 
blue color under the microscope.  
 
3.3.2 Cryopreservation of cells 
For long-term preservation, eukaryotic cells were stored in the gas phase over liquid nitrogen in 
presence of dimethyl sulfoxide (DMSO). The cells were pelleted by centrifugation and resus-
pended in cold (4°C) RPMI supplemented with 50% FCS and 10% DMSO. The cell suspensions 
were aliquoted in 2 mL cryovials, which were pre-cooled on ice. To follow a gentle freezing 
procedure, the cryovials with cells were first cooled on ice for up to 20 minutes, then placed into 
styrofoam boxes and stored at -80°C for a few days, and finally transferred to liquid nitrogen 
tank. 
 
Frozen cells were thawed as fast as possible by adding pre-warmed (37°C) cell culture medium 
to the cryovial. The DMSO-containing cell suspensions were diluted in at least 20 mL medium, 
pelleted by centrifugation and the supernatant was removed completely. The cell pellets were 
resuspended in the respective medium and taken into culture. If required, selection pressure 
was applied by supplementing the cell culture medium with antibiotics no earlier than two days 
after thawing. 
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3.3.3 Transfection of cells with plasmid DNA 
For production of mini-EBV virions (section 3.5.1), EBV-packaging cell line TR-2/293 was trans-
fected with mini-EBV plasmid and helper plasmids by using polyethyleneimine (PEI) as 
transfection agent. This cationic polymer forms complexes with the DNA, which bind to the 
negatively charged cell membrane and are incorporated into the cell by endocytosis (Vancha et 
al., 2004). For a 15-cm cell culture dish of subconfluent TR-2/293 cells, 120 µL PEI (1 mg/mL; 
MW≈25 000 g/mol; Aldrich) were used to transfect a total amount of 20 µg of endotoxin-free 
plasmid DNA (prepared with Endofree® Plasmid Maxi Kit). Plasmid DNA and PEI were sepa-
rately mixed with 4 mL serum-free OptiMEM medium each and incubated for 5 minutes at room 
temperature. Then, DNA and PEI mixtures were combined and incubated for 20 minutes at 
room temperature to enable DNA/PEI complex formation. Old medium was removed from the 
cells and the DNA-PEI transfection mixture was added to the cells together with 12 mL fresh 
serum-free OptiMEM so that the cells were covered by 20 mL medium in total. After 5 hours of 
incubation, medium containing the transfection mixture was replaced by fresh RPMI supple-
mented with 10% FCS. 
  
Fibroblast cell lines were transfected with the plasmids encoding recombinant HLA molecules or 
HLA chimeras by electroporation using the Amaxa Cell Line Nucleofector Kit R and Nu-
cleofector I Device (program V-01) according to the manufacturer's instructions for WI-38 cells 
(Lonza). The enhanced green fluorescent protein (EGFP) expressing plasmid pEGFP-C1 (BD 
Biosciences Clontech) was used as a transfection control and demonstrated transfection rates 
of 60–70%. After 24 hours, transfectants were kept under selection pressure by adding G-418 
(200 µg/mL). On day 4 post transfection fibroblasts were infected with MVA or HCMV and used 
as target cells for T cell effector assays 24 or 48 hours post infection (hpi), respectively. 
 
3.3.4 Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) of healthy adult donors were purified from whole 
venous blood samples of standard blood donations or from buffy coats by density gradient 
centrifugation using Ficoll/Hypaque (Biochrom). Blood samples were transferred to 50 mL Fal-
con tubes (≤ 30 mL/tube) and diluted with PBS to 40 mL/tube. Thereby, the pre-concentrated 
buffy coats had to be mixed with PBS in a ratio of at least 1:1. The diluted blood was carefully 
underlayered with 10 mL room-temperature Ficoll/Hypaque. The Falcon tubes were centrifuged 
at 2000 rpm (centrifuge "Multifuge 3 L-R") and room temperature for 25 minutes and with lowest 
breaking rate for deceleration. During centrifugation, Ficoll separates the whole blood compo-
nents according to their density: erythrocytes which are more dense are able to pass the Ficoll 
underlayer and sediment at the bottom of the tube, whereas less dense PBMCs are trapped 
immediately above, at the interphase between Ficoll and diluted plasma. Using a 10 mL pipette, 
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PBMCs were carefully collected without aspirating any erythrocytes and transferred to a clean 
50 mL Falcon tube. PBMCs were washed 3–5 times with 50 mL PBS in order to remove remain-
ing Ficoll and to deplete thrombocytes. Freshly isolated PBMCs were either frozen or directly 
used for establishment of permanent B cell lines, T and NK cell cultures or monocyte-derived 
dendritic cells. 
 
For determination of total PBMC number, cells were diluted in Türk's solution (0.01% crystal 
violet, 1% acetic acid) and counted in a Neubauer counting chamber. Türk's solution is a hypo-
tonic acidic agent that lyses erythrocytes, which might still be present in the PBMC preparation 
but leaves white blood cells intact. The crystal violet dye stains cells in slight blue, thus facilitat-
ing the counting.  
 
An aliquot of the diluted plasma was collected for determination of the EBV and HCMV IgG 
serostatus of the blood donors (Max von Pettenkofer-Institute, München, Germany). 
 
3.3.5 Establishment of permanent B cell lines 
3.3.5.1 CD40-stimulated B cell lines 
Long-term EBV-free B cell cultures were established from PBMCs as described in Wiesner et 
al., 2008. Unseparated PBMCs were plated on irradiated CD40L-expressing murine fibroblasts 
(LL8) in flat-bottom 96-well plates. To consider varying proliferative capacity of B cells from 
different donors, individual microcultures with 10, 5, 2.5 and 1.25x 104 cells per (well in 200 µL 
medium and with 6 replicates per cell number were set up. Cells were cultivated in standard cell 
culture medium supplemented with rhuIL-4 (R&D Systems). Cyclosporin A (1 µg/mL, Novartis) 
was present for the first 4 weeks in order to inhibit T cell and NK cell growth. Cells were restimu-
lated every week by replating on fresh LL8 cells. Outgrowth of B cells became prominent after 
approximately 4 weeks and cells were expanded stepwise to 48-, 24- and 12-well plates. For 
long-term cultivation and freezing, a well-proliferating culture derived from the lowest initial 
PBMC number that had led to rubust outgrowth was chosen from each donor. These cultures 
were maintained in 12-well plates by weekly replating on irradiated (180 Gy) LL8 cells in the 
presence of 2 ng/mL rhuIL-4. 
  
In EBV carriers (>95% of the adult human population) one in about 100 000 B cells is latently 
infected with endogenous EBV (Miyashita et al., 1995). Therefore, established CD40-stimulated 
B cell lines were tested for the presence of wild-type EBV DNA (BXLF1 gene encoding gp85) by 
PCR as described before (section 3.2.2). The majority of cultures was negative for wild-type 
EBV. 
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3.3.5.2 EBV-transformed mini-lymphoblastoid cell lines 
Mini-lymphoblastoid cell lines (mLCLs) stably expressing pp65 or IE-1 protein and control 
mLCLs (without HCMV antigen) were generated as described by Moosmann et al. (2002). 
PBMCs were infected with B cell-transforming mini-Epstein-Barr virus (mini-EBV) carrying a 
mini-EBV genome with or without the relevant HCMV transgene under control of the SV40 pro-
moter (Moosmann et al., 2002). In a well of a flat-bottom 96-well plate, 4x 105 PBMCs in 100 µL 
medium per well were coincubated overnight with 100 µL/well of mini-EBV-containing medium. 
As a negative control and to detect transformation by endogenous EBV, 100 µL medium was 
used instead of mini-EBV supernatant. The next day, half of the supernatant was replaced by 
fresh medium. The cells were cultivated in standard cell culture medium and fed every week. 
Cyclosporin A (1 µg/mL, Novartis) was present for the first 4 weeks. Outgrowing mLCLs were 
visible after approximately 3 weeks and expanded stepwise from 96-well plates to cell culture 
flasks. 
 
Established mLCLs were tested for the presence of a mini-EBV-specific sequence (encoding 
chloramphenicol acetyltransferase) and the absence of a wild-type EBV-specific sequence 
(BXLF1 gene encoding gp85) by PCR as described before (section 3.2.2). 
 
3.3.6 Establishment and maintenance of T cell cultures 
3.3.6.1 Generation of HCMV-specific polyclonal T cell lines 
Polyclonal T cell cultures specific for pp65 or IE-1 antigen of HCMV were established from 
freshly isolated or cryopreserved PBMCs of HCMV-seropositive donors. IE-1- or pp65-specific T 
cells were reactivated and expanded in vitro by repeated restimulation of PBMCs with irradiated 
(50 Gy) autologous mLCLs expressing the appropriate antigen. Endogenously processed pep-
tides of the HCMV antigens are loaded on MHC class I and II molecules expressed by the 
mLCLs and presented to T cells. By using autologous mLCLs, the whole repertoire of pp65- or 
IE-1-specific memory T cells existing in one donor can theoretically be reactivated and enriched 
without stimulating alloreactive T cell specificities. 
 
Cocultivations of PBMCs/T cells and mLCLs were performed in 12-well plates (3 mL/well) in 
standard cell culture medium. On day 0, 2x 106 PBMC/mL were stimulated with 5x 104 irradiated 
mLCLs/mL. On day 10 and weekly thereafter, cells were collected, pelleted, resuspended in 
fresh medium with irradiated mLCLs and distributed to new 12-well plates. The following cell 
concentrations were used:  
  
day 10: 2x 106 T cells/mL and 5x 105 mLCLs/mL; 
day 17 and later: 1x 106 T cells/mL and 2.5 x105 mLCLs/mL.  
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From day 17, medium was supplemented with 50-100 U/mL rhuIL-2 („Proleukin S“, Novartis). 
Between restimulations, the T cell cultures were fed with fresh medium as necessary and ex-
panded in case of strong proliferation. The cell cultures were stimulated over approximately 50 
days. During this period, the proportion of CD4+ and CD8+ T cells was followed by FACS stain-
ing.  
 
As a rapid alternative to mLCL-stimulation, individual T cell specificities can also be reactivated 
and expanded by peptide-stimulation. Thereby, PBMCs are loaded with the antigenic peptide 
and can function as antigen-presenting cells for T cells. This method was used for detection of 
low-frequency CD4+ EFF-specific T cells. PBMCs (2x 107) in 4 mL standard cell culture medium 
were loaded with 5 µg/mL EFF peptide for 2 hours at 37°C. Cells were washed 3 times with 
PBS, mixed with 2x 107 unlabeled PBMCs and adjusted to a concentration of 2.5x 106 cells/mL. 
PBMCs were incubated with EFF-peptide in standard cell culture medium supplemented with 10 
U/mL rhuIL-2 for 5–6 days. Then, IL-2 concentration was raised to 25 U/mL and cells were kept 
until day 11–14.  
 
3.3.6.2 Generation of HCMV-specific monoclonal T cell lines 
T cell clones were obtained by limiting dilution from mLCL-stimulated polyclonal T cell lines or 
directly from PBMCs after peptide-stimulation and IFN-γ secretion assay (Miltenyi Biotec). T 
cells were seeded into round-bottom 96-well plates (200 µL/well) with 0.7 or 2.5 cells/well, so 
that outgrowing T cell clones should result from one single cell expressing one specific T cell 
receptor. Proliferation of antigen-specific T cells was stimulated with a feeder mixture containing 
standard cell culture medium supplemented with 1000 U/mL rhuIL-2, 1× 105/mL irradiated (50 
Gy) HLA-matched pp65- or IE-1-expressing mLCLs and 1.5× 106 /mL of a mixture of irradiated 
(50 Gy) allogeneic PBMCs from at least three different donors. Outgrowing T cell clones were 
visible after 3–4 weeks and expanded in round-bottom 96-well plates by restimulating every 2 
weeks under the same conditions. T cell clones were screened by IFN-γ ELISA for antigen and 
peptide specificity. Thereby, the target cells were autologous mLCLs expressing the appropriate 
HCMV antigen, pp65 or IE-1, autologous ctrl-mLCLs (without antigen) and autologous CD40-
stimulated B cells loaded with a potential target peptide or unloaded. T cell clones identified to 
be antigen- or peptide-specific were expanded and aliquots of well-growing clones were cryo-
preserved.  
  
3.3.7 Generation of monocyte-derived dendritic cells 
The recognition of IE-1 by CD4+ T cells was analyzed in context of an HCMV infection of mono-
cyte-derived dendritic cells (DCs). DCs were generated from whole blood of HLA-matched 
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healthy donors using a modified published protocol (Jonuleit et al., 2000). Freshly isolated 
PBMCs were incubated in standard cell culture medium in 80 cm2 flasks (5x 107 cells in 15 
mL/flask) for 2 hours in order to adhere the monocytes to the plastic surface. Then, supernatant 
containing the remaining PBMCs was discarded and residual non-adherent cells were rinsed off 
the plates with a 10 mL plastic pipette in two washing steps using prewarmed (37°C) RPMI + 
P/S/Na-Se (without FCS). Immature DCs were generated by cultivating the monocytes for 3 
days in RPMI + 2% human serum + P/S/Na-Se (15 mL/flask) supplemented with rhuGM-CSF 
(Genzyme, 100 ng/mL) and rhuIL-4 (R&D Systems, 20 ng/mL). For maturation of DCs, cells 
were stimulated for another 24 hours with rhuTNF-α (Biochrom, 10 ng/mL), rhuIL-1β (Biochrom, 
10 ng/mL), PGE2 (Sigma, 1 µg/mL) and rhuIL-6 (Biochrom, 15 ng/mL), which were all directly 
added into the old medium. DCs were infected with MVA for 24 hours or with HCMV for 48 
hours and used as targets in CD4+ T cell effector assays (IFN-γ ELISA, calcein-release assay). 
 
3.3.8 Isolation and cultivation of primary NK cells 
The inhibitory effect of HLA-C*0702 on NK cell lysis of HCMV-infected fibroblasts was investi-
gated with NK cells expressing the HLA-C*0702-specific killer-cell immunoglobulin-like (KIR) 
receptor KIR2DL3. KIR2DL3-positive NK cells were enriched from PBMCs of donor AJU by 
immunomagnetic separation (section 3.4.1). KIR2DL3-enriched NK cells were expanded in bulk 
as a polyclonal NK cell line and in parallel under conditions of limiting dilution in order to obtain 
NK cell clones. In both cases, NK cells were cultivated in round-bottom 96-well plates (200 
µL/well) in standard cell culture medium supplemented with 500 U/mL rhuIL-2 (Novartis) and 
restimulated every two weeks with a feeder mixture consisting of 2× 105/mL irradiated (50 Gy) 
allogeneic mLCLs and 1× 106/mL irradiated (50 Gy) allogeneic PBMCs from at least three differ-
ent donors. NK cell lines were analyzed for expression of NK cell inhibitory receptors (KIRs and 
NKG2A) by flow cytometry and analyzed for cytotoxicity against target cells by calcein-release 
assay.  
 
3.3.9 Cytotoxicity analysis 
The cytotoxicity of CD4+ or CD8+ T cells and NK cells against target cells was measured by 
calcein-release assay. Target cells were mLCLs, CD40-stimulated B cells, HCMV-infected or 
not infected fibroblasts, HCMV-infected or not infected mo-DCs. The target cells (1–2× 106 per 
50 mL Falcon tube) were labeled with 5 µg/mL calcein acetoxymethylester (AM) (Invitrogen) in 1 
mL medium for 30 minutes at 37°C. For peptide-loading of fibroblasts and mo-DCs as positive 
controls, cells (in 1 mL medium) were incubated with peptide (5 µg/mL) for 1 hour at 37°C, add-
ing calcein for the last 30 minutes. After washing three times with PBS, 5000 targets/well were 
coincubated with effector cells in V-bottom 96-well plates (200 µL/well) using effector/target-ra-
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tios between 2/1 and 8/1. For each type of target, spontaneous release (no effector cells added, 
0% lysis) and maximal release (0.5% of Triton-X100 added, 100% lysis) was determined. After 
3.5 hours of incubation at 37°C and 5% CO2, 150 µL/well of supernatant were transferred to a 
flat-bottom 96-well plate, and fluorescence intensity at 485/535 nm (excitation/emission) was 
measured in a Wallac Victor counter (Perkin-Elmer). 
 
3.3.10 Regression assay 
Cytotoxic effects of IE-1-specific CD4+ T cell clones were also analyzed by regression assay. 
Cocultivation of mLCLs with T cells may result in a regression of mLCL growth compared to the 
cultivation of mLCLs without T cells. This "outgrowth inhibition" can be due to direct cytolytic T 
cell activity or be mediated by released cytokines. To test whether the cytotoxic effects are 
dependent on the presence of the target antigen or not, outgrowth of ctrl- and IE-1-mLCLs was 
compared in the assay. Cocultivations of mLCLs and T cells were performed in round-bottom 
96-well plates (200 µL/well, standard cell culture medium) with a constant number of 10 000 T 
cells/well. HLA-matched mLCLs were seeded at doubling dilutions ranging from 10 000 to 4.9 
cells per well with 10 replicates per dilution. Cultures of diluted mLCLs without T cells were set 
up in parallel to determine unimpaired outgrowth. As additional control, T cells were incubated 
without mLCLs. The cells were fed weekly with fresh standard cell culture medium and moni-
tored for mLCL outgrowth using an inverted microscope. After 4–6 weeks, wells with viable, 
proliferating mLCLs (mLCL "outgrowth") were detected by MTT assay. 
 
3.3.11 MTT assay 
Mammalian cell viability or proliferation was detected with a colorimetric assay using the 
tetrazolium salt MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Mosmann, 
1983). In the mitochondria of living cells, yellow MTT is reduced by dehydrogenase enzymes to 
insoluble purple formazan. After solubilization of formazan into a colored solution, absorbance 
can be quantified in a spectrophotometer.  
The MTT assay was used at the end of a regression assay to determine wells with cell "out-
growth". Cells were resuspended in the round-bottom 96-well plates used for the regression 
assay and 50 µL/well of the cell suspensions were transferred to flat-bottom 96-well plates. An 
MTT stock solution (5 mg/mL, thiazolyl blue, Sigma-Aldrich) was prepared in PBS, filtrated us-
ing a 0.22 µm filter and stored at 4°C. Prior to use, the MTT stock solution was diluted 5-fold in 
standard cell culture medium and 50 µL/well were added to the cell suspensions. The plates 
were incubated at 37°C for 2–4 hours to allow reduction of MTT to the formazan product. Then, 
100 µL/well of 10% SDS (in PBS, Carl Roth) were added and the plates were incubated 
overnight at room temperature in order to dissolve the insoluble formazan into a purple colored 
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solution. The absorbance of the solution was quantified at 595 nm using a spectrophotometer. 
Wells were scored positive (= viable cells/outgrowth) when the absorption value was >0.2.  
 
3.4 Immunological methods 
3.4.1 Immunomagnetic separation of cell populations 
Subpopulations of PBMCs like CD4+ T cells, KIR2DL3+ NK cells and peptide-specific T cells 
were isolated by magnetic separation using the MACS (magnetic cell sorting)-technology from 
Miltenyi Biotec (Bergisch-Gladbach). This method is based on paramagnetic particles 
("MicroBeads", 50 nm), which are conjugated to highly specific antibodies directed against cell 
surface antigens. MicroBeads are non-toxic and biodegradable so that they do not have to be 
removed for any following experiment. Cell subpopulations coupled to MicroBeads were 
manually separated by using MACS columns placed on a magnetic separator. The magnetic 
field retains cells labeled with the paramagnetic beads in the column while allowing unlabeled 
cells to pass through. After removing the columns from the magnetic field, MicroBead-coupled 
cells were eluted and collected separately. The purity of the isolated cell populations was 
checked by flow cytometry. In all separation procedures, PBS + 2% FCS was used as washing 
buffer and for elution of cells from the columns. 
 
CD4+ T cells were positively isolated from polyclonal IE-1-mLCL-stimulated T cell lines using 
CD4 MicroBeads according to the manufacturer's instructions. Approximately 1–2x 107 polyclo-
nal T cells were used for CD4+ T cell isolation with MS columns. CD4+ T cell-enriched and 
CD4+ T cell-depleted fractions were collected separately and analyzed for CD4+ T cell content 
by flow cytometry. Isolated CD4+ T cells were immediately used for generation of T cell clones 
or in IFN-γ ELISpot assays. 
 
Enrichment of KIR2DL3+ NK cells from freshly isolated PBMCs of donor AJU was performed by 
a two-step MACS separation procedure according to the manufacturer's instructions. First, 
CD3+ cells (T cells, NKT cells) were depleted from PBMCs (~1x 108) using CD3 MicroBeads 
and LD columns. Then, remaining PBMCs (~1x 107) were labeled with PE-conjugated anti-
KIR2DL2/3 antibody (30 µL for 1x 107 cells; clone CH-L, BD Pharmingen) and PE MicroBeads. 
Labeled cells were separated using MS columns. After each separation step, resulting cell frac-
tions were analyzed for expression of CD56, KIRs and NKG2A. Freshly isolated cells were 
taken into culture as described before (section 3.3.8).  
  
CD8+ peptide-specific T cells were isolated after peptide stimulation and IFN-γ secretion assay 
directly from PBMCs of donors with initial high numbers of memory T cells specific for that 
particular peptide. Freshly isolated CD4+ T cell-depleted (CD4 MicroBeads) PBMCs were di-
luted to 2.5x 106/mL in standard cell culture medium supplemented with 50 U/mL rhuIL-2 and 
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stimulated with 0.5 µg/mL peptide for 12 hours at 37°C. Then, peptide-specific IFN-γ secreting 
cells were isolated using the IFN-γ secretion assay according to the manufacturer's instructions. 
IFN-γ secreting cells were magnetically labeled with a combination of an IFN-γ Catch Reagent, 
a PE-conjugated IFN-γ detection antibody, and anti-PE MicroBeads. Labeled cells were en-
riched with an MS column. The cells were analyzed for CD3, CD4 and CD8 expression and 
IFN-γ secretion by flow cytometry immediately before and after separation. The isolated cells 
were directly used for generation of T cell clones by limiting dilution. In this way, CRV-specific T 
cells clones were established from PBMCs of donor AJJ. 
 
3.4.2 Phenotypic analysis of cells by flow cytometry 
3.4.2.1 Staining of cell surface antigens 
Cells were stained for expression of surface antigens with specific antibodies conjugated to 
FITC, PE, PE-Cy5 or APC. All centrifugation steps were carried out in a table centrifuge at 1000 
x g, 4°C and 4 minutes. Pre-cooled (4°C) PBS + 2% FCS was used as washing buffer. The 
following cell numbers were stained in a 1.5 mL reaction tube (Eppendorf): PBMCs/3x 105, 
polyclonal T cells/1–3x 105, NK cells/1–3x 105, fibroblasts/5x 104. Before staining, cells were 
pelleted and remaining cell culture medium was washed away. The cells were resuspended in 
30 µL PBS + 2% FCS containing the appropriate amounts of antibodies according to the 
manufacturer's recommendations and incubated for 20 minutes on ice. After staining, cells were 
washed and either resuspended in PBS + 2% FCS for direct analysis on the flow cytometer or 
fixed with 1% formaldehyde (Carl Roth) and stored at 4°C for up to one week. 
 
Polyclonal T cell lines were analyzed for their CD4+ and CD8+ T cell content using CD3-PE-
Cy5 (clone HIT3a, BioLegend), CD4-FITC (clone RPA-T4, BD Biosciences) and CD8α-APC 
(clone RPA-T8, BioLegend) antibodies. 
  
For analysis of relative MHC class I expression levels on fibroblasts infected with wild-type 
HCMV or immunoevasion defective HCMV strains, HLA-ABC-PE (clone W6/32, BioLegend), 
HLA-A2-PE (clone BB7.2, BioLegend) and HLA-B7-PE (clone BB7.1, Millipore) antibodies and 
corresponding PE-labeled isotype controls (IgG2a, IgG2b and IgG1, all from BioLegend) were 
used. Specific mean fluorescence intensities (MFIs) were calculated by subtracting the MFIs of 
the isotype controls from the MFIs of the specific stainings. To calculate the relative MHC class I 
expression levels, specific MFI values obtained for CMV-wt or mutant CMV-infected cells (moi = 
5) were standardized to the specific MFI of CMV-∆all (US2/3/6/11 deleted) infected cells (moi = 
5) which was set to 100% MHC class I surface expression. 
 
The following antibodies were used for characterization of polyclonal and clonal NK cells: CD56-
PE-Cy5 (clone HCD56, BioLegend), KIR2DL1-FITC (clone HP-3E4, BD Pharmingen), 
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KIR2DL2/3-PE (clone CH-L, BD Pharmingen), KIR3DL1-FITC (clone DX9, BioLegend) and 
NKG2A-APC (clone 131411, Beckman Coulter).  
 
3.4.2.2 Peptide/HLA class I multimer staining 
Antigen-specific CD8+ T cell populations were quantified ex vivo using the MHC class I multi-
mer technology. This method uses the natural ligand of the TCR, the MHC class I/peptide com-
plex, to stain for epitope-specific T cells. As the association of TCR and MHC/peptide is 
characterized by a high dissociation rate, the avidity of this interaction is increased by 
multimerization of MHC/peptide complexes to tetramers, pentamers or even higher multimers. 
 
For quantification of TPR-specific T cells, 5x 105 PBMCs were incubated with 1 µL HLA-
B*0702/TPR Pentamer (Proimmune, Oxford, UK) in a total volume of 40 µL PBS + 2% FCS for 
10 minutes at room temperature. After washing, cells were counterstained with Pentamer-bind-
ing Pro5 Fluorotag R-PE (Proimmune) and CD8α-APC (BioLegend) for 20 minutes on ice. 
Then, cells were washed and either resuspended in PBS + 2% FCS for direct analysis on the 
flow cytometer or fixed with 1% formaldehyde (Carl Roth) and stored at 4°C for up to one week. 
 
CRV-specific CD8+ T cells were stained using an MHC-streptagII-StrepTactin multimer reagent 
(Streptamer) as first described in (Knabel et al., 2002) as a "reversible" T cell staining proce-
dure. When using conventional MHC multimer reagents, the functional analysis of MHC multi-
mer-stained cells is hampered by the persistence of TCR-MHC interactions and subsequently 
induced signaling events. Streptamers can be disassembled into MHC monomers by addition of 
Biotin. Since MHC monomers do not stably bind to TCRs, this results in a rapid loss of the stain-
ing reagent. CRV/HLA-C*0702 monomers were generated within a collaboration with the group 
of Michael Neuenhahn/Dirk Busch (Institute for Medical Microbiology, Immunology and Hygiene, 
Technische Universität München) and kindly provided for staining of CRV-specific CD8+ T cells. 
For multimerization of streptamer complexes, soluble CRV/HLA-C*0702-streptagII monomeric 
complexes were incubated with PE-labeled StrepTactin for 45 minutes at molar ratios of MHC 
molecule/StrepTactin molecule = 1/1. Then, 5x 105 PBMCs were incubated with an aliquot of 
the assembled streptamer reagent containing 2.5 µg CRV/HLA-C*0702 monomer in a total vol-
ume of 30 µL PBS + 2% FCS for 30 minutes on ice. Cells were counterstained by directly add-
ing CD8α-APC (BioLegend) to the streptamer staining mixture and incubating for 20 minutes on 
ice. After washing, cells were either resuspended in PBS + 2% FCS for direct analysis on the 
flow cytometer or fixed with 1% formaldehyde (Carl Roth) and stored at 4°C for up to one week. 
  
Cells were analyzed on a BD Biosciences FACSCalibur flow cytometer. Data analysis was per-
formed using the FlowJo 9.4.11 software (Tree Star). Viable lymphocytes were gated according 
to their characteristic position in the two-dimensional forward/side scatter (FSC/SSC) dot plot. 
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The axes of the dot plot diagrams shown in this work are scaled logarithmic, comprising 100 to 
104 arbitrary units of the mean fluorescence intensity (MFI).  
 
3.4.3 HLA class I- and KIR-blocking studies with NK cells 
To evaluate the role of HLA-C*0702 in NK cell-mediated killing of infected cells, the interaction 
of HLA class I molecules on target cells and KIR receptors on NK cells was blocked by specific 
antibodies. MHC class I molecules were masked at the surface of target cells using purified 
HLA-ABC- or HLA-A2-specific antibodies (W6/32 or BB7.2, respectively; BioLegend), which 
were added at 60 µg/mL to the target cells for 1 hour at 37°C prior to addition of effector cells. 
Similarly, to inhibit KIR2DL2/3 interaction with its MHC class I ligands, NK cells were preincu-
bated with an antibody blocking KIR2DL2/3 (clone DX27, BioLegend) (Valiante et al., 1997) at 
60 µg/mL for 1 hour at 37°C prior to addition of target cells. Purified Mouse IgG2a and IgG2b 
(BioLegend) were used as isotype controls. 
 
3.4.4 ELISA for quantification of cytokine-release 
The release of effector cytokines like interferon γ (IFN-γ), granulocyte-macrophage colony-
stimulating factor (GM-CSF), tumor necrosis factor (TNF)-α, IL-2, IL-4, or IL-10 is a marker for 
antigen- or peptide-specific activation of CD4+ and CD8+ T cells. In this work, polyclonal T cell 
lines and CD4+ or CD8+ T cell clones were stimulated for cytokine secretion by cocultivation 
with target cells that presented specific peptides on MHC class I or II molecules. Above men-
tioned cytokines were quantified by Enzyme-Linked Immunosorbent Assay (ELISA) using 
ELISA kits from the manufacturer Mabtech (Nacka Strand, Sweden). All ELISA assays per-
formed in this work were "sandwich" ELISAs and based on alkaline phosphatase (ALP) for 
colorimetric detection of the cytokine concentrations. 
 
Effector cells (1–4x 104/well, as indicated in the figure legends) were cocultivated overnight (16–
18 hours) with target cells (1–5× 104/well, as indicated in the figure legends) in 200 µL/well of a 
V-bottom 96-well plate at 37°C and 5% CO2. Then supernatants were harvested, and an ELISA 
was performed according to the manufacturer’s guidelines (Mabtech, Nacka, Sweden). ELISA 
antibodies were diluted in sterile PBS without Mg2+ and added to the plates in 50 µL/well. Un-
less otherwise noted, all incubation steps were carried out at room temperature. For washing, 
plates were rinsed 4 times with PBS + 0.05% Tween. ELISA plates (Immunoplates MaxiSorp® 
96-w flat-bottom) were coated with a monoclonal "capture" antibody (2 µg/mL) specific for the 
appropriate cytokine by overnight incubation at 4°C. The next day, unbound antibody was 
washed away and nonspecific binding sites on the plates were blocked by incubation with 
standard cell culture medium for 1 hour. Then, 50 µL of the cell supernatants were applied to 
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the plates and incubated for 2 hours to allow cytokine binding to the capture antibody. For 
quantification purposes, a cytokine standard was prepared and incubated in parallel on each 
plate. Then, plates were washed and incubated with a second cytokine-specific biotinylated 
antibody (1 µg/mL) for 1 hour. The antibody "sandwiches" were labeled for 1 hour with 
Streptavidin-ALP (diluted 1:1000), which binds to the second antibody via biotin. Immobilized 
cytokines were detected by applying 50 µL/well ALP substrate solution with para-nitrophenyl-
phosphate (p-NPP). The ALP substrate stock solution contained 50% diethanolamine and 5 
mg/mL p-NPP in sterile water (pH 9.5). Immediately before use, the stock solution was diluted 
5-fold in sterile water and the ALP cofactor Mg2+ was added as MgSO4 in a final concentration 
of 0.8 mM. ALP catalyzes the hydrolysis of colorless p-NPP to the yellow p-nitrophenol, which 
was detected with a spectrophotometer at 405 nm. 
 
3.4.5 ELISpot for quantification of IFN-γ-secreting cells 
Enzyme-Linked ImmunoSpot (ELISpot) assays were used to determine the frequency of pep-
tide-specific T cells in freshly isolated PBMCs and polyclonal T cell lines by detection of IFN-γ-
secretion at the single cell level. The assays were performed using the Human IFN-γ ELISpot 
Kit (ALP) from Mabtech (Nacka, Sweden) according to the manufacturer’s protocol. ELISpot 
antibodies were diluted in sterile PBS without Mg2+ and added to the plates in 50 µL/well. Un-
less otherwise noted, washing was performed by rinsing the plates 5 times with PBS + 0.05% 
Tween. As a first step, an IFN-γ-specific monoclonal antibody (15 µg/mL) was immobilized on 
the membrane of 96-well MultiScreen HTC Filter Plates (Millipore) by overnight incubation at 
4°C. The next day, plates were washed 5 times with PBS without Mg2+ and nonspecific binding 
sites were blocked with standard cell culture medium for 1 hour at room temperature. Then, the 
cells were added to the plates in 200 µL standard cell culture medium per well and incubated in 
presence of antigenic stimuli for 16–18 hours at 37°C to allow IFN-γ release and binding to the 
"capture" antibody. To detect peptide-specific T cells within PBMCs, 200 000 cells were distrib-
uted to each well and directly loaded with antigenic peptide. For characterization of polyclonal T 
cell lines, autologous CD40-stimulated B cells were loaded with antigenic peptides and coincu-
bated at 5x 104/well together with the T cells at 5000 or 10 000 cells/well (as indicated). TPA 
(12-O-tetradecanoylphorbol-13-acetate; 50 ng/mL) and ionomycin (0.5 µM), which both trigger 
strong T cell activation and IFN-γ secretion in an antigen-independent way, were added to-
gether to the PBMCs or T cells as positive control. The next day, cells were removed by wash-
ing and the plates were incubated with biotinylated anti-IFN-γ antibody (1 µg/mL) for 2 hours at 
room temperature. After another washing step, the antibody "sandwiches" were labeled for 1 
hour at room temperature with Streptavidin-ALP (diluted 1:1000). Immobilized cytokines were 
detected using the AP Conjugate Substrate Kit (Bio-Rad) according to the manufacturer's 
instructions. The AP Conjugate Substrate Kit contains 5-bromo-4-chloro-3'-indolylphosphate 
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(BCIP) and nitro-blue tetrazolium chloride (NBT). BCIP is hydrolyzed by the ALP leading to the 
reduction of NBT and the formation of purple insoluble precipitates which appear as spots on 
the membrane. Spots were visually counted after scanning. 
 
3.5 Virus-based methods 
3.5.1 Epstein-Barr virus 
Infectious virions carrying mini-EBV genomes were produced by transfection of mini-EBV DNA 
into the EBV-packaging cell line TR-2/293 which carries a non-packageable terminal repeat-
deleted EBV genome that fully supports the packaging of terminal repeat-carrying EBV con-
structs (Delecluse et al., 1999). TR-2/293 cells were grown in 15-cm dishes to semiconfluency 
and transfected with a mixture of mini-EBV plasmid and two additional plasmids coding for 
individual EBV-derived factors. Per 15-cm dish, 10 µg mini-EBV DNA, 5 µg plasmid p509 
(encoding the EBV lytic transactivator BZLF1) (Delecluse et al., 1999) and 5 µg plasmid p2670 
(encoding the viral glycoprotein BALF4/gp110) (Neuhierl et al., 2002) were transfected using 
120 µL PEI (described in 3.3.3). Virus-containing supernatant was harvested 3 days after 
transfection, freed from cellular debris by centrifugation and filtration (0.8 µm), and directly used 
for infection of PBMCs or stored at -80°C. 
 
3.5.2 Modified vaccinia virus Ankara 
Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia virus, which has 
lost its ability to replicate efficiently in primate cells. However, MVA provides endogenous 
expression of recombinant genes at very high levels even after infection of cells, which are non-
permissive for productive virus replication. 
  
MVA recombinants expressing pp65 or IE-1 or no HCMV antigen (Khan et al., 2005) were 
propagated on baby hamster kidney (BHK-21) cells. Semiconfluent BHK-21 cells were infected 
with MVAs at a multiplicity of infection (moi) of 0.1. Freshly thawed virus was vortexed briefly 
and directly added into the cell culture medium. The cells were harvested 2–3 days after infec-
tion when a widespread cytopathic effect was visible. To release virus from cells, stocks were 
subjected to three rounds of freeze-thaw/vortexing. Cell debris was removed by centrifugation 
and MVA stocks were aliquoted for storage at -80°C. Viral titers were determined by limiting 
dilution on BHK-21 cells seeded in flat-bottom 96-well plates. Wells displaying a cytopathic ef-
fect were visually scored one week after infection. The 50% infectious tissue culture dose 
(TCID50) was calculated by the Spearman-Kaerber approximation. Typical titers reached up to 
5x 108 TCID50/mL. Multiplicity of infection (moi) was defined as TCID50 units per cell. For antigen 
presentation assays, LCLs or fibroblasts were infected with MVAs at an moi of 10 for 24 hours. 
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3.5.3 Human cytomegalovirus 
Stocks of HCMV AD169 and immunoevasin deletion mutants were generated and maintained 
by virus passage on primary human fibroblasts. HCMV replicates lytically in fibroblast cell lines 
leading to the release of progeny virus and pseudovirions into the cell culture supernatant. 
 
For the preparation of high-titer HCMV stocks, semiconfluent MRC-5 cells were infected with 
virus at an moi of 0.1. After approximately 14–18 days, most cells displayed a cytopathic effect, 
and supernatants were harvested and cleared from cellular debris by 2 rounds of centrifugation 
for 10 minutes at 300 x g and room temperature. Virus stocks were aliquoted and stored at -
80°C. Virus titers were determined by infection of subconfluent MRC-5 cells in flat-bottom 96-
well plates at limiting dilution. Cytopathic effect was visually identified no earlier than two weeks 
after infection, when virus had spread over the whole well and the TCID50 was calculated. Typi-
cal virus titers were between 1x 106 and 1x 107 TCID50/mL. Again, moi was defined as TCID50 
units per cell.  
  
For studying T cell recognition or NK cell-mediated lysis of HCMV-infected fibroblasts in effector 
assays, fibroblasts were seeded in cell culture flasks (80 cm2, DMEM + 10% FCS + P/S/Na-Se, 
15 mL/flask), grown to 70–80% confluency, and infected with HCMV at an moi of 5 by directly 
adding the virus containing supernatant into the cell culture medium. For some experiments, 
fibroblasts were pretreated with 300 U/mL rhuIFN-γ (PAN Biotech) for 72 hours prior to infection 
in order to enhance basal level of MHC expression. For use as T and NK cell targets in the 
effector assays, infected fibroblasts were harvested by trypsinization at 24–96 hours post infec-
tion. 
 
HCMV immunoevasion of T cell recognition at the immediate-early (IE) phase of the viral 
replication cycle was analyzed by cultivating infected fibroblasts under conditions that allowed 
only expression of IE proteins according to a protocol from J. Hesse and B. Plachter (un-
published). MRC-5 fibroblasts were seeded in cell culture flasks (80 cm2, DMEM + 10% FCS + 
P/S/Na-Se, 12 mL/flask) and grown to 70–80% confluency. 1 hour prior to infection, an inhibitor 
of protein translation, cycloheximide (CHX, 250 µg/mL), was added to the cell culture medium in 
order to accumulate IE-expressed mRNAs. Next, fibroblasts were infected with HCMV at an moi 
of 5 for 1.5 hours in a total of 5 mL/flask of DMEM + 10% FCS + P/S/Na-Se supplemented with 
CHX (250 µg/mL). After 1.5 hours, medium was filled up to 12 mL again, thereby adjusting CHX 
concentration to retain 250 µg/mL. 8 hours post infection, CHX was removed by washing 2 
times with PBS and translation of mRNA was allowed for 13.5 hours. During this time, expres-
sion of early and late proteins was blocked by addition of the transcriptional inhibitor actinomy-
cin D (ActD, 10 µg/mL). Then, the infected fibroblasts were harvested by trypsinization, fixed 
with formaldehyde to prevent any further antigen processing, and subjected to T cell recognition 
in IFN-γ ELISA assays using 20 000 target cells and 40 000 T cells. 
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4 Results 
The observation that reconstitution of HCMV-specific T cell immunity and adoptive T cell trans-
fer in immunocompromised patients correlate with protection from HCMV disease revealed that 
antiviral T cell responses are the predominant mechanism of HCMV control (Jackson et al., 
2011). In healthy virus carriers, HCMV-specific T cell responses comprise approximately 10% of 
the CD4+ and CD8+ T cell memory compartments and are focused on an immunodominant 
subset of HCMV antigens, including the IE-1 protein (Khan et al., 2005; Sylwester et al., 2005). 
As a transcription activator, IE-1 is expressed among the first proteins in infected cells and func-
tiones in driving the lytic replication cycle of HCMV by inducing viral and cellular genes. More 
importantly, IE-1 expression initiates virus reactivation from latency (Sinclair and Sissons, 
2006). Consequently, IE-1-specific T cells and not T cells directed against late expressed struc-
tural proteins might be particularly efficient in controling HCMV reactivation and virus spread. 
For this reason, the IE-1 protein has to be considered as a preferable target for HCMV-specific 
immunotherapy including adoptive T cell transfer and vaccination. A basic prerequisite for the 
design of efficient immunotherapeutic strategies is the detailed knowledge about the structure of 
the IE-1-specific T cell repertoire. In the present work, both arms of the IE-1-specific T cell re-
sponse, CD4+ and CD8+ T cells, were characterized in detail. The main challenges were: 
definition of IE-1 T cell epitopes, identification of immunodominant T cell specificities and 
evaluation of T cell effector functions in context of an HCMV infection. 
 
4.1 Generation and analysis of IE-1-specific polyclonal T cell lines 
HCMV-specific memory T cells can be reactivated and expanded in vitro from peripheral blood 
mononuclear cells (PBMCs) of HCMV carriers by antigen-specific stimulation using the well-
established mini-lymphoblastoid cell line (mini-(m)LCL)-system. Mini-LCLs are permanent grow-
ing B cell lines carrying a mini-EBV vector that mediates growth transformation of B cells but 
does not support lytic EBV replication. Furthermore, mLCLs show a high expression of MHC 
class I and II molecules, as well as of costimulatory molecules (B7.1, B7.2, ICAM-1 and LFA-3) 
(Kilger et al., 1999; Moosmann et al., 2002). As mLCLs constitutively express EBV latent anti-
gens (e.g. EBNA2, EBNA3a, EBNA3c, LMP1, LMP2a) (Kempkes et al., 1995), which elicit good 
T cell responses in vivo, they can be used to efficiently reactivate and expand EBV-specific T 
cells from PBMCs of EBV-seropositive donors (Wallace et al., 1982). In the same way, mLCLs 
expressing a foreign antigen can be used to reactivate CD8+ and CD4+ foreign antigen-specific 
T cells, as previously reported for pp65 (Moosmann et al., 2002). In this work, mini-LCLs 
expressing IE-1 were used to reactivate and enrich IE-1-specific T cells from PBMCs of HCMV-
seropositive donors, thereby giving rise to polyclonal T cell lines. By using the autologous IE-1-
mLCL for the stimulation procedure, all IE-1-specific memory T cells that recognize peptides 
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presented by the combination of HLA allotypes present in one donor might theoretically be 
reactivated. In addition, autologous stimulation avoids the expansion of alloreactive T cell 
species. 
 
4.1.1 Generation of mini-lymphoblastoid cell lines 
Mini-LCLs were generated from different blood donors by coincubation of isolated PBMCs with 
mini-EBV-containing supernatant. After establishment of stably growing cell lines approximately 
8 weeks after infection, each mLCL was checked by PCR for the presence of a mini-EBV-spe-
cific sequence (chloramphenicol acetyltransferase, cam) (Fig. 4.1). In EBV-seropositive donors 
approximately one out of 100 000 B cells is latently infected with endogenous EBV (Miyashita et 
al., 1995). To verify that an established cell line is a pure culture of mini-EBV-transformed cells 
and not contaminated with cells transformed by endogenous wild-type EBV, each cell line was 
also PCR-tested for a wild-type EBV-specific sequence (viral glycoprotein gp85). All mLCLs 
analyzed were cam-positive. Only 1% of mLCLs tested contained wild-type EBV DNA. 
 
 
Fig. 4.1: PCR analysis of mini-EBV-infected B cell lines. Independent mLCLs (lines 2–15) were tested 
for the presence of a mini-EBV-specific sequence (cam) and the absence of a wild-type EBV-specific se-
quence (gp85) by PCR. B95.8-transformed B cells (LCLs) were used as a positive control for endoge-
nous wild-type EBV transformation (lines 1, 16); cam: product size = 294 bp; gp85: product size = 461 bp. 
 
Expression of foreign antigens including pp65 and IE-1 from mLCLs was verified in previous 
studies using intracellular staining and Western blot analysis (Moosmann et al., 2002; Wiesner, 
2005). Foreign antigen expression remained stable over the whole cultivation period, which was 
sometimes more than 6 months (Moosmann et al., 2002). In this work, IE-1 and pp65 expres-
sion by mLCLs was tested exemplarily by using well-characterized antigen-specific CD8+ T cell 
clones. Upon specific stimulation with an autologous or HLA-matched mLCL, a CD8+ T cell 
clone produces IFN-γ, which can then be detected by ELISA. IE-1 and pp65 expression by 
HLA-A*0201-positive mLCLs was verified using autologous T cell clones specific for HLA-
A*0201-presented peptides, the VLE peptide in IE-1 (Khan et al., 2002) and the NLV peptide in 
pp65 (Wills et al., 1996; Diamond et al., 1997) (Fig. 4.2). All mLCLs tested expressed the 
respective HCMV antigen encoded by the mini-EBV vector used for B cell transformation. Mini-
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LCLs which have shown to be mini-EBV-positive and wild-type EBV-free and expressed HCMV 
antigens were used for the generation of polyclonal T cell lines. 
 
      
Fig. 4.2: Verification of IE-1 and pp65 expression by mLCLs using antigen-specific CD8+ T cell 
clones in an IFN-γ ELISA assay. A: IE-1-specific T cell clone ALTM#106 VLE. B: pp65-specific T cell 
clone ALTP#53 NLV. For each T cell clone, 20 000 T cells per well were incubated with 50 000 autolo-
gous target cells per well for 16–18 hours. Antigen-specific IFN-γ secretion was measured by ELISA. 
CD40-stimulated B cells pulsed with the target peptides of the T cell clones were used as positive 
controls. Ctrl-mLCLs expressing no foreign antigen and CD40-stimulated B cells without peptide were 
used as negative controls. Means and standard deviations of duplicates are shown. 
 
4.1.2 Generation of polyclonal T cell lines by mLCL-stimulation 
Twelve HCMV-seropositive donors covering a broad range of HLA types (Table 2.1) were cho-
sen. IE-1-specific polyclonal T cell lines were established from these donors by stimulation of 
PBMCs with autologous IE-1-expressing mLCLs according to a previously described protocol 
(Moosmann et al., 2002). In addition, ctrl-mLCL-stimulated polyclonal T cell lines were gener-
ated from each donor as negative controls. Polyclonal T cells were cultivated over a period of 
43–54 days by repeated stimulation with irradiated mLCLs on d0, d10 and weekly thereafter. 
Only the ctrl-mLCL-stimulated T cell line of donor F65 could not be maintained, due to a 
contamination of the mLCL. To follow the progress of relative T cell numbers with each round of 
stimulation, the T cell numbers counted during the restimulation procedure were set in relation 
to the number of initially used PBMCs (Fig. 4.3). During the first 3 rounds of stimulation, the 
relative T cell numbers of most T cell lines, ctrl- and IE-1-mLCL-stimulated, declined or did not 
change much. This might be explained by the fact that PBMCs also contain other cells than T 
cells, for example B cells, NK cells and monocytes, which die during the first weeks of cultiva-
tion due to a lack of specific stimulation. For the same reason, T cells, which are not stimulated 
by mLCL-presented peptides, are eliminated from the cultures. By contrast, T cells specific for 
EBV latent antigen- or HCMV IE-1-derived peptides presented by the mLCLs should be able to 
proliferate in response to antigen-specific stimulation. However, as these T cells comprise only 
few percent of total PBMCs it takes around 3 rounds of restimulation (17 days) until proliferation 
of antigen-specific T cells results in increase of relative T cell numbers. As most non-specific T 
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cells should be dead at that time due to lack of a stimulation signal, low-dose IL-2 can be added 
to the cultures to enhance T cell proliferation in an antigen-independent way. After the third 
restimulation, the relative T cell numbers of most polyclonal T cell lines increased constantly, 
indicating that there were EBV- or IE-1-specific T cells in the PBMCs of the donors. 
 
 
 
Fig. 4.3: Proliferation curves of polyclonal T cell lines stimulated with ctrl-mLCL (A) or IE-1-mLCL 
(B). Polyclonal T cell lines were established from PBMCs of 12 HCMV-seropositive donors by repeated 
stimulation with irradiated mLCLs on d0 (1st stimulation), d10 (2nd stimulation) and weekly thereafter (7 
stimulations in total). T cell numbers were counted during each restimulation procedure and were set in 
relation to the number of initially used PBMCs. The ctrl-mLCL-stimulated T cell line of donor F65 could 
not be maintained and is therefore not shown in A. 
 
 
The mLCL-procedure is reported to work nicely for the expansion of pp65-specific T cells 
(Moosmann et al., 2002; Wiesner et al., 2005). Therefore, a pp65-mLCL-stimulated T cell line 
was established in parallel from one donor, ALT, and used for comparative analysis (Fig. 4.4). 
Ctrl-, IE-1- and pp65-stimulated T cell cultures of donor ALT show similar proliferative behavior 
with an initial decline in relative T cell numbers followed by a constant increase. However, com-
pared to IE-1- and pp65-stimulated cell lines, proliferation of the ctrl-mLCL-stimulated culture is 
slower which is probably due to the lack of stimulation of HCMV-specific T cells.   
 
 
Fig. 4.4: Proliferation curves of polyclonal T cell 
lines of donor ALT. PBMCs of donor ALT were 
stimulated in parallel with irradiated ctrl-, IE-1- or pp65-
mLCLs on d0 (1st stimulation), d10 (2nd stimulation) 
and weekly thereafter (7 stimulations in total). T cell 
numbers were counted during each restimulation 
procedure and were set in relation to the number of 
initially used PBMCs. 
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4.1.3 Characterization of polyclonal T cell lines 
The polyclonal T cell lines were analyzed after 6–7 rounds of restimulation (43–54 days) for 
expression of the cell surface molecules CD8 and CD4 by flow cytometry (Fig. 4.5). With excep-
tion of the T cell lines from donor AES, all T cell cultures were dominated by CD8+ T cells (aver-
age 90.0%; average CD4+ T cells 6.1%; AES: 30.7% CD8+, 64.3% CD4+). AES was the only 
donor known to be EBV-seronegative; it is not clear whether this is causally connected to the 
predominance of CD4+ T cells in this donor's cell line (EBV-seropositive: ALT, AJJ, ARZ, AJU, 
F46, F60, F61, F64; EBV serostatus not known: F59, F63, F65). When comparing ctrl- and IE-1-
mLCL-stimulated cell lines from the same donor, the CD4+ T cell fraction tended to be higher in 
the ctrl-mLCL-stimulated cell lines (average ctrl cell lines: 9.3 %; average IE-1-stimulated cell 
lines: 3.0%). One possible explanation could be that the relatively high number of IE-1-specific 
CD8+ T cells in PBMCs led to their dominance in the stimulated T cell lines; in contrast, there 
are few IE-1-specific CD4+ T cells in the peripheral blood of the donors.   
 
 
 
Fig. 4.5: Expression of the cell surface molecules CD8 and CD4 by the polyclonal T cell lines. IE-1-
mLCL- and ctrl-mLCL-stimulated polyclonal T cell lines of 12 donors were analyzed for CD8 and CD4 
surface expression by flow cytometry. FACS dot plots are shown for the ctrl-mLCL-stimulated (upper 
panel) and the IE-1-mLCL-stimulated (lower panel) polyclonal T cell lines of donors ALT (d43), F61 (d47) 
and F63 (d46). 
 
To assess the enrichment of IE-1-specific T cells in the IE-1-mLCL-stimulated cultures, the 
reactivity of ctrl- and IE-1-mLCL-stimulated T cell lines (d46–54) was compared in T cell effector 
assays (Fig. 4.6). IFN-γ secretion upon specific stimulation is a characteristic effector function of 
CD8+ T cells, which largely dominated the polyclonal T cell lines. Moreover, IFN-γ secretion is 
also characteristic for virus-specific CD4+ T cells of the Th1 type, which have been described to 
dominate the CD4+ T cell response to HCMV (Rentenaar et al., 2000) and EBV (Ning et al., 
2011). Antigen-specific IFN-γ secretion was measured by ELISA assay. Autologous ctrl- and IE-
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1-mLCLs, as well as autologous EBV-free CD40-stimulated B cells were used as T cell targets. 
All ctrl-mLCL-stimulated T cell lines recognized both types of mLCL to a similar level, suggest-
ing the enrichment of T cells specific for EBV latent antigens expressed by the mLCLs. By con-
trast, the IE-1-mLCL-stimulated T cell cultures from 8 donors showed a much stronger reactivity 
to autologous IE-1-expressing mLCLs than to ctrl-mLCLs, indicating that IE-1-specific T cells 
had been specifically enriched by mLCL-stimulation as intended. IE-1-mLCL-stimulated T cell 
cultures of 3 donors did not show a preferential recognition of the IE-1-mLCL, suggesting that 
low numbers of IE-1-specific T cells were present in the peripheral blood of these donors. In 
addition, both polyclonal T cell cultures of donor AES recognized autologous CD40-stimulated B 
cells, suggesting that broadly reactive or self-specific T cells were reactivated and expanded in 
these cultures. 
 
 
Fig. 4.6: Target specificity of ctrl-mLCL-stimulated (A) and IE-1-mLCL-stimulated (B) polyclonal T 
cell lines. The reactivity of ctrl-mLCL- and IE-1-mLCL-stimulated T cell lines (d46–54) in response to 
autologous ctrl-mLCL, IE-1-mLCL and CD40-stimulated B cells was compared in an IFN-γ ELISA assay. 
10 000 T cells per well were incubated overnight with 20 000 target cells per well. Means and standard 
deviations of 3–4 replicates are shown. 
 
For donor ALT, the IE-1-, pp65- and ctrl-mLCL-stimulated T cell lines were comparatively ana-
lyzed in the IFN-γ ELISA assay (Fig. 4.7 A) for reactivity against autologous ctrl-, pp65- and IE-
1-mLCL as well as autologous CD40-stimulated B cells. Again, the cell line expanded with the 
ctrl-mLCL recognized all three types of mLCL to a similar extent, indicating recognition of EBV 
latent antigens expressed by the mLCLs. By contrast, IE-1- and pp65-expanded polyclonal T 
cell lines displayed dominant specificity for the respective HCMV antigen, suggesting the 
presence of pp65- as well as IE-1-specific T cells in the PBMCs of donor ALT. CD40-stimulated 
B cells were not recognized by any of the three T cell lines. In addition, direct cytotoxic activity 
of the three polyclonal T cell lines against the same target cells was assessed in a calcein-
release assay (Fig. 4.7 B). Direct cytotoxicity is the most important effector function of CD8+ T 
cells and has also been reported for CD4+ T cells directed against EBV (Morales et al., 2012) 
and HCMV antigens (Elkington et al., 2004). Cytotoxicity and IFN-γ secretion were equally 
antigen-specific and closely correlated with each other, demonstrating that mLCL-stimulation 
produced T cell lines with an intact repertoire of effector functions. 
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Fig. 4.7: Specific reactivity of ctrl-, pp65- and IE-1-mLCL-stimulated T cell cultures of donor ALT in 
IFN-γ ELISA (A) and cytotoxicity assay (B). For the ELISA, 10 000 T cells were incubated with 20 000 
target cells per well. To measure cytotoxicity in a calcein-release assay, 40 000 T cells were added to     
5 000 target cells per well. Means and standard deviations of 4 replicates are shown. 
 
For donor ALT, the expansion of epitope-specific T cells in the IE-1-, pp65- and ctrl-mLCL-
stimulated T cell lines was analyzed on day 43 using HLA class I/peptide multimeric complexes 
(Fig. 4.8). The multimers were chosen according to the HLA type of donor ALT and the bound 
peptides are listed in Table 4.1. T cells directed against EBV lytic antigens were also stained, to 
confirm that EBV lytic-cycle antigens were not expressed and presented by mLCLs. The precur-
sor frequencies of epitope-specific T cells in PBMCs of donor ALT are also given in Table 4.1. 
The T cell line stimulated with the ctrl-mLCL showed a clear expansion of T cells specific for 
EBV latent antigens LMP2 and EBNA3A. The pp65-mLCL-stimulated cell line was strongly 
dominated by pp65 NLV-specific T cells. The IE-1-mLCL-stimulated T cell line showed only a 
slight enrichment of IE-1 VLE-specific T cells, suggesting that other IE-1-specific T cells with un-
known specificity dominated the culture and led to the strong recognition of IE-1 in the ELISA 
and cell lysis assays. Interestingly, in both HCMV antigen-stimulated cell lines, coexpansion of 
EBV-specific T cells was fully suppressed. At least in the case of the pp65-mLCL, this was not a 
reflection of the differences in numbers of specific T cells in PBMCs, because pp65 NLV-spe-
cific T cells and EBV CLG-specific T cells were present in similar numbers in PBMCs, but the 
former were strongly dominant over the latter in stimulated T cell lines. Analysis of T cells stimu-
lated with IE-1-mLCL also suggested a preferential expansion of T cells specific for the HCMV 
antigen. A low synthesis rate of certain EBV latent proteins, compared to pp65 and IE-1, could 
have resulted in a lower cell surface presentation of EBV antigens (Hill et al., 1995) and, conse-
quently, reduced stimulation of EBV-specific T cells. 
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Table 4.1: Antigenic peptides used for staining of epitope-specific T cells in the polyclonal T cell 
lines of donor ALT and frequencies of peptide-specific T cells in the PBMCs of donor ALT. T cell 
frequencies were determined by staining with specific HLA/peptide multimers and are indicated as % 
lymphocytes.  
 
peptide antigen HLA restriction % of lymphocytes 
NLV HCMV pp65 A*0201 0.05 
TPR HCMV pp65 B*0702 0.02 
VLE HCMV IE-1 A*0201 0.25 
CLG EBV LMP2 A*0201 0.05 
RPP EBV EBNA3A B*0702 0.01 
GLC EBV BMLF1 A*0201 0.01 
FLY EBV LMP2 A*0201 0.00 (3/75 000) 
IED EBV LMP2 B*4002 0.00 (1/91 300) 
YVL EBV BRLF1 A*0201 0.00 (3/95 000) 
 
 
 
Fig. 4.8: Staining of epitope-specific T cells 
in the polyclonal T cell lines of donor ALT 
with HLA/peptide multimeric complexes. A: 
ctrl-mLCL-stimulated T cell line; B: pp65-
mLCL-stimulated T cell line; C: IE-1-mLCL-
stimulated T cell line. EBV- (grey), pp65- 
(blue) and IE-1- (red) peptide multimers were 
matched to the HLA type of donor ALT. HLA 
multimers are identified by the first three 
amino acids of the incorporated antigenic pep-
tide, in one-letter amino acid code. The 
polyclonal T cell lines were stained on day 43. 
Stainings without multimer and stainings for T 
cells specific for EBV lytic antigens served as 
negative controls. 
 
 
 
 
 
 
 
 
4.2 IE-1-specific CD4+ T cell repertoire  
Much emphasis has been placed on the importance of cytotoxic CD8+ T cells in the recognition 
of HCMV-infected cells (section 4.3). However, there is evidence that CD4+ T cells also play a 
crucial role in the control of HCMV infection. Adoptive T cell transfer studies in immunosuppres-
sed patients have shown that the development of an HCMV-specific CD4+ helper T cell 
response is essential for maintaining a long-term virus-specific CD8+ T cell immunity (Walter et 
al., 1995). Several HCMV antigens have been described as CD4+ T cell targets, among them 
the IE-1 protein (Sylwester et al., 2005). In fact, IE-1-specific T cells were among the first 
HCMV-specific CD4+ T cells to be characterized in detail (Alp et al., 1991; Davignon et al., 
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1995), but nontheless there is little information on the structure of the CD4+ T cell repertoire 
against IE-1 available to date. For this reason, one aim of the present work was to characterize 
IE-1-specific CD4+ T cells in terms of frequency, target peptide specificity and effector func-
tions. As previously reported for pp65, mLCLs expressing a foreign antigen can be used to 
reactivate CD4+ antigen-specific T cells (Moosmann et al., 2002). Therefore, the IE-1-mLCL-
stimulated polyclonal T cell lines were considered to be an appropriate source of IE-1-specific 
CD4+ T cells. 
 
4.2.1 Analysis of the CD4+ fraction of the polyclonal T cell lines 
As shown before, the IE-1-specific polyclonal T cell lines were largely dominated by CD8+ T 
cells which makes it difficult to detect specific effects of CD4+ T cells within these cultures. 
Therefore, the CD4+ T cell fraction was positively isolated from the IE-1-stimulated T cell lines 
of eight different donors (ALT, ARZ, AJU, F46, F61, F63, F64, F65) by using CD4 MicroBeads. 
The two T cell populations, depleted and enriched for CD4+ T cells, obtained by immunomag-
netic separation were analyzed for CD4 and CD8 surface expression by flow cytometry. FACS 
plots for two representative T cell lines (from donors AJU and F61) are shown in Fig. 4.9. The 
fraction enriched for CD4+ T cells had an average CD4+ T cell content of 96.6% and a reduc-
tion of CD8+ T cells to 1.4%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9: IE-1-mLCL-stimulated polyclonal T cell lines before and after immunomagnetic separa-
tion. CD4+ T cells were positively isolated from the polyclonal T cell lines using anti-CD4 immunomag-
netic beads (CD4 MicroBeads). The polyclonal T cell lines (not separated) as well as the resulting cell 
fractions from separation, CD4+ enriched and CD4+ depleted, were stained for CD4 and CD8 cell surface 
expression and analyzed by flow cytometry. Data are shown for the polyclonal T cell lines of two 
representative donors, AJU (d54) and F61 (d47). 
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The isolated CD4+ T cell fractions from the IE-1-stimulated T cell lines were screened for the 
presence of IE-1 epitope-specific CD4+ T cells in IFN-γ ELISpot assays by using an overlapping 
15-meric peptide library covering IE-1 (Fig. 4.10). In previous studies on the pp65 CD4+ T cell 
response, 15-meric peptide libraries have shown to be suitable tools for the stimulation of CD4+ 
T cell responses, which were approximately equal to those elicited with soluble protein antigen 
(Maecker et al., 2001). The peptide library used in this work contained 120 peptides spanning 
the entire IE-1 sequence of HCMV strain AD169, with subsequent peptides overlapping 11 
amino acids (Table 2.2). Nine additional 15-meric peptides containing sequence variants pre-
sent in the HCMV strains Toledo and TB40E were included in the study (Table 2.2, peptides 
#121-129). For convenience, the 129 peptides were subdivided into 23 subpools in a cross-ma-
trix fashion, such that every single peptide was contained in one "vertical" subpool (#1–12) and 
one "horizontal" subpool (#13–23) (Fig. 2.1).  
 
In the ELISpot assays, autologous CD40-stimulated B cells were used as antigen-presenting 
cells (APCs). ELISpot results are shown in Fig. 4.10. The CD4+ T cell cultures of all eight 
donors contained IE-1 peptide-specific T cells. The T cells of donors AJU, F63, F64 and F65 
recognized a very broad panel of IE-1 peptide subpools indicating the presence of T cells 
directed against various IE-1 peptides. However, the complex subpool recognition patterns 
prevented direct identification of individual T cell epitopes from the peptide cross-matrix. By 
contrast, the CD4+ T cells of donors ALT, ARZ, F46 and F61 recognized only a limited number 
of peptides. CD4+ T cells of donors ARZ and F46 were predominantly stimulated by subpools 
#5, 6 and 17, which only overlap in the individual IE-1 peptides #53 and 54. For donors ALT and 
F61, the subpool recognition pattern of the CD4+ T cells largely overlapped with the recognition 
pattern of the CD8+ T cells (Fig. 4.23), indicating that some signals might be caused by 
remaining CD8+ T cells within the positively isolated CD4+ T cells (Fig. 4.9). After subtraction of 
potential CD8+ T cell signals, peptides #53 and 54 were identified as CD4+ T cell targets also 
for donor ALT. For donor F61, epitope mapping was not possible from this assay. 
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Fig. 4.10: Frequency and epitope specificity of IE-1-specific CD4+ T cells. The CD4+ T cell fraction 
of the IE-1-stimulated polyclonal T cell lines of eight different donors (A–H) was analyzed for IE-1 reactiv-
ity in IFN-γ ELISpot assays. IE-1-epitope-specific T cells were detected using a 15-meric peptide library 
consisting of peptides covering the IE-1 sequence from AD169 and sequence variants from strains To-
ledo and TB40E. Peptides were pooled in a cross-matrix orientation ("vertical" subpools: #1–12; "horizon-
tal" subpool: #13–23) and loaded on CD40-stimulated B cells (50 000/well). Means and standard devia-
tions of duplicates are shown. 
 
4.2.2 Generation of T cell clones and screening for IE-1 recognition 
As demonstrated above, mLCL-stimulated T cell lines contained IE-1-specific CD4+ T cells. In 
the following, more detailed information was obtained about the IE-1-specific CD4+ T cell reper-
toires present in the blood donors by analyzing T cell clones generated from the IE-1-stimulated 
polyclonal T cell lines. A T cell clone arises from a single T cell and therefore expresses only 
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one TCR with one specificity. Due to this attribute, T cell clones are precise tools to identify tar-
get peptides of IE-1-specific CD4+ T cells as well as the HLA class II molecules that present 
them to the T cells. T cell clones were established from CD4+-enriched polyclonal T cell lines by 
limiting dilution and were tested for their reactivity against autologous ctrl- and IE-1-mLCLs as 
well as autologous CD40-stimulated B cells. CD4+ helper T cell responses are classically divi-
ded into T helper 1 (Th1) and T helper 2 (Th2) responses. Th1 cells produce effector cytokines 
such as IFN-γ and TNF-α, whereas Th2 cells secrete IL-4, IL-5, IL-10, and IL-13. It is reported 
that most HCMV-specific memory CD4+ T cells secrete the Th1 cytokine IFN-γ, whereas the 
Th2 cytokine IL-4 is secreted by only very few HCMV-specific CD4+ T cells (Rentenaar et al., 
2000). Therefore, reactivity of the generated T cell clones against mLCLs and CD40-stimulated 
B cells was determined by measuring antigen-specific IFN-γ secretion by ELISA. For some do-
nors, IL-4 or IL-10 ELISAs were performed in parallel to the IFN-γ ELISA with the same cell 
supernatants. However, clones producing only IL-4 or IL-10 but no IFN-γ were not identified. An 
extract of a T cell clone screening is shown in Fig. 4.11. The number of T cell clones screened 
per donor was dependent on the number of available T cell clones and was at least 100. 
Between 3 and 33.5% of the clones exhibited clear IE-1 specificity. As the CD4+ fraction of the 
T cell lines contained residual CD8+ T cells, identified IE-1-specific T cell clones were further 
screened for CD4 and CD8 surface expression by flow cytometry (data not shown) in order to 
exclude CD8+ T cell clones from the following experiments. 
 
 
Fig. 4.11: Screening of CD4+ T cell clones for IE-1 reactivity. T cell clones of donor F65 were tested 
for their reactivity towards autologous ctrl-mLCL, IE-1-mLCL, and CD40-stimulated B cells in an IFN-γ 
ELISA assay (50 000 target cells/well, T cells not counted). Only T cell clones that displayed clear IE-1-
mLCL reactivity and no reactivity against ctrl-mLCL and CD40-stimulated B cells, such as clones #2, 4, 7, 
18, 23, 25, 29, 31 in this experiment, were used for subsequent experiments. 
 
4.2.3 Definition of IE-1 CD4+ T cell epitopes 
T cell clones displaying clear IE-1 specificity in the ELISA assays were used for the definition of 
IE-1 epitopes. In a first round of experiments, the peptides targeted by the T cell clones were 
mapped within the IE-1 sequence using the same 23 subpools containing 15-meric peptides of 
IE-1 as described before in 4.2.1. Autologous ctrl-mLCLs or CD40-stimulated B cells were 
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loaded with the peptide subpools and used as APCs for T cells. IFN-γ secretion upon T cell 
stimulation was measured by ELISA assay. For almost all T cell clones tested, a clear peptide 
subpool recognition pattern was obtained which could be used to fine map targeted peptides 
within the IE-1 sequence using the peptide "cross-matrix" (Fig. 2.1). Representative examples 
of subpool recognition patterns are shown in Fig. 4.12 for CD4+ T cell clones of four different 
donors. Most patterns displayed recognition of three subpools, two "vertical" and one "horizon-
tal" (Fig. 4.12 A and B), which corresponds to the recognition of two adjacent overlapping 15-
meric peptides. If the two "vertical" subpools were recognized with similar intensity, the 11 
amino acid overlap between the peptides was defined as the putative minimal epitope. If one of 
the adjacent peptides was preferentially recognized, this 15-mer was considered to largely con-
tain the minimal epitope. In some cases, the subpool recognition pattern contained only one 
"horizontal" and one "vertical" subpool (Fig. 4.12 C); in this case the corresponding 15-meric 
sequence was defined as the epitope. Finally, a few subpool patterns contained subpool #23 
(Fig. 4.12 D), which comprises 9 variant peptides with single amino acid exchanges found in 
HCMV strains Toledo and TB40E. A signal for subpool #23 indicates that the clone was able to 
recognize an IE-1 sequence variant in addition to the sequence of the AD169 IE-1 protein, 
which was expressed in the mLCLs used for expansion of the polyclonal T cell lines, and should 
therefore be recognized by default. Subpool #23 contained only some of the sequences that 
vary between AD169 and other strains; there are many more such variations in IE-1, so a lack 
of reactivity with this subpool did not necessarily indicate a lack of reactivity to IE-1 from other 
HCMV strains. 
 
 
Fig. 4.12: Mapping of CD4+ T cell epitopes within the IE-1 sequence. Autologous ctrl-mLCLs or 
CD40-stimulated B cells were used as APCs for T cells and loaded with 23 peptide subpools containing 
120 IE-1 AD169 15-meric peptides and 9 sequence variants of strains Toledo and TB40E (Fig. 2.1). 
APCs (20 000/well) and T cells (10 000/well) were coincubated for 16–18 hours and IFN-γ secretion was 
measured by ELISA. Respresentative recognition patterns are shown for T cell clones of four different 
donors (A–D). Means and standard deviations of duplicate samples are shown. 
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In a second round of experiments, the HLA class II molecules were identified that presented the 
IE-1 peptides targeted by the CD4+ T cell clones. HLA class II molecules exist in three different 
isoforms, termed HLA-DR, -DQ and -DP, which are simultaneously expressed in every donor. 
Each isoform consists of two polypeptide chains, α and β, which are encoded by separate 
genes in the HLA class II region and are both involved in presentation of the antigenic peptide. 
With exception of the gene encoding the DR α chain, all of these genes are polymorphic. The 
exact number of different HLA-DR, -DQ and -DP allotypes expressed in one donor depends on 
the number of α and β chain genes and alleles present on each chromosome (described in 
detail in 1.1.1). The available HLA class II types of the donors are listed in Table 2.1. To deal 
with the frequent association of certain α or β chain alleles of different isoforms, the presenting 
class II isoform was determined in a first experiment, by assessing T cell reactivity to au-
tologous IE-1-expressing mLCL in the presence of blocking antibodies directed against HLA-
DR, -DQ or -DP. For most T cell clones, a clear impairment of IE-1 recognition by exactly one of 
the anti-HLA-DR, -DQ or -DP antibodies could be detected in IFN-γ ELISA assays, identifying 
the presenting HLA class II isoform. Examples for T cell clones restricted through HLA-DR, -DQ 
and -DP are shown in Fig. 4.13.  
  
In further experiments, it was attempted to determine the exact combination of presenting α and 
β chains for each target peptide by testing the reactivity of the T cell clones towards IE-1-
mLCLs. The respective ctrl-mLCLs were also included in the experiment in order to identify IE-
1-independent alloreactive mLCL recognition. However, alloreactivity was only detected for very 
few T cell clones and was not characterized in more detail. An exact HLA class II restriction 
could be determined for approximately half of the T cell clones tested. For some T cell clones, 
(highly resolved) HLA class II types were not available for all HLA class II loci. Some T cell 
clones showed IE-1 recognition of mLCLs that were not matched for the relevant HLA loci. This 
indicates that the TCRs of such T cell clones are able to recognize their target peptides on 
different HLA class II allotypes. Further studies with a broader panel of mLCLs that are typed in 
high resolution for all MHC class II loci, complemented by experiments with transgenic targets 
expressing single MHC class II allotypes, will help to determine the HLA restrictions of such T 
cell clones and to identify the different HLA class II allotypes that are able to promiscuously 
present the same peptides. For some T cell clones, the HLA restriction was narrowed down to 
two different HLA class II allotypes encoded by separate DRB genes, e.g. DRB1*1501 and 
DRB5*0101. These genes are closely associated, thus preventing the generation of mLCLs that 
express only one of them. Consequently, only transfection experiments with recombinant HLA-
DR β chains will allow the identification of the relevant HLA class II allotype.   
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Fig. 4.13: Determinition of HLA restriction. A: For identification of the peptide-presenting HLA class II 
isoform, autologous IE-1-expressing mLCLs (20 000/well) were incubated with blocking antibodies (10 
µg/mL) directed against HLA-DR, -DQ or -DP prior to addition of T cells (10 000/well). After overnight 
coincubation, impairment of IE-1 recognition by the antibodies was detected by IFN-γ ELISA. T cell 
clones restricted through each HLA class II isoform are shown as examples. B: The exact combination of 
an HLA class II α and β chain presenting a certain target peptide was determined by testing the reactivity 
of the respective T cell clone towards IE-1 ("IE")-mLCLs in an IFN-γ ELISA assay. Ctrl ("c")-mLCLs were 
included in the experiment to control for alloreactive mLCL recognition. HLA-DQ-restricted T cell clone 
F61M#223 VKS is shown as an example. This clone recognizes its target peptide on IE-1-mLCLs of do-
nors F61, F64 and AJU, which have only DQA1*0201 and DQB1*0202 in common. 
 
Table 4.2 summarizes the CD4+ IE-1-specific T cell clones analyzed for each donor and the 
peptides identified as T cell targets. For all donors except F46, T cell clones were selected at 
random for unbiased determination of specificity. For donor F46, CD4+ T cell clones were 
selectively screened with a peptide that was identified before as an epitope candidate in other 
donors (Fig. 4.10). Therefore, unbiased information on the composition of the CD4+ IE-1-
specific T cell repertoire of donor F46 is not available. Fig. 4.14 gives a simplified overview of 
the T cell specificities and HLA-restrictions found in the other 7 donors. A range of 3 to 7 
different peptides was targeted by the T cell clones of each donor. With exception of the clone 
F64M#228 KDE, all T cell clones recognized the IE-1 sequence variants of HCMV strains 
Toledo and TB40E in addition to the AD169 IE-1 sequence. T cell clones restricted through 
either one of the three HLA class II isoforms, HLA-DR, -DQ and -DP, could be identified, even in 
the same donor (AJU). Two peptides, EFFTKNSAFPKTT and VKSEPVSEIEEVAPE, were 
found to be targeted by T cell clones of 4 and 2 donors, respectively. Both peptides were pre-
sented by different donors on the same HLA class II molecules. By contrast, some of the 
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peptides were also recognized by T cell clones of different donors and with different HLA 
restrictions. Interestingly, these clones frequently showed recognition of IE-1-mLCLs from the 
other donors harboring T cells against the same peptide. For example, the HLA-DP-restricted 
peptide SVMKRRIEEICMKVFAQYI was recognized by clones of donors ARZ, AJU, and F61 
which do only share DPA1*0103 allele encoding the α chain, but no DPB allele encoding the β 
chain. SVM-specific clones of all three donors do recognize the IE-1-mLCLs of the other donors 
(data not shown). 
 
 
Table 4.2: Overview of identified IE-1 CD4+ T cell epitopes. Single 15-mers or two adjacent 15-mers 
of the AD169 IE-1 peptide library were identified as T cell targets in the ELISA assays. For adjacent 15-
mers, putative minimal epitopes were defined based on the magnitude of IFN-γ secretion in response to 
the subpools containing the individual 15-mers and are denoted in bold letters. Peptides recognized by T 
cell clones of different donors on the same or on different HLA molecules are highlighted with colors. T 
cell clones that recognized a sequence variant of IE-1 found in HCMV strains Toledo and TB40E in addi-
tion to an AD169 IE-1 peptide are highlighted in grey. T cell clones that did not recognize such sequence 
variants are denoted in red (only F64M#228 KDE).   
 
donor clone # recognized peptide HLA-restriction 
ALT 
  
  
  
  
19, 22, 37, 65, 80, 82 YRNIEFFTKNSAFPKTTNG DRB1*1501 or DRB5*0101 
51 CSPDEIMAYAQKIFKILDE DR 
70 EKFTGAFNMMGGCLQNALD DR 
47, 53, 66, 114 FPKTTNGCSQAMAALQNLP DQ 
63 FPKTTNGCSQAMAAL n. d. 
ARZ 
  
  
  
  
50, 93, 94, 101, 155, 158, 159 YRNIEFFTKNSAFPKTTNG DRB1*1501 or DRB5*0101 
105 KDELRRKMMYMCYRN DRB1*1501 or *0501 
18, 37, 73, 123, 125 ARAKKDELRRKMMYMCYRN DPA1*0103 + DPB1*0201 
98 KDELRRKMMYMCYRNIEFF DPA1*0103 + DPB1*0201 
27 SVMKRRIEEICMKVFAQYI DPA1*0103 + DPB1*0201 or *0301 
AJU 
  
  
  
  
11, 17, 34, 64, 112, 118, 137, 153, 155, 
159, 179, 190, 200 LVKQIKVRVDMVRHRIKEH DR 
31 IKVRVDMVRHRIKEHMLKK DRB1*1301 
120 LITKPEVISVMKRRIEEIC DR 
52 AIAEESDEEEAIVAY DQ 
6, 10, 50, 76, 81, 90, 106, 109, 115, 139 SVMKRRIEEICMKVFAQYI DPA1*0103 + DPB1*0401 or *2001 
F46 1, 48, 60, 66, 73, 74, 79 YRNIEFFTKNSAFPKTTNG DRB1*1501 or DRB5*0101 
F61 
  
  
29 ENSDQEESEQSDEEEEEGA DQA1*0201 + DQB1*0202 
223 VKSEPVSEIEEVAPE DQA1*0201 + DQB1*0202 
94, 97, 126, 154 SVMKRRIEEICMKVFAQYI DP 
F63 
  
  
  
6, 25, 27, 46, 65 RRKMMYMCYRNIEFFTKNS DR 
41, 58, 84 CLQNALDILDKVHEPFEEM DR 
99, 108, 121 EDKREMWMACIKELHDVSK DR 
31 HEPFEEMKCIGLTMQSMYE n. d. 
F64 
  
  
  
  
  
  
58, 69, 168, 189 VDMVRHRIKEHMLKK DRB1*1301 
65, 169, 181 RHRIKEHMLKKYTQT DRB1*1301 
138 YRNIEFFTKNSAFPK DRB1*1301 
139 LVKQIKVRVDMVRHRIKEH DRB1*1301 
228 KDELRRKMMYMCYRN DRB1*1301 
236 CSPDEIMAYAQKIFKILDE DRB1*1301 
51, 115, 124, 132, 231 VKSEPVSEIEEVAPE DQA1*0201 + DQB1*0202 
F65 
  
  
  
  
  
  
11, 18, 21, 42, 48, 50, 59, 61, 64, 91, 
97, 123, 124, 146, 148, 150, 156, 159  RRKMMYMCYRNIEFFTKNS DRB3*0202 
84, 92 YRNIEFFTKNSAFPKTTNG DRB1*1501 or DRB5*0101 
128, 148 GAFNMMGGCLQNALD DRB1*1501 or DRB5*0101 
63, 87, 138, 140, 151, 160 EGAQEEREDTVSVKSEPVS n.d. 
107 LDEERDKVLTHIDHIFMDI n.d. 
101 LVKQIKVRVDMVRHRIKEH n.d. 
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Fig. 4.14: T cell specificities and HLA-restrictions found in the donors ALT, ARZ, AJU, F61, F63, 
F64 and F65. This graph gives a simplified summary of the complex data listed in Table 4.2. T cell clones 
with 3 to 7 different peptide specificities (x-axis) and HLA-DR, -DQ and -DP restrictions were found in the 
donors. The number of T cell clones analyzed per target peptide is represented by the y-axis. 
 
One major goal of HCMV research is the establishment of an active immune prophylaxis by 
vaccination in order to prevent congenital HCMV infection, which is the leading cause of mental 
retardation in children. One strategy of vaccine development is the generation of peptide vac-
cines for stimulation of HCMV-specific T cells. The prerequisite for the design of an effective 
peptide vaccine is the identification of immunodominant regions within HCMV T cell antigens 
such as the IE-1 protein. The detailed characterization of the IE-1-specific CD4+ T cell reper-
toire within this study enables the evaluation of the IE-1 primary structure with regard to 
immunogenicity towards CD4+ T cells. The identified IE-1 CD4+ T cell epitopes are highlighted 
in the IE-1 amino acid sequence shown in Fig. 4.15. At first glance, with exception of the first 80 
amino acids, the whole IE-1 sequence is well accessible for recognition by CD4+ T cells. How-
ever, a more precise analysis revealed that some IE-1 sections are more frequently targeted by 
T cells than others (Fig. 4.15 in bold letters). Such hotspots of immunogenicity are mainly found 
in the first half of the protein. For example, 6 different epitopes were mapped to aa 85–107 and 
8 different epitopes to aa 197–235. 
 
 
Fig. 4.15: Distribution of CD4+ T cell epitopes within the IE-1 sequence. Sequences recognized by 
CD4+ T cell clones are denoted in red letters. Sequences containing overlapping T cell epitopes are de-
noted in bold letters. 
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The characterization of the CD4+ T cell repertoire against IE-1 revealed that all donors carrying 
HLA-DRB1*1501 and DRB5*0101 (which are regularly associated) have CD4+ T cells recogniz-
ing the adjacent peptides #53 and 54 of the IE-1 peptide library. In the polyclonal T cell lines of 
2 out of 3 DRB1*1501/DRB5*0101-positive donors comprehensively analyzed for IE-1 epitopes, 
such T cells represented the dominant IE-1 CD4+ T cell specificity. The comparatively high fre-
quency of these T cells and the fact that DRB1*1501 is the most frequent HLA-DRB1 allele in 
the German population (~15%) (Schmidt et al., 2009) renders this T cell species a good can-
didate for adoptive T cell therapy. For this reason, these T cells were submitted to closer analy-
sis in terms of minimal target peptide and precursor frequency in unstimulated PBMCs. T cell 
clones of donors ALT, ARZ, F46 and F65 were available for definition of the minimal epitope. 
These clones recognized peptides #53 and 54 equally well in the IFN-γ ELISA assays (data not 
shown). Consequently, the minimal epitope should largely comprise the oberlapping region of 
the two peptides (YRNIEFFTKNSAFPKTTNG). For definition of the exact epitope residues, T 
cell recognition of various peptides, 11 to 15 aa in length and all contained in peptides #53 and 
54, was compared in peptide titration studies (Fig. 4.16). Autologous CD40-stimulated B cells 
were used as APCs and pulsed with 10-fold serially diluted peptides. T cell stimulation was 
measured by IFN-γ ELISA. With peptide recognition down to a concentration of 10-10 mol/L, the 
T cell clones showed the highest avidity for peptides that minimally contained the central 11 
amino acids of the sequence (E)FFTKNSAFPKT(T) plus at least one additional flanking amino 
acid at one end. Thus, the definition of a minimal epitope was not without ambiguity for this 
specificity. As the 13-meric peptide EFFTKNSAFPKTT triggered highest IFN-γ secretion at the 
lowest peptide concentrations able to stimulate T cell activation (10-10–10-8 mol/L), this peptide 
was operationally defined as the minimal epitope, abbreviated EFF. 
 
  
 
Fig. 4.16: Determination of the minimal CD4+ T cell epitope contained within peptides #53 and 54 
of the IE-1 peptide library. The avidity of the T cell clone F46M#1 towards 11–15-meric peptides con-
tained within peptides #53 and 54 was assessed in peptide titration studies. Autologous CD40-stimulated 
B cells (50 000/well) were loaded with 10-fold diluted peptides and coincubated with T cells (20 000/well). 
T cell recognition was measured by IFN-γ ELISA. Means of triplicate samples are shown. Standard devia-
tions are not shown in order to preserve readability of the diagram. 
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EFF-specific T cells were further analyzed for their precursor frequency in unstimulated PBMCs 
of DRB1*1501/DRB5*0101-positive donors. PBMCs were tested for recognition of the 23 IE-1 
subpools using IFN-γ ELISpot assays. A clear signal for subpools #5, 6 and 17 (containing the 
EFF peptide) could not be detected in total PBMCs of such donors. Only in donor ALT, a signal 
of 15 spots in 200 000 PBMCs was visible for subpool #17. Spots caused by EFF-specific T 
cells in wells with subpools #5 and 6 could not be identified due to the presence of a very domi-
nant CD8+ T cell population identified in donor ALT (described in 4.3.). This result indicates that 
EFF-specific T cells are rather rare in unstimulated PBMCs of HCMV carriers. A subsequent 
experiment was performed to test whether EFF-specific T cells can be specifically enriched by 
peptide stimulation of PBMCs of DRB1*1501/DRB5*0101-positive donors. PBMCs of ALT, ARZ, 
AES and F65 were coincubated with EFF peptide for 11–14 days. EFF-specific T cells could be 
strongly enriched in three (ALT, ARZ, F65) out of the four donors tested. Frequencies of EFF-
specific T cells in unstimulated PBMCs and peptide-stimulated T cell lines of donor ARZ were 
qualitatively compared by IFN-γ ELISpot assays (Fig. 4.17). 
 
Fig. 4.17: Frequencies of EFF-specific T cells in unstimulated PBMCs (A) and an EFF peptide-
stimulated T cell line (B) of DRB1*1501/DRB5*0101-positive donor ARZ. EFF-specific T cells were 
identified with IFN-γ ELISpot assays. Therefore, 200 000 cells/well were incubated overnight either with 
the 23 IE-1 subpools (A) or with the total IE-1 peptide library and the EFF peptide (B). As a positive con-
trol, cells were incubated with global T cell activators TPA and ionomycin (only shown in B).  
 
4.2.4 Analysis of effector functions of IE-1-specific CD4+ T cells 
CD4+ T cell responses may play an important role in the defense of viruses by providing di-
verse antiviral effector functions. CD4+ T cells primarily mediate helper function for both hu-
moral and cell-mediated immune mechanisms. According to their distinct patterns of cytokine 
secretion, CD4+ T cells are classically categorized into Th1 and Th2 cells (Cousins et al., 
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2002). Th1 cells (IL-2, IFN-γ, TNF-α) are critical for activation of APCs, increase in antigen 
presentation, and induction of CTL proliferation. Furthermore, the Th1 cytokines IFN-γ and TNF-
α mediate direct antiviral and growth-inhibitory effects. Th2 cytokines (IL-4, IL-5, IL-6, IL-10, IL-
13 and IL-25) stimulate naive B cells to become plasma cells that secrete specific antibodies 
with particular isotypes. In addition to Th1 and Th2 cells, CD4+ T cell subsets have been identi-
fied with acquired cytotoxic activity, thus being able to directly kill infected target cells in an 
MHC class II-dependent manner (Marshall and Swain, 2011). HCMV-specific CD4+ T cells 
have been primarily associated with the Th1 type due to secretion of IFN-γ and TNF-α 
(Rentenaar et al., 2000; van Leeuwen et al., 2006), and due to their crucial role in maintaining 
adoptively transferred HCMV-specific CD8+ T cell immunity (Walter et al., 1995). However, as 
HCMV infection also elicits a broad antiviral neutralizing antibody response, it should be consi-
dered that Th2 cells might also be involved in anti-HCMV immunity (Jackson et al., 2011). 
Interestingly, a panel of direct cytolytic CD4+ T cells has been identified to target HCMV 
antigens pp65, gB and gH (Hopkins et al., 1996; Elkington et al., 2004; Weekes et al., 2004). 
 
In this context, the functional characteristics of anti-IE-1 CD4+ T cell responses were evaluated 
here. Two CD4+ T cell effector functions, cytokine secretion and direct cytotoxicity, were as-
sessed using CD4+ IE-1-specific T cell clones. Mini-LCLs and monocyte-derived dendritic cells 
(mo-DCs) served as T cell targets, as these cells constitutively express high levels of MHC 
class II molecules. Amongst these professional APCs, DCs deserve particular attention be-
cause they are natural targets of HCMV infection in vivo. Furthermore, precursor cells of the 
myeloid lineage are considered to be reservoirs of latent virus in vivo and their differentiation 
into monocytes, DCs or macrophages triggers virus reactivation. Mature DCs were generated 
from peripheral blood monocytes using a modified protocol from Jonuleit et al. (2000). CD4+ IE-
1-specific T cell clones were analyzed for secretion of Th1 (IL-2, IFN-γ, TNF-α) and Th2 (IL-4, 
IL-10) cytokines in response to peptide-stimulation using ELISA assays. As Th1 and Th2 cells 
reportedly produce GM-CSF upon stimulation (Cousins et al., 2002), GM-CSF ELISAs were 
performed as positive controls. Mo-DCs were loaded with the IE-1 peptides identified as targets 
of the CD4+ T cell clones (Table 4.2). The cytokine profiles obtained from four different T cell 
clones are shown in Fig. 4.18. All T cell clones tested secreted the Th1 cytokines IL-2, IFN-γ 
and TNF-α. Production of the Th2 cytokine IL-10 could not be detected for any of the four T cell 
clones tested. Interestingly, two of the T cell clones, ALTM#22 EFF and ARZM#37 ARA, 
showed secretion of the Th2 cytokine IL-4 in addition to the Th1 cytokines. T cell subsets with 
less differentiated cytokine profiles than Th1 and Th2 cells have been reported before, for 
example for HSV (Yasukawa et al., 1991), and are designated as Th0 cells. Th0 cells arise in 
the absence of clear polarizing signals and can mediate intermediate effector functions of Th1 
and Th2 types (Romagnani, 1994). However, it cannot be excluded that cytokine secretion 
phenotypes may be modulated during in vitro cultivation. 
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Fig. 4.18: Cytokine profiles of CD4+ IE-1-specific T cell clones. Peptide-pulsed monocyte-derived 
(mo)-DCs (generated from donor ARZ, 10 000/well) were coincubated overnight with T cells (10 
000/well). Secretion of GM-CSF, IFN-γ, IL-2, IL-4, IL-10 and TNF-α was detected by ELISA. Means and 
standard deviations of triplicate samples are shown. 
 
The less common effector function of CD4+ T cells, direct cytotoxicity, was evaluated for a 
broad panel of CD4+ IE-1-specific T cell clones using calcein-release assays (Fig. 4.19). The T 
cell clones were tested for antigen-specific lysis of B cell lines and mo-DCs in separate experi-
ments. In the first experiment (Fig. 4.19 A), autologous or HLA-matched IE-1-mLCLs, ctrl-
mLCLs and CD40-stimulated B cells were used as T cell targets, in the second experiment (Fig. 
4.19 B), autologous or HLA-matched mo-DCs, peptide-loaded or without peptide, were used to 
detect antigen-specific lysis. The panel of CD4+ T cell clones tested in the two separate experi-
ments was largely overlapping. As a positive control for T cell lysis, both experiments were per-
formed in parallel with CD8+ cytotoxic T cell clones recognizing the well-described IE-1 epitope 
VLE (Khan et al., 2002). In both experiments, the majority of CD4+ T cell clones did not show 
clear IE-1-specific cell lysis. However, each experiment identified a few T cell clones displaying 
IE-1-dependent cytotoxicity. In the B cell experiment, two clones of donor AJU (AJUM#17 LVK 
and #118 LVK) recognizing the same epitope, and two clones of donor F64 (F64M#115 VKS 
and #69 VDM) recognizing different epitopes, showed preferential lysis of the IE-1-mLCL. In the 
DC experiment, only T cell clones of donor F64 (including F64M#69 VDM tested in the B cell 
experiment) showed clear IE-1 peptide-specific target lysis. The T cell clones of donor AJU 
identified as cytotoxic in the B cell experiment did not show any significant lysis in the DC 
experiment. Further experiments will be necessary to define the mechanisms that give rise to 
these differences in cytotoxic potential of IE-1-specific CD4+ T cell clones against different 
types of target cells. Potential factors might be differences in the expression of different HLA 
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class II molecules and allotypes, or a modulation of CD4+ T cell reactivity by cell-type-specific 
costimulatory or coinhibitory molecules on APCs. In summary, from a broad panel of CD4+ T 
cell clones tested, only a minority displayed antigen-dependent cell lysis. Furthermore, levels of 
specific lysis detected for these CD4+ T cell clones were smaller than for CD8+ T cell clones 
specific for epitopes from the same antigen. 
 
 
Fig. 4.19: Analysis of direct cytotoxic effects of IE-1-specific CD4+ T cell clones. CD4+ T cell clones 
from donors ALT, F46, ARZ, AJU, F64 and F61 were tested for IE-1-specific lysis of autologous (ALT, 
ARZ, AJU) or HLA-matched (F46, F64, F61) B cell lines (IE-1-mLCLs, ctrl-mLCLs and CD40-stimulated B 
cells) (A) and autologous (ARZ, AJU) or HLA-matched (ALT, F46, F64, F61) monocyte-derived DCs 
(pulsed with IE-1 peptides or without peptides) (B) in separate experiments. In both experiments, 
cytotoxicity was detected by calcein-release assay using 5000 targets/well and two different 
effector/target-ratios: 8/1 and 2/1. Only the data for E/T = 2/1 are shown. Means and standard deviations 
of triplicate samples are shown. 
 
Although the majority of IE-1-specific CD4+ T cell clones did not display significant direct cyto-
toxic capacity, it has to be considered that these clones might still provoke indirect cytotoxic or 
growth-inhibitory effects towards surrounding cells in vivo via the secreted cytokines. For exam-
ple, the Th1 cytokine IFN-γ is described to mediate broad anti-proliferative and pro-apoptotic 
effects (Schroder et al., 2004). In this study, two EFF-specific T cell clones that did not display 
clear direct cytotoxicity in the calcein-release assays were analyzed for indirect cytotoxicity and 
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growth-inhibitory effects by regression assay (Fig. 4.20). In this assay, T cells were cocultivated 
with different amounts of HLA-matched mLCLs per well. Wells with proliferating mLCLs (mLCL 
"outgrowth") were detected after 5–6 weeks by MTT assay. To know whether potential inhibitory 
effects of T cells are IE-1-dependent, proliferation of ctrl- and IE-1-mLCLs was examined in 
parallel. A CD8+ cytotoxic T cell clone directed against the IE-1 VLE-epitope was included in 
the experiment as a control. Fig. 4.20 A shows the proliferative behavior of mLCLs in absence 
of T cells. 100% outgrowth of IE-1- and ctrl-mLCLs can be achieved with a minimal number of 
625 and 2500 mLCLs/well, respectively. Partial outgrowth of IE-1- and ctrl-mLCLs can already 
be detected at lower cell numbers, 156 and 625 cells/well, respectively. Cocultivation of mLCLs 
with the IE-1-specific CD8+ cytotoxic T cells (Fig. 4.20 B) resulted in IE-1-dependent inhibition 
of mLCL proliferation. Inhibitory effects on ctrl-mLCL proliferation were minimal. By contrast, the 
two IE-1-specific CD4+ T cell clones could not completely inhibit outgrowth of either mLCL (Fig. 
4.20 C and D). However, a clear increase of the minimal cell number necessary for 100% or 
partial outgrowth was detectable for both mLCLs, indicating that the T cells possess growth-
inhibitory properties. Furthermore, IE-1-mLCL outgrowth was reduced much more strongly than 
ctrl-mLCL outgrowth, suggesting that the anti-proliferative effects mediated by the T cells were 
largely IE-1-specific.  
 
 
Fig. 4.20: Analysis of indirect cytotoxic and growth-inhibitory effects of IE-1-specific CD4+ T cell 
clones by regression assay. Outgrowth of IE-1- and ctrl-mLCLs (from donor ALT) was measured in 
absence (A) and presence (B–C) of T cells (10 000/well). Effects of IE-1-specific CD4+ T cell clones 
ALTM#22 EFF (C) and F46M#1 EFF (D) on mLCL outgrowth were compared to the direct cytotoxic 
effects of IE-1-specific CD8+ T cell clone F61M#134 VLE (B). The assay was performed with 10 
replicates for each number of mLCLs/well. Mini-LCL outgrowth was detected by MTT assay after 5–6 
weeks. 
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4.2.5 T cell recognition of HCMV-infected target cells 
In previous experiments, CD4+ IE-1-specific T cell clones were shown to produce high amounts 
of cytokines, especially IFN-γ (Fig. 4.13 and Fig. 4.18), in response to cells endogenously 
expressing IE-1 or exogenously loaded with IE-1 peptides. This potent effector function sug-
gests an important role of these T cells in the immune response to HCMV. However, IE-1 
presentation in HCMV-infected cells might be altered due to lower availability of target peptides 
or immunomodulatory functions of the virus. Hence, the actual role of CD4+ IE-1-specific T cells 
in the HCMV immune response is determined by their ability to recognize IE-1 in context of an 
HCMV infection. A commonly used cellular system for studying HCMV infection in vitro are 
primary human fibroblasts. These cells show a high permissiveness for productive infection by 
HCMV laboratory strain AD169, which was the available HCMV strain for this study. However, 
fibroblasts do not constitutively express MHC class II molecules. MHC class II expression was 
induced in fibroblasts by treatment of the cells with IFN-γ (data not shown). However, although 
the fibroblasts thereby acquired the ability to present exogenously loaded IE-1-peptides to the 
CD4+ T cell clones, recognition of HCMV-infected fibroblasts by the CD4+ T cells could hardly 
be detected. In search of an appropriate cell system with high constitutive expression of MHC 
class II molecules and permissiveness for HCMV infection, mo-DCs were evaluated as T cell 
targets. As shown above, mo-DCs presented exogenously loaded IE-1 peptides to CD4+ T cell 
clones (Fig. 4.18). Mature mo-DCs permit, to some extent, the infection with the fibroblast-
adapted HCMV strain AD169, and infected mo-DCs support all phases of viral gene expression, 
but do not release infectious progeny virus (Senechal et al., 2004). Autologous or HLA-matched 
mature mo-DCs were generated from peripheral blood monocytes and infected with AD169 at 
an moi = 5 for 48 hours. IFN-γ released during cocultivation of infected mo-DCs and T cells was 
measured by ELISA. Fig. 4.21 summarizes the outcome of several infection experiments with a 
broad panel of CD4+ T cell clones. Strikingly, all T cell clones tested recognized AD169-infected 
mo-DCs. Antigen-specific IFN-γ secretion varied between the T cell clones tested. Only the 
HLA-DP-restricted SVM-specific T cell clones of donors ARZ and F61 showed similar IFN-γ 
secretion in response to infected cells and peptide-loaded cells. This could reflect different 
avidities of the T cell clones or different availabilities of the target peptides. However, also virus-
mediated immunomodulatory effects on MHC class II presentation have to be considered. 
HCMV encodes at least two proteins, gpUS3 and gpUS2, which are able to interfere with the 
MHC class II pathway of antigen presentation (Tomazin et al., 1999; Hegde et al., 2002). Such 
immunomodulatory proteins might differentially affect antigen presentation on different MHC 
class II isoforms or allotypes. Peptide titration studies and experiments using HCMV 
immunoevasin deletion mutants might clarify if the HLA-DP-restricted SVM-specific T cell clones 
possess particular high avidity or are less affected by viral immunoevasion compared to the 
other T cell clones. In summary, this experiment showed two things: first, mature mo-DCs are 
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an adequate system to study CD4+ T cell responses to HCMV infection; second, owing to their 
good recognition of infected DCs, which are also naturally targeted by HCMV in vivo, CD4+ IE-
1-specific T cells are likely to play an important role during the anti-HCMV immune response. 
 
  
 
Fig. 4.21: Recognition of HCMV-infected monocyte-derived (mo-)DCs by CD4+ IE-1-specific T cell 
clones. CD4+ T cell clones of 5 different donors were tested for recognition of HCMV-infected (48 hpi) 
mo-DCs by IFN-γ ELISA. DCs that were not infected (ni) and peptide-loaded DCs were used as negative 
and positive controls, respectively. Depending on the donor, autologous (ARZ) or HLA-matched (ALT, 
F46, F61, F64) mo-DCs were available. 10 000 T cells/well were incubated overnight with 10 000 mo-
DCs/well. Means and standard deviations of triplicate samples are shown. 
 
4.3 IE-1-specific CD8+ T cell repertoire 
CD8+ cytotoxic T cells (CTLs) are considered to be pivotal for defense against virus infections 
because they can directly interfere with virus spread by killing of infected cells upon cell-to-cell 
contact. IE-1-specific CD8+ T cells can be detected in the majority of healthy virus carriers 
(Khan et al., 2005; Sylwester et al., 2005) and are associated with control of HCMV. For exam-
ple, after allogeneic SCT a delay in IE-1-specific CD8+ T cell reconstitution correlated with 
HCMV disease (Sacre et al., 2008). Another study on solid organ transplant patients indicated 
an outstanding role of IE-1-specific CD8+ T cells, as CTLs targeting IE-1 but not T cells directed 
against an immunodominant structural protein, pp65, were correlated with protection from viral 
disease (Bunde et al., 2005). IE-1-specific CTLs might control HCMV infection with particular 
efficiency because their target protein, IE-1, is expressed very early during lytic infection but 
Results 
 
82 
also during reactivation from latency, thereby enabling the eradication of HCMV-infected cells 
before progeny virus is released. Within this work, IE-1-specific CD8+ T cells were isolated from 
the IE-1-stimulated polyclonal T cell lines and reevaluated with a focus on identification of 
efficient candidate epitopes for adoptive T cell therapy. 
 
4.3.1 Analysis of the CD8+ fraction of the polyclonal T cell lines 
As shown above, IE-1-stimulated polyclonal T cell lines were largely dominated by CD8+ T cells 
and preferentially recognized IE-1-expressing mLCLs, compared to ctrl-mLCLs and CD40-
stimulated B cells, in IFN-γ ELISA assays (Fig. 4.6). These findings strongly suggest an enrich-
ment of IE-1-specific CTLs in the polyclonal T cell lines stimulated with IE-1. To obtain infor-
mation on the frequency of IE-1-specific CD8+ T cells, IFN-γ ELISpot assays were performed 
on CD4+ T cell-depleted polyclonal T cell lines of eleven donors at day 46–54 of cultivation (Fig. 
4.22). In this assay, T cells were stimulated with autologous ctrl- or IE-1-mLCL. Most T cell lines 
showed preferential reactivity against the IE-1-mLCL, indicating a predominance of IE-1-specific 
CD8+ T cells in the cultures. In the T cell lines of donors ALT, AJJ, F46, F59 and F61, more 
than 10% of polyclonal T cells selectively recognized the IE-1-mLCL, whereas recognition of 
other mLCL determinants was minor, as shown by the control. It is well established for virus-
specific T cells that ELISpot assays underestimate the frequency of antigen-specific T cells, 
because not all antigen-specific T cells secrete sufficient amounts of cytokine within the time 
frame of an ELISpot assay to be detected; in peripheral blood, multimer staining typically yields 
four times higher numbers of specific T cells than ELISpot assay (Tan et al., 1999). Therefore, 
the actual proportion of IE-1-specific T cells in the polyclonal T cell cultures is supposedly higher 
than the proportion of cells that reacted in the ELISpot assay. 
 
 
Fig. 4.22: Frequency of IE-1-specific T cells in the IE-1-stimulated polyclonal T cell lines. The 
reactivity of CD4+ T cell-depleted IE-1-stimulated polyclonal T cell lines (day 46-54) of 11 different donors 
in response to autologous IE-1- and ctrl-mLCL was analyzed by IFN-γ ELISpot assays (5000 T cells and 
50 000 mLCLs per well). Means and standard deviations of duplicate samples are shown.  
 
Next, the IE-1-stimulated polyclonal T cell lines were evaluated for the presence and frequency 
of T cells specific for individual IE-1 epitopes in IFN-γ ELISpot assays (Fig. 4.23 B). For epitope 
mapping, the polyclonal T cell lines were challenged with autologous CD40-stimulated B cells 
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loaded with each of the 23 IE-1 peptide subpools (described in 4.2.1). To estimate the enrich-
ment rate of IE-1 epitope-specific T cells, ELISpot assays were performed in parallel with 
unstimulated PBMCs of the same donors (Fig. 4.23 A). An enrichment of IE-1 peptide-specific T 
cells could be detected in the polyclonal T cell lines of all donors tested. Interestingly, with the 
only exception of donor F64, the enrichment of IE-1-specific T cells in the polyclonal T cell lines 
inversely correlated with the T cell precursor frequency in unstimulated PBMCs. The highest 
enrichment rates (above 300-fold) of IE-1 peptide-specific T cells were detected for donors 
ARZ, AES and F63, where the frequency of precursor cells in PBMCs was below the detection 
limit of IFN-γ ELISpot assays (approximately 10 spots). Conversely, the lowest T cell enrich-
ment rates (40–60-fold) were achieved in donors AJJ, AJU and F59, which were among the 
donors with the highest precursor frequencies of IE-1-specific T cells in unstimulated PBMCs 
(0.05–0.15% of PBMCs). This finding might indicate two things: first, a preceding extensive 
enrichment of IE-1-specific T cells in vivo might hamper subsequent strong expansion in vitro; 
second, T cell specificities with low precursor frequencies in PBMCs should still be considered 
for adoptive T cell therapy because these T cells can be strongly expanded in vitro, resulting in 
similarly high T cell numbers in polyclonal T cell lines as found for T cells with high precursor 
frequencies. Furthermore, for donors ALT, AJU and F60, the ratios of T cell numbers recogniz-
ing different peptide subpools were not maintained during expansion. T cells directed towards 
peptides in subpools #5 and/or 6 were expanded much more strongly than T cells specific for 
subpool #7, suggesting that certain T cell specificities possess higher proliferative capacity than 
others.  
  
In the following, the IE-1 peptides recognized by the polyclonal T cell lines were predicted from 
the peptide subpool recognition patterns using the peptide cross-matrix (Fig. 2.1). For donors 
with complex recognition patterns (e.g. F63) due to the presence of T cells against more than 
one IE-1 peptide, published target peptides could be identified in most cases. IE-1 epitopes 
have been described for frequent HLA-A and -B allotypes including HLA-A*0201 and -B*1801 
which are present in some of the donors analyzed. T cells towards published IE-1 epitopes were 
confirmed by challenging PBMCs of the donors with the minimal epitope sequences (usually 9 
amino acids, data not shown). Table 4.3 gives an overview of the identified IE-1 peptides tar-
geted by the polyclonal T cell lines of the 11 donors tested. Only one IE-1-specific T cell species 
was found in donors ARZ, AES, F61 and F64. Two equally dominant or one dominant and one 
subdominant T cell species were identified in donors ALT, AJJ, AJU, F46, F59 and F60. For 
donor F63, two published IE-1 epitopes were identified, however, the subpool recognition pat-
tern indicated that a third T cell population with so far unknown specificity was also present. In 
total, four new IE-1 CD8+ T cell epitopes were identified within this study. T cells targeting these 
IE-1 epitopes were characterized in more detail, as described below, using specific T cell clones 
established by limiting dilution from the polyclonal T cell lines. 
Results 
 
84 
 
Results 
 
85 
 
Fig. 4.23: Frequency and epitope specificity of IE-1-specific T cells in PBMCs and polyclonal T cell 
lines of 11 donors. The unstimulated PBMCs (A) and IE-1-stimulated CD8+ polyclonal T cell lines (B) of 
11 different donors were analyzed for IE-1 reactivity in IFN-γ ELISpot assays. IE-1 epitope-specific T cells 
were detected using a 15-meric peptide library covering the IE-1 sequence from AD169 and sequence 
variants from strains Toledo and TB40E. Peptides were subpooled in a cross-matrix orientation ("vertical" 
subpools: #1–12; "horizontal" subpool: #13–23) and directly loaded on PBMCs (200 000/well) (A) or on 
autologous CD40-stimulated B cells as APCs (5x 104/well) (B). Means and standard deviations of 
duplicate samples are shown. 
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Table 4.3: IE-1 CD8+ T cell epitopes recognized by the polyclonal T cell lines of 11 donors. IE-1 
peptides targeted by the polyclonal T cell lines were predicted from the peptide subpool recognition pat-
terns of the ELISpot assays (Fig. 4.23) using the peptide cross-matrix (Fig. 2.1). For published epitopes, 
the references are denoted. Newly identified IE-1 epitopes targeted by the T cells of only one donor or 
several donors are highlighted in blue or red color, respectively. New IE-1 epitopes were characterized 
further below in more detail. 
donor target peptides in IE-1 aa position minimal epitope HLA-restriction reference 
ALT 
  
VLEETSVML 316–324 A*0201 (Khan et al., 2002) 
CRVLCCYVL 309–317 C*0702 this study, section 4.3.2 
AJJ 
  
VLEETSVML 316–324 A*0201 (Khan et al., 2002) 
CRVLCCYVL 309–317 C*0702 this study, section 4.3.2 
ARZ VLAELVKQIKVRVDMVRHR n.d. C*0602 this study 
AJU 
 
VLEETSVML 316–324 A*0201 (Khan et al., 2002) 
CRVLCCYVL 309–317 C*0702 this study, section 4.3.2 
AES ESDEEEAIVAYTLATAGVS n.d. n.d. this study 
F46 
  
CRVLCCYVL 309–317 C*0702 this study, section 4.3.2 
RHRIKEHMLK 97–106 A*0301 this study 
F59 
  
ELRRKMMYM 199–207 B*1801 (Retiere et al., 2000) 
DEEEAIVAY 379–387 B*1801 (Retiere et al., 2000) 
F60 
  
VLEETSVML 316–324 A*0201 (Khan et al., 2002) 
CRVLCCYVL 309–317 C*0702 this study, section 4.3.2 
F61 VLEETSVML 316–324 A*0201 (Khan et al., 2002) 
F63 KEVNSQLSL 42–50 B*4001 (Khan et al., 2007) DEEEAIVAY 379–387 B*1801 (Retiere et al., 2000) 
F64 VLEETSVML 316–324 A*0201 (Khan et al., 2002) 
 
 
Three of the four newly identified IE-1 epitopes within this study were only found in one donor 
each (ARZ, AES and F46). T cell clones could be established from the polyclonal T cell lines of 
two of the donors, ARZ and F46, and were used to determine the HLA restriction of the 
corresponding two new IE-1 epitopes in IFN-γ ELISA assays (Fig. 4.24). The T cell clones were 
challenged with IE-1- and ctrl-mLCLs of several donors partially matched or not matched for 
various HLA class I allotypes (Fig. 4.24 A and C). The T cell clone of ARZ recognized only IE-1-
mLCLs of donors expressing HLA-C*0602 (Fig. 4.24 A). This HLA restriction could be molecu-
larly confirmed using class I-deficient L721.221 LCLs that were stably transfected with HLA-
C*0602, thus expressing HLA-C*0602 as their only HLA class I molecule. These cells were in-
fected with IE-1-expressing modified vaccinia virus Ankara (MVA) and used as T cell targets in 
an IFN-γ ELISA assay (Fig. 4.24 B). T cell clones of ARZ recognized IE-1 only in context of 
HLA-C*0602, thus confirming the HLA-C*0602 restriction of these T cells, whereas control-
transfected and control MVA-infected targets were not recognized. 
 
The T cell clones of donor F46 showed IE-1-specific IFN-γ secretion only upon stimulation with 
mLCLs of donors expressing HLA-A*03(01) (Fig. 4.24 C), thus defining HLA-A*03(01) as the IE-
1 peptide-presenting HLA allomorph. In addition, these T cell clones showed IE-1-independent 
recognition of mLCLs of donors ARZ, ASG and F64, which are completely mismatched with F46 
in all HLA-A, -B and -C allotypes. This alloreactive T cell recognition appeared to depend on 
HLA-A*29(02), which was the only HLA molecule shared by these donors and absent in all 
other donors tested. Cross-reactivity of HCMV-specific T cells against alloantigens is no 
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unusual phenomenon (Amir et al., 2011). Alloreactive T cells are associated with graft rejection 
and graft-versus-host disease after HLA-mismatched transplantation. Especially with regard to 
adoptive T cell therapy in transplant patients, further experiments should be considered to 
characterize the basis of this alloreactive T cell recognition. For example, it would be interesting 
to know whether the T cell clones recognize a particular self peptide on HLA-A*29(02) or if the 
TCR/MHC interaction is peptide-independent. Based on common amino acid residues of well-
described HLA-A*03(01)-presented peptides (Hill et al., 1995; Pepperl et al., 1998), the 10-mer 
RHRIKEHMLK was defined as the minimal T cell epitope. 
 
 
Fig. 4.24: HLA restriction of T cell clones of donors F46 and ARZ. T cell clones of donors ARZ (A, 
clone ARZM#161 VLA) and F46 (C, clone F46M#131 RHR) were challenged with IE-1 ("IE")- and ctrl 
("c")-mLCLs of several donors partially matched or not matched for different HLA-A, -B and -C allotypes. 
HLA restriction found in A for the T cell clones of donor ARZ was confirmed by stimulating T cell clones 
(B, ARZM#19 VLA) with L721.221 cells transfected with HLA-C*0602 or C*0702 and infected, or not, with 
IE-1-expressing modified vaccinia virus Ankara (MVA). For all experiments, 10 000 T cells were incu-
bated overnight with 20 000 target cells and specific IFN-γ secretion was measured by ELISA. 
 
4.3.2 Identification of a dominant HLA-C-restricted T cell species 
Interestingly, among the donors with the highest IE-1-specific T cell numbers in the IFN-γ 
ELISpot assays (Fig. 4.23), 5 donors (ALT, AJJ, AJU, F46 and F60) shared a pattern in which 
subpools #5, 6, (7), 19 and 23 were dominantly recognized by their polyclonal T cell lines (Fig. 
4.23 B). According to the peptide cross-matrix, the IE-1 region containing the T cell epitope 
comprised individual peptides #76, 77 and 78 and their sequence variants #125, 126 and 127. 
To define a minimal epitope, these peptides were individually tested for recognition by the 
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polyclonal T cell line of donor ALT in an IFN-γ ELISpot assay (Fig. 4.25 A). Two earlier de-
scribed nonameric IE-1 T cell epitopes located in this region were included in the assay: 
VLEETSVML (VLE, IE-1aa316-324) (Khan et al., 2002) and CRVLCCYVL (CRV, IE-1aa309-317) (Kern 
et al., 1999). The VLE epitope was described as A*0201-restricted by Khan et al., 2002 and 
confirmed as a dominant IE-1 epitope in several studies (Elkington et al., 2003; Khan et al., 
2007). The CRV epitope was identified in early studies as a major target of T cells from B*07-
positive donors (Kern et al., 1999). In the ELISpot assay, the CRV nonamer and the 15-mers 
containing it or its variant CRVLCCYIL, but not the other peptides tested in the assay, were 
dominantly recognized by the T cells from donor ALT. 
  
For further analyses, CD8+ T cell clones were established by limiting dilution of IE-1 mini-LCL-
stimulated cultures of donors ALT, AJU and F46. Between 200 and 240 clones from each donor 
were tested for reactivity towards autologous IE-1-mLCL, ctrl-mLCL and CRV nonamer-loaded 
CD40-stimulated B cells in IFN-γ ELISA assays (data not shown). Of the T cell clones screened 
from donors ALT, AJU and F46, 96%, 78% and 84% were specific for IE-1, and among these 
87%, 24% and 88% were specific for the CRV nonamer. CRV-specific T cell clones from a 
fourth donor, AJJ, were obtained by overnight stimulation of PBMCs with the CRV peptide, fol-
lowed by IFN-γ capture-based immunomagnetic isolation and limiting dilution. Using these T cell 
clones, the minimal epitope was verified in an IFN-γ ELISA assay by comparing the avidity of 
the T cells against 10-fold diluted candidate peptides, 8 to 10 amino acids in length and loaded 
on autologous CD40-stimulated B cells (Fig. 4.25 B). The T cell clones reacted more strongly to 
CRVLCCYVL than to each longer, shorter or shifted peptide, confirming that this peptide was 
indeed the minimal epitope. Furthermore, the peptide CRVLCCYIL, which is the only known 
existing variant of CRVLCCYVL, was recognized with similar sensitivity by the T cell clones 
tested. CRVLCCYVL is present in HCMV strains including AD169, Towne, strain W and Merlin, 
its variant CRVLCCYIL in strains including Toledo, Davis and TB40E (Fig. 4.25 C). 
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Fig. 4.25: Definition of the CRV nonamer as dominant IE-1 epitope. A: The minimal IE-1 epitope 
dominantly recognized by the polyclonal T cell line of donor ALT was determined in IFN-γ ELISpot as-
says. T cells (5000/well) were incubated overnight with autologous CD40-stimulated B cells (50 000/well) 
loaded with single IE-1-derived 15-aa or 9-aa peptides. Means and standard deviations of triplicate 
samples are shown. B: To confirm the minimal epitope, T cell clones of donor ALT were tested for their 
reactivity against titrated IE-1 peptides of 8–10 amino acids in length in IFN-γ ELISA assays. 20 000 T 
cells were incubated overnight with 50 000 autologous peptide-loaded CD40-stimulated B cells per well in 
duplicates. Data are shown for clone ALTM#127 CRV. C: Alignment of the CRV nonameric sequences of 
different HCMV strains.  
 
The postulated HLA-B*0702 restriction of the CRV epitope was deduced from an observed 
correlation of CRV peptide-specific T cells with the donors' HLA-B type (Kern et al., 1999). How-
ever, subsequent studies observed that the CRV peptide could not be refolded with HLA-B7 in 
order to produce HLA/peptide multimers (Khan et al., 2004). Indeed, the sequence of the CRV 
nonamer deviates from confirmed HLA-B*0702-restricted peptides with the latter having a pro-
line (P) in amino acid position two as a conserved anchor residue (Rammensee et al., 1999; 
Weekes et al., 1999). Therefore, the HLA restriction of the CRV epitope was reconsidered in 
this study. CRV-specific T cell clones from donors ALT, AJJ, AJU and F46 were challenged in 
an IFN-γ ELISA assay with IE-1-expressing and ctrl-mLCLs from various donors sharing differ-
ent HLA alleles with the T cell donors (Fig. 4.26 A). The T cell clones responded only to IE-1-
mLCLs coexpressing HLA-B*0702 and -C*0702. Due to the close association of HLA-B*0702 
and -C*0702 in the German population, donors with only one of these two HLA alleles were not 
available. Therefore, the HLA restriction of the CRV epitope was determined by transfecting WI-
38 fibroblasts (HLA-B*0702/-C*0702-negative) with plasmids encoding single candidate HLA 
allotypes, HLA-B*0702 or -C*0702. IE-1 was endogenously expressed in the transfected fibro-
blasts by infection with IE-1-encoding MVA. As a positive control for recognition in context of 
HLA-B*0702, a T cell clone specific for the HLA-B*0702-restricted pp65 epitope TPR (Wills et 
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al., 1996; Weekes et al., 1999) was challenged with transfected fibroblasts infected with MVA-
pp65. CRV-specific T cell clones from three different donors recognized IE-1 in the context of 
HLA-C*0702, but not HLA-B*0702 (Fig. 4.26 B). Hence, the postulated HLA-B*0702-restriction 
of the CRV epitope has to be considered as an error. 
 
 
Fig. 4.26: Determination of the HLA restriction of the CRV epitope. A: CRV-specific T cell clones 
from donors ALT, AJJ, AJU and F46 were challenged in an IFN-γ ELISA assay with IE-1- and ctrl-mLCLs 
from various donors sharing different HLA alleles with the T cell donors. 10 000 T cells/well were incu-
bated overnight with 20 000 mLCLs/well in two replicates. Data are shown for one representative T cell 
clone, AJU#90 CRV. B: CRV-specific T cell clones of donors AJJ, AJU and ALT (10 000 T cells/well) 
were tested in an IFN-γ ELISA assay for recognition of the CRV peptide on WI-38 fibroblasts transfected 
with candidate HLAs, B*0702 or C*0702, and infected with IE-1-encoding MVA (10 000 fibroblasts/well). 
No infection and wild-type (wt) MVA infection served as negative controls. T cell clone F37#5 specific for 
the HLA-B*0702-presented pp65 epitope TPR served as positive control for HLA-B*0702 restriction. 
Means and standard deviations of 3 replicates are shown. 
 
4.3.3 Frequency of HLA-C*0702-specific T cells in PBMCs of HCMV carriers 
In the following, the frequency of CRV-specific memory T cells in PBMCs of 15 HLA-C*0702-
carrying donors was investigated in IFN-γ ELISpot assays (Fig. 4.27 A). Strikingly, CRV 
nonapeptide-specific T cells could be detected in all donors tested, with an average of 345 IFN-
γ spots (range 29-837 spots) in 200 000 PBMCs. For selected donors, these ELISpot data were 
correlated with phenotypic analyses using HLA-C*0702/CRV-streptamer complexes obtained 
from a cooperation with the group of Michael Neuenhahn/Dirk Busch from Technische Universi-
tät München (Fig. 4.27 B). T cells directed towards the pp65-derived TPR epitope reported to be 
immunodominant in HLA-B*0702-positive HCMV carriers (Wills et al., 1996; Weekes et al., 
1999; Hebart et al., 2002) were stained for comparison. With 0.74–4.48% of total lymphocytes, 
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HLA-C*0702/CRV streptamer-positive cells are of high frequency in all three donors tested. The 
CRV-specific T cell numbers detected by multimer staining exceeded the number of IFN-γ-
secreting T cells in the ELISpot assays by several times. HLA-C*0702/CRV streptamer-positive 
cells were also more frequent than HLA-B*0702/TPR pentamer-positive cells. PBMCs of 
HCMV-positive/HLA-C*0702-negative donor SA05 and HCMV-negative/HLA-C*0702-positive 
donor ASM were stained as negative controls and did not show significant multimer-positive T 
cell populations. 
 
 
Fig. 4.27: Frequency of CRV-specific T cells in PBMCs. A: CRV nonamer-specific T cells were de-
tected in 15 HCMV-seropositive donors by ELISpot assays (200 000 PBMCs/well in 2–4 replicates). B: 
For selected donors, CRV-specific T cells were quantified by fluorescent staining with HLA-C*0702/CRV 
streptamer and anti-CD8 antibody. For comparison, HLA-B*0702/TPR pentamer staining was performed 
for the same donors. For each donor, stainings without multimers (ctrl) served as controls.  
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For the 15 HLA-C*0702-positive donors, the entire IE-1 sequence was screened for the T cell 
epitopes recognized by these donors in ELISpot assays using 120 IE-1 AD169 peptides distrib-
uted to 10 subpools, each comprising 12 successive 15-mers with 11 aa overlaps (Fig. 4.28 A). 
In most donors, the highest reactivity was detected against the subpool containing CRV 
(encompassing IE-1 amino acids 288-347). PBMCs were further tested for recognition of pub-
lished single IE-1 epitopes matching the donors' HLA types (data not shown). In 11 out of 15 
donors, CRV was the dominant IE-1 T cell epitope. In the remaining 4 donors (ALT, AJU, LM02 
and LM16), CRV was subdominant, and T cells were mainly directed against VLE (A*0201-re-
stricted) (Khan et al., 2002), DEEEAIVAY (B*1801-restricted) (Gavin et al., 1993; Retiere et al., 
2000) or ELKRKMIYM (B*0801-restricted) (Retiere et al., 2000; Saulquin et al., 2000). Six of the 
15 HLA-C*0702-positive donors analyzed also expressed HLA-A*0201, thus allowing the 
comparison of CRV- and VLE-specific T cell numbers (Fig. 4.28 B). With an average of 247 
spots per 200 000 PBMCs, CRV-specific T cells were 3-fold more frequent than VLE-specific T 
cells (average 84 spots). Finally, numbers of total IE-1-reactive T cells were compared between 
HLA-C*0702-positive and randomly chosen HLA-C*0702-negative donors using a full-length IE-
1 15-meric peptide library (Fig. 4.28 C). Total pp65-specific T cell numbers were determined in 
these donors for comparison. The HLA-C*0702-positive donors exhibited much higher average 
IE-1-specific T cell numbers, thus confirming the dominance of the HLA-C*0702-restricted 
epitope CRV within the IE-1-specific T cell repertoire. In contrast, pp65-specific T cells did not 
significantly differ in number between the two groups of donors. 
  
 
Fig. 4.28: Comparison of IE-1 epitope-specific T cell frequencies in IFN-γ ELISpot assays. A: For 
15 HLA-C*0702-positive donors, the IE-1 sequence was assessed for T cell epitopes using 120 IE-1 
AD169 peptides distributed to 10 subpools, each comprising 12 successive 15-mers with 11 aa overlaps. 
The last amino acid position represented in each subpool is indicated. B: CRV- and VLE-specific T cell 
numbers were compared in HLA-C*0702/-A*0201-positive donors. C: IE-1-specific T cell frequencies 
were compared in HLA-C*0702-positive and HLA-C*0702-negative donors. All IFN-γ ELISpot assays 
were performed with 200 000 peptide-loaded PBMCs/well and with 2-4 replicates per condition. 
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4.4 T cell recognition of IE-1 in context of an HCMV infection 
Despite the identification of IE-1-specific CD8+ T cells in a majority of HCMV carriers (Sylwester 
et al., 2005), the importance of these T cells has remained doubtful because some studies have 
described that IE-1-specific CTL recognition of HCMV-infected fibroblasts is strongly impaired in 
vitro (Gilbert et al., 1993; Besold et al., 2007). This observation was mainly attributed to the ac-
tion of HCMV-encoded immunoevasive proteins that interfere with MHC class I antigen 
presentation (Reddehase, 2002; Manley et al., 2004). Furthermore, a selective abrogation of IE-
1 peptide presentation by the HCMV matrix protein pp65 has been reported (Gilbert et al., 
1996). So far, T cell recognition of HCMV-infected fibroblasts was mainly studied with T cell 
clones directed against described HLA-A*0201-restricted IE-1 epitopes (Khan et al., 2005; Be-
sold et al., 2007; Besold et al., 2009). Therefore, it was now investigated whether recognition of 
infected fibroblasts by HLA-C*0702-restricted CRV-specific T cells was similarly impaired. 
 
4.4.1 Time course of IE-1 recognition on HCMV-infected fibroblasts by specific 
CD8+ T cell clones 
IE-1 recognition in context of an HCMV infection of fibroblast cells was comparatively analyzed 
with VLE- and CRV-specific T cell clones in IFN-γ ELISA assays. T cell clones specific for 
A*0201-restricted epitope NLV from pp65 were tested in parallel. Before infection with HCMV, 
fibroblasts were cultivated in standard culture medium (Fig. 4.29 A) or in IFN-γ-supplemented 
medium (Fig. 4.29 B) for 72 hours. The proinflammatory cytokine IFN-γ is abundantly produced 
during virus defense in vivo by CD8+ T cells, Th1 cells and NK cells. It enhances antigen 
presentation by infected cells and, accordingly, CD8+ T cell recognition, by increasing the 
expression of TAP components and MHC class I molecules (Benz and Hengel, 2000). In vitro T 
cell recognition experiments on infected fibroblasts provided evidence for an IFN-γ-dependent 
conditional presentation of an IE-1 peptide of MCMV (Hengel et al., 1994; Geginat et al., 1997). 
T cell clones were challenged with infected cells pretreated or not pretreated with IFN-γ, at 24, 
48, 72 and 96 hours post infection. In accordance with the literature, the structural protein pp65, 
which is introduced into cells upon infection by viral particles, was strongly recognized by NLV-
specific T cells already at 24 hours post infection (McLaughlin-Taylor et al., 1994; Varnum et al., 
2004). With IFN-γ pretreatment, recognition of NLV-specific T cells proportionately increased 
with the amount of virus applied (moi 5 vs. 10). Without IFN-γ pretreatment this effect was not 
detected at the 24-hour time point, probably because HLA molecules, not antigen, is limiting in 
this condition. T cell recognition of pp65/NLV decreased over time after infection, which corre-
lates with a progressive impairment of antigen presentation by viral immunoevasins (McLaugh-
lin-Taylor et al., 1994; Besold et al., 2007). T cell recognition of the HLA-A*0201-restricted IE-1 
epitope VLE was abolished at all time points post infection and in both pretreatment conditions. 
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By contrast, the HLA-C*0702-restricted IE-1 epitope CRV was recognized on infected fibro-
blasts during the whole 96 hours tested. The pretreatment of fibroblasts with IFN-γ led to a 
particularly strong recognition of CRV in infected cells, similar to peptide-loaded target cells. 
Furthermore, CRV recognition closely followed the expected kinetics of IE-1 expression in in-
fected fibroblasts (Besold et al., 2009) with a peak at 48–72 hours post infection. Thus, the 
HLA-C*0702-restricted CRV epitope escapes the mechanisms that prevent the presentation of 
other IE-1 epitopes in infected cells. 
 
 
Fig. 4.29: Time course of pp65- and IE-1-specific CD8+ T cell recognition of infected fibroblasts. IE-
1 and pp65 T cell epitopes were analyzed for their HLA-A*0201- or C*0702-restricted presentation to T 
cell clones at 24, 48, 72 and 96 hours post infection by IFN-γ ELISA assay. MRC-5 fibroblasts were (B) or 
were not (A) pretreated with IFN-γ 72 hours prior to infection at moi of 5 or 10. At the indicated time 
points post infection, 10 000 fibroblasts were incubated with 10 000 T cells for 16–18 hours. Not infected 
(n.i.) and peptide-loaded (+pep) cells served as controls at each time point and are depicted for 48 hours 
post infection. Means and standard deviations of triplicate samples are shown. One out of three 
independent experiments with clones ALTP#21 NLV, F61M#38 VLE and AJJM#7 CRV is shown. Experi-
ments were performed with a total of 3 NLV-, 6 VLE- and 12 CRV-specific T cell clones, from 3 different 
donors for each specificity. 
 
To exclude that the observed differential recognition of NLV, VLE and CRV epitopes was due to 
avidity differences of the specific T cell clones, peptide titration experiments were performed 
(Fig. 4.30). In IFN-γ ELISA assays, NLV-, VLE- and CRV-specific T cell clones were challenged 
with autologous or HLA-matched CD40-stimulated B cells loaded with serially 10-fold diluted 
NLV, VLE and CRV peptides. Among the T cells tested, the NLV-specific T cell clones showed 
lowest avidity for their target peptides, with a recognition of NLV peptide down to 10-8 mol/L. 
VLE- and CRV-specific T cell clones showed similarly high avidity for their target peptides with 
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recognition down to 10-9 mol/L. Hence, avidity differences of the T cell clones were not responsi-
ble for the observed differential T cell recognition of HCMV-infected fibroblasts. 
 
 
Fig. 4.30: Avidities of NLV-, VLE- and CRV-specific T cell clones for their target peptides. Two sets 
of NLV-, VLE- and CRV-specific T cell clones (A and B) were compared for their reactivity against 10-fold 
diluted target peptides in IFN-γ ELISA assays. T cells (10 000/well) were incubated overnight with CD40-
stimulated B cells (20 000/well) loaded with their target peptides. Means and standard deviations of three 
replicates are shown. 
 
4.4.2 Influence of pp65 on T cell recognition of IE-1 
Early studies described that a pp65-associated kinase activity, potentially polo-like kinase 1 
(Gallina et al., 1999), selectively blocks presentation of IE-1-derived peptides, associated with 
phosphorylation of the IE-1 protein (Gilbert et al., 1996). However, most of their experiments 
employed overexpression of the two HCMV proteins by vaccinia vectors, not genuine HCMV 
infection. The mechanism by which phosphorylation of IE-1 purportedly interferes with T cell 
recognition is unclear. Gilbert and colleagues suggested that the modification of IE-1 might limit 
its access to the antigen processing machinery (Gilbert et al., 1996). To test whether pp65 inter-
feres with VLE and CRV peptide presentation to T cells, VLE- and CRV-specific T cell clones 
were challenged with fibroblasts infected with a pp65-deleted HCMV strain or wild-type HCMV. 
Not infected and peptide-loaded fibroblasts served as controls. NLV-specific T cell clones were 
used to verify presence or absence of the pp65 protein. IFN-γ secretion and direct cytotoxicity 
were analyzed as effector functions of the T cell clones by ELISA (Fig. 4.31 A) or calcein-re-
lease assay (Fig. 4.31 B), respectively. NLV-specific T cell clones recognized target cells only in 
the context of wild-type HCMV infection. Concerning IE-1 recognition, deletion of pp65 did not 
restore VLE recognition nor enhance CRV recognition by specific T cell clones. Hence, pp65 is 
not responsible for the observed differential recognition of IE-1 by VLE- and CRV-specific T cell 
clones. 
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Fig. 4.31: Evaluation of a possible interference of pp65 with IE-1 presentation. To evaluate the influ-
ence of pp65 on IE-1 presentation, VLE- and CRV-specific T cell clones, and for comparison pp65 NLV-
specific T cell clones, were challenged with IFN-γ-pretreated fibroblasts infected with a pp65-deleted 
HCMV strain or wild-type HCMV for 24 hours. Not infected and peptide-loaded fibroblasts served as con-
trols. IFN-γ secretion and direct cytotoxicity were analyzed by ELISA (A, 10 000 T cells and 10 000 target 
cells per well in 3 replicates) and calcein-release assay (B, 5000 target cells and 20 000 T cells per well 
in 5 replicates), respectively. 
 
Gilbert et al. hypothesized that phosphorylation of IE-1 was responsible for abrogation of IE-1 
presentation by preventing IE-1 protein from being processed to generate appropriate HLA 
class I peptides (Gilbert et al., 1996). Alternatively, amino acids that are part of the T cell 
epitope peptides themselves could be phosporylated, and this might affect peptide binding to 
HLA class I or T cell recognition. Indeed, the VLE nonamer (VLEETSVML) contains two poten-
tial phosphorylation sites, a threonine at position five and a serine at position six. These resi-
dues are plausible target sites of Polo-like kinases, which prefer acidic residues at the –2 posi-
tion relative to the phosphorylation site (Nakajima et al., 2003). Therefore, the recognition of 
phosphorylated and not phosphorylated VLE peptide by VLE-specific T cell clones was 
comparatively assessed in peptide titration studies (Fig. 4.32). The reactivity of VLE-specific T 
cell clones against CD40-stimulated B cells loaded with the VLE variants in different concentra-
tions was analyzed in IFN-γ ELISA assays. All VLE-specific T cell clones tested showed similar 
avidity to VLE and its phosphovariants. This result indicates that phosphorylation of the VLE 
peptide, whether mediated by pp65 or not, is not the mechanism responsible for impairing VLE 
peptide presentation. 
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Fig. 4.32: Avidity of VLE-specific T cell clones for phosphorylated target peptides. Two VLE-spe-
cific T cell clones (A and B) were tested for their reactivity against VLE peptide and phosphorylated VLE 
variants in IFN-γ ELISA assays. CD40-stimulated B cells were loaded with 10-fold diluted peptides. 
Excessive peptides were washed away in order to prevent dephosphorylation of free peptides by serum 
phosphatases and subsequent presentation to T cells. 10 000 T cells/well were incubated overnight with 
20 000 target cells/well. Means and standard deviations of three replicates are shown. 
 
4.4.3 Influence of HCMV immunoevasins on T cell recognition of IE-1 
HCMV encodes at least four immunoevasive proteins, gpUS2, 3, 6 and 11, that prevent the 
presentation of viral peptides by MHC class I molecules to CD8+ T cells (Manley et al., 2004; 
Khan et al., 2005; Besold et al., 2009). Each of these immunoevasins acts via downregulation of 
MHC class I surface expression, however, by different molecular mechanisms: gpUS6 interferes 
with peptide transport into the endoplasmatic reticulum (ER), gpUS3 retains MHC class I mole-
cules in the ER, and gpUS2 and 11 target MHC class I heavy chains for cytoplasmic degrada-
tion (Ahn et al., 1996; Jones et al., 1996; Wiertz et al., 1996a; Wiertz et al., 1996b; Ahn et al., 
1997). In the following experiments, the influence of gpUS2–11 on the presentation of IE-1 pep-
tides by different HLA allomorphs was investigated in detail for a larger panel of allomorphs than 
previously studied.   
 
First, the time course of HLA class I expression on the surface of infected fibroblasts was 
reevaluated by flow cytometry (Fig. 4.33). Antibodies were available against total HLA-A/B/C as 
well as HLA-A2 and -B7 which are expressed on MRC-5 fibroblasts in addition to HLA-C*0702. 
Specific mean fluorescent intensities (MFIs) were generally higher after IFN-γ pretreatment 
(data not shown) confirming an enhancement of HLA expression under this condition. To as-
sess specific effects of HCMV immunoevasins, HLA expression data were normalized to the 
data obtained after infection with an HCMV mutant deleted for the four HLA class I immunoeva-
sins gpUS2, 3, 6, and 11 (CMV-∆all) (Besold et al., 2009). Infection with wild-type HCMV re-
duced HLA-A2 and HLA-B7 expression to very low levels, irrespective of pretreatment with IFN-
γ. In contrast, total HLA-A/B/C expression was less strongly reduced, suggesting that certain 
HLA molecules, potentially including HLA-C*0702, are more resistant to HCMV-mediated 
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downregulation than HLA-A2 and -B7. Unfortunately, an HLA-C7-specific antibody was not 
available to confirm this hypothesis. 
 
 
Fig. 4.33: Time course of MHC class I surface expression of infected fibroblasts. HLA-A/B/C, HLA-
A2 and HLA-B7 surface expression on infected fibroblasts was analyzed over time by flow cytometry. 
MRC-5 cells that had or had not been pretreated with IFN-γ for 72 hours were infected with CMV-wt or 
CMV-∆all (US2/3/6/11 deleted) at an moi of 5. The specific mean fluorescence intensities (MFIs) were 
calculated by subtracting the MFIs of isotype controls from the MFIs of specific stainings. Values were 
standardized to the specific MFIs of CMV-∆all-infected cells set to 100%. Means and standard deviations 
of three (HLA-ABC and -A2) or two (HLA-B7) independent experiments are shown. 
 
In previous studies, deletion of gpUS2–11 from HCMV AD169 restored efficient HLA-A*0201-
restricted IE-1 peptide presentation to specific T cell clones (Khan et al., 2005; Besold et al., 
2007). However, comparative analyses with IE-1-specific T cell clones of different HLA re-
strictions have not been performed so far. Therefore, the influence of gpUS2–11 on the T cell 
recognition of IE-1 epitopes presented by different HLA class I allomorphs was studied in the 
next experiment (Fig. 4.34). T cell clones of four HLA restrictions other than HLA-A*0201 and -
C*0702 were established from IE-1-mLCL-stimulated polyclonal T cell cultures by limiting dilu-
tion: the epitopes presented by HLA-A*6801 (ATT), B*0801 (QIK) and B*4001 (KEV) were al-
ready described (Elkington et al., 2003; Khan et al., 2007); the A*0301 epitope was identified 
within this study (section 4.3.1). IFN-γ pretreated fibroblast cells were infected with wild-type 
HCMV or CMV-∆all and subjected to T cell recognition 48 hours post infection. Not infected and 
peptide-loaded cells served as controls. T cell recognition was measured by IFN-γ ELISA. 
Among the 15 T cell clones with 6 different HLA restrictions, only the four HLA-C*0702-re-
stricted clones showed a distinct reactivity to fibroblasts infected with wild-type HCMV. In con-
trast, CMV-∆all-infected cells were recognized by all T cell clones. T cell reactivities against 
CMV-∆all were very similar to reactivities against target cells exogenously loaded with peptide, 
suggesting that CMV-∆all was devoid of any relevant immunoevasive function. In summary, 
viral immunoevasins completely blocked antigen presentation by each of the HLA-A and HLA-B 
alleles tested, but not by HLA-C*0702. 
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Fig. 4.34: Impact of HCMV immunoevasins on the T cell recognition of IE-1 epitopes presented by 
different HLA allomorphs. IE-1-specific T cell clones with different HLA restrictions were used in IFN-γ 
ELISA assays to analyze the influence of gpUS2–11 on IE-1 recognition. To cover every required HLA 
allotype, three primary fibroblast cell lines were used: MRC-5 for CRV (C*0702) and VLE (A*0201), WI-38 
for ATT (A*6801) and QIK (B*0801), BFF2 for RHR (A*0301) and KEV (B*4001). Fibroblasts were pre-
treated with IFN-γ for 72 hours and infected with CMV-wt or CMV-∆all at moi = 5 for 48 hours. Not in-
fected (n.i.) and peptide-loaded (n.i.+ peptide) cells served as negative and positive controls, respectively. 
10 000 fibroblasts were incubated overnight with 10 000 T cells per well in triplicates. One to four 
representative T cell clones of each epitope specificity are shown from one out of three independent 
experiments. 
 
4.5 Allotype-specific action of HCMV immunoevasins 
As shown in the previous section, recognition of IE-1 epitopes by specific T cell clones of differ-
ent HLA-A and -B restrictions is severely suppressed by the action of HCMV immunoevasins 
gpUS2–11, even after pretreatment of cells with IFN-γ. By contrast, CRV-specific T cell recogni-
tion is largely intact, suggesting that HLA-C*0702 is spared by individual immunoevasins. Sev-
eral studies have addressed HLA class I allele-specific effects of HCMV immunoevasins, in 
particular of US2 and US11 (Schust et al., 1998; Barel et al., 2006). However, most of these 
studies have been limited to molecular or phenotypic investigations of transfected or transduced 
cell systems. Consequently, the impact of observed HLA class I allotype-specific effects of 
individual immunoevasins on the T cell recognition of infected cells has remained unexplored. 
 
Therefore, this study aimed at providing a first systematic analysis of HLA class I allotype-spe-
cific effects of individual immunoevasins by using a set of HCMV strains, each deleted for three 
of the four virus-encoded immunoevasins US2, US3, US6 and US11. CD8+ T cell clones 
recognizing IE-1- and pp65-derived peptides on different HLA allomorphs were challenged with 
fibroblasts infected with the HCMV deletion mutants. In addition to investigate their allele-spe-
cific action, the following part of this work was also dedicated to characterize HCMV class I-spe-
cific immunoevasins in terms of molecular target structures, cooperation among each other, 
specialization for different phases of the viral replication cycle and compensation of their effects 
by IFN-γ.  
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4.5.1 Glycoproteins US2 and US11 
The viral early proteins gpUS2 and gpUS11 both independently target HLA class I molecules for 
proteasomal degradation (Wiertz et al., 1996a; Wiertz et al., 1996b; Jones and Sun, 1997) but 
differ in their specificity for HLA class I alleles (Schust et al., 1998; Barel et al., 2003a; Barel et 
al., 2003b). In the following experiments, HLA class I allotype-specific patterns of US2- and 
US11-mediated interference with CD8+ T cell recognition were determined (Fig. 4.35). Fibro-
blasts pretreated (Fig. 4.35 B) or not pretreated (Fig. 4.35 A) with IFN-γ were infected with 
HCMV strains expressing only US2 (CMV-US2) or only US11 (CMV-US11), but not the other 
three proteins of the US2/3/6/11 group (Besold et al., 2009), and used to challenge CD8+ T cell 
clones with different HLA restrictions in IFN-γ ELISA assays. The analyses included T cell 
clones recognizing IE-1-derived peptides presented by HLA-A*0201 (VLE), C*0702 (CRV), 
A*6801 (ATT), B*0801 (QIK), A*0301 (RHR) and B*4001 (KEV). The recognition of IE-1 by T 
cell clones restricted through B*0801 was not impaired under both pretreatment conditions 
when US2 or US11 was present. HLA-B*4001- and C*0702-dependent presentation was also 
largely intact after IFN-γ pretreatment. Without IFN-γ pretreatment, HLA-C*0702-mediated T cell 
recognition was moderately reduced by US2 and US11, with some differences between the four 
CRV-specific T cell clones tested. HLA-A*0201-restricted recognition was fully abolished for 
most T cell clones by each of the immunoevasins US2 and US11 and in both pretreatment 
conditions. The allomorphs HLA-A*0301, A*6801 and B*4001 were differentially affected by 
US2 and US11: A*6801 and B*4001 were more strongly affected by US2, A*0301 by US11. As 
expected, the impairment of T cell recognition was more pronounced without IFN-γ pretreatment 
for all three allomorphs. 
  
These ELISA data were compatible with HLA expression data obtained by surface staining of 
HLA-A/B/C, A2 and B7 (Fig. 4.33 and 4.36). Each of US2 and US11 alone led to a strong 
downregulation of HLA-A2 surface expression in infected MRC-5 fibroblasts (Fig. 4.36), 
indistinguishable from wild-type HCMV-infected cells. By contrast, surface expression of an 
MRC-5-encoded HLA-B allele, HLA-B7, and of total HLA-A/B/C was less affected by US2 and 
US11. For all HLA allomorphs investigated, the decrease in the relative expression levels was 
largely independent of pretreatment with IFN-γ. However, the specific mean fluorescent intensi-
ties (MFIs) obtained for IFN-γ-pretreated cells (data not shown) were generally higher compared 
to untreated cells confirming an enhancement of HLA expression under this condition. These 
higher MHC class I expression levels appeared to compensate for some effects of US2 and 
US11 (Fig. 4.35 B; C*0702, B*4001, A*0301). In summary, infection with CMV-wt strongly 
reduced HLA-A2 and -B7, but less so total HLA-A/B/C indicating that MHC allomorphs other 
than HLA-A2 and -B7 are more resistant to HCMV immunoevasins. 
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Fig. 4.35: Impact of HCMV immunoevasins US2 and US11 on the recognition of IE-1 T cell epitopes 
with different HLA restrictions. IE-1-specific T cell clones were used in IFN-γ ELISA assays to analyze 
antigen recognition on fibroblast cells infected with immunoevasion-defective HCMV strains CMV-∆all 
(US2/3/6/11 deleted), CMV-US2 (US3/6/11 deleted) and CMV-US11 (US2/3/6 deleted). To cover every 
required HLA allotype, three primary fibroblast cell lines were used: MRC-5 for CRV (C*0702) and VLE 
(A*0201), WI-38 for ATT (A*6801) and QIK (B*0801), BFF2 for RHR (A*0301) and KEV (B*4001). Fibro-
blasts were pretreated with IFN-γ for 72 hours (B) or not pretreated (A) prior to infection with the different 
HCMV strains at moi = 5 for 48 hours. Not infected (n.i.) fibroblasts served as controls. 10 000 fibroblasts 
were incubated overnight with 10 000 T cells per well in triplicates. One to four representative T cell 
clones of each epitope specificity are shown from one out of three independent experiments. 
 
 
 
 
Fig. 4.36: Impact of US2 and US11 on HLA class I surface expression of infected fibroblasts. HLA 
class I expression was analyzed by flow cytometry of HCMV-infected MRC-5 cells that had or had not 
been pretreated with IFN-γ for 72 hours before infection. MRC-5 cells were infected at moi = 5 with wild-
type HCMV ("wt") or recombinant viruses CMV-US2 (US3/6/11-deleted, "US2") and CMV-US11 (US2/3/6-
deleted, "US11") for 48 hours. The specific mean fluorescence intensities (MFIs) were calculated by 
subtracting the MFIs of isotype controls from the MFIs of specific stainings. Values were standardized to 
the specific MFIs of CMV-∆all (US2/3/6/11 deleted) infected cells set to 100%. Means and standard 
deviations of two (HLA-B7 and -A2) or three (HLA-ABC) independent experiments are shown. 
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Furthermore, HLA allomorph-specific effects of US2 and US11 on target cell killing, another im-
portant effector function of CD8+ T cells, were analyzed by calcein-release assay (Fig. 4.37). 
MRC-5 fibroblasts pretreated with IFN-γ (Fig. 4.37 B) or not pretreated (Fig. 4.37 A) were in-
fected with wild-type HCMV or mutant viruses deleted for all immunoevasins (CMV-∆all) or 
expressing only US11 (CMV-US11) or US2 (CMV-US2). Not infected and peptide-loaded fibro-
blasts served as controls. T cell clones were specific for NLV/pp65 (HLA-A*0201), VLE/IE-1 
(HLA-A*0201) and CRV/IE-1 (HLA-C*0702). All T cell clones efficiently killed fibroblasts infected 
with CMV-∆all or loaded with peptide. HLA-C*0702-restricted IE-1-specific T cell clones showed 
unimpaired lysis of cells infected with CMV-US2 or CMV-US11, and were capable to lyse wild-
type HCMV-infected cells under both pretreatment conditions. By contrast, HLA-A*0201-re-
stricted IE-1-specific T cell clones only marginally lysed wild-type HCMV, CMV-US2 or CMV-
US11-infected cells. As expected (Fig. 4.29), T cells specific for pp65 (NLV) were capable of 
killing wild-type HCMV-infected cells, however, to a lesser extent than peptide-loaded cells 
when the fibroblasts were not pretreated with IFN-γ. In contrast to HLA-A*0201-restricted VLE-
specific T cells, A*0201-restricted NLV-specific T cell killing of infected cells was not significantly 
affected by either US2 and US11, which might be due to the high abundance of pp65 in infected 
fibroblasts before de novo expression of viral genes including US2 and US11. In summary, allo-
type-specific interference with T cell recognition of the IE-1 antigen similarly affected cytokine 
secretion and T cell-mediated killing. 
   
 
Fig. 4.37: Effect of HCMV immunoevasins on IE-1 epitope-specific T cell cytotoxicity. MRC-5 fibro-
blasts were pretreated with IFN-γ for 72 hours (B) or not pretreated (A) and infected at moi = 5 with viral 
strains CMV-wt, CMV-∆all (US2/3/6/11 deleted), CMV-US11 (US2/3/6 deleted) or CMV-US2 (US3/6/11 
deleted). Cytotoxicity was determined at 48 hours post infection in a calcein-release assay using an effec-
tor/target ratio of 4. Fibroblasts that were not infected (n.i.) or peptide-loaded (n.i.+peptide) were negative 
and positive controls, respectively. Means and standard deviations of three to four replicates are shown. 
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4.5.2 Function of domains of HLA class I molecules in immunoevasion 
The T cell experiments showed that HLA-C*0702- and A*0201-mediated antigen presentation 
were affected to a very different degree by US2 and US11. These viral glycoproteins target 
MHC class I molecules for intracellular degradation by direct interactions with different parts of 
the MHC heavy chain: US2 interacts with amino acids near the boundary of the HLA α2 and α3 
domains, US11 with regions in the α1/α2 domains and, more importantly, in the cytosolic tail of 
the HLA molecule (Barel et al., 2003a; Barel et al., 2006). The aim of the following experiment 
was to assess whether antigen presentation to CD8+ T cells, and destabilizing interactions with 
HCMV immunoevasins, were mediated by separate domains of HLA class I molecules. To this 
purpose, chimeric HLA class I heavy chains containing the N-terminal part of one of these HLA 
allomorphs (comprising the α1/α2 domains that present antigen) and the C-terminal part of the 
other allomorph (comprising the α3 domain, transmembrane region and cytosolic tail, suppos-
edly targeted by viral destabilization) were constructed. To test the functionality of the con-
structs, WI-38 fibroblasts, which are negative for HLA-A*0201 and -C*0702, were transfected 
with plasmids encoding parental or chimeric HLA, infected with MVA-IE-1, and tested for 
recognition by IE-1-specific T cells in an IFN-γ ELISA assay (Fig. 4.38). The HLA-A*0201-re-
stricted VLE peptide was only recognized on HLA-A*0201 and chimeric HLA-A2/C7 (A*0201 N-
terminus, C*0702 C-terminus) (Fig. 4.38 A), whereas the HLA-C*0702-restricted CRV peptide 
was only recognized on HLA-C*0702 and chimeric HLA-C7/A2 (C*0702 N-terminus, A*0201 C-
terminus) (Fig. 4.38 B), confirming that the chimeric molecules had full capability to present anti-
gen. 
 
 
Fig. 4.38: Functional evaluation of chimeric HLA class I molecules. WI-38 fibroblasts (HLA-
A*0201/C*0702-negative) were transfected with plasmids encoding HLA-A*0201, HLA-C*0702, or chi-
meric HLA class I heavy chains HLA-A2/C7 (A*0201 N-terminus, C*0702 C-terminus) or HLA-C7/A2 
(C*0702 N-terminus, A*0201 C-terminus), and subsequently infected with MVA-IE-1 at moi = 10 for 24 
hours. Presentation of IE-1 epitopes was detected by VLE- and CRV-specific T cell clones in an IFN-γ 
ELISA assay (10 000 T cells and 10 000 target cells per well). Means and standard deviations of three 
replicates are shown for 3 T cell clones generated from 3 different donors for each specificity. 
 
Then, the effects of US2 and US11 on antigen presentation by native and chimeric molecules 
were tested in the context of an HCMV infection (Fig. 4.39). Again, WI-38 fibroblasts were trans-
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fected with plasmids encoding parental or chimeric HLAs, infected with CMV-wt, CMV-∆all, 
CMV-US11 or CMV-US2 and used to stimulate VLE- and CRV-specific T cell clones in an IFN-γ 
ELISA assay. As expected, T cell recognition of the HLA-A*0201 and HLA-C*0702 epitopes was 
differentially affected by different HCMV strains in cells transfected with native MHC class I 
genes: recognition of A*0201/VLE was strongly reduced by wild-type HCMV, CMV-US2, or 
CMV-US11, whereas recognition of C*0702/CRV was not impaired by CMV-US2 or CMV-US11 
and only partially by wild-type HCMV infection. Strikingly, in the chimeric HLA-A2/C7 or -C7/A2 
molecules a complete exchange of the patterns of sensitivity to HCMV immunoevasins was 
observed. Thus, while the α1/α2 domains present antigen to T cells, the C-terminal part including 
the α3 domain largely governs the sensitivity of MHC class I molecules to HCMV immunoeva-
sins, and these functions are separable and exchangeable. 
 
 
Fig. 4.39: Functional separation of epitope presentation and US2 and US11 immunoevasion. WI-38 
fibroblasts (HLA-A*0201/C*0702-negative) were transfected (A) with plasmids encoding HLA-A*0201 or 
HLA-C*0702, or (B) with chimeric HLA class I heavy chains HLA-A2/C7 (A*0201 N-terminus, C*0702 C-
terminus) or HLA-C7/A2 (C*0702 N-terminus, A*0201 C-terminus), and subsequently infected with CMV-
wt, CMV-∆all, CMV-US2 or CMV-US11. Not infected (n.i.) and peptide-loaded (+pep) fibroblasts served 
as negative and positive controls, respectively. Antigen-specific T cell recognition was detected by 
measuring IFN-γ secretion by ELISA after overnight incubation of 10 000 clonal T cells with 10 000 target 
cells per well. Three T cell clones generated from 3 different donors were used as effectors for each 
specificity. Means and standard deviations of triplicate samples from one of two independent experiments 
are shown. 
 
4.5.3 Time course of interference with IE-1 and pp65 epitope presentation 
In the presence of US2 and US11, CD8+ T cell recognition of IE-1 peptides presented on HLA-
B and -C allotypes was not significantly affected (Fig. 4.36). Likewise, HLA-A*0301 epitope 
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presentation was largely intact. This implies that the other two HCMV-encoded immunoevasins, 
US3 and US6, largely prevented peptide presentation by the B alleles and largely contributed to 
prevent A*0301-mediated presentation. To guarantee an optimal protection of infected cells 
against T cell recognition, HCMV immunoevasins are expressed at overlapping phases during 
the viral replication cycle. The US3 protein has been identified as an IE-gene product, with the 
US3 transcripts appearing as early as one hour post infection (Weston, 1988; Tenney and Col-
berg-Poley, 1991; Liu et al., 2002). US2 protein expression was detected by 4 hours post infec-
tion, was most abundant at 6 to 10 hours post infection, and persisted at lower but constant 
levels through the remainder of the replicative cycle, thus indicating early-late expression kinet-
ics (Jones and Sun, 1997). Similarly, US11 transcripts appeared at early times post infection 
and then progressively decreased in abundance at late times post infection (Jones and Muzi-
thras, 1991). US6 mRNA is most abundant at late times post infection (Jones and Muzithras, 
1991), resulting in a decrease of peptide transport rates to background levels at 96 hours post 
infection (Hengel et al., 1996). To get an overall picture of the concerted action of all four 
immunoevasins over time, CD8+ T cell recognition of pp65 and IE-1 epitopes on fibroblasts 
infected with CMV-wt, CMV-∆all, CMV-US11, CMV-US2, CMV-US6, or CMV-US3 was asses-
sed at 24, 48, 72 and 96 hours post infection in IFN-γ ELISA assays (Fig. 4.40 and Fig. 4.41). 
By using fibroblasts pretreated with IFN-γ for 72 hours prior to infection (Fig. 4.40 B and Fig. 
4.41 B) and not pretreated fibroblasts (Fig. 4.40 A and Fig. 4.41 A), the compensatory effects of 
the proinflammatory cytokine IFN-γ on the action of individual immunoevasins were also analy-
zed. The experiment included IE-1-specific T cell clones specific for VLE (A*0201), RHR 
(A*0301), ATT (A*6801), QIK (B*0801), or CRV (C*0702) as before, and for an additional 
epitope restricted through HLA-B*1801, ELRRKMMYM (Retiere et al., 2000) (Fig. 4.40). Also 
included were pp65-specific T cell clones that recognized NLV (A*0201), TPR (B*0702), as 
described in previous parts of this work, RPH (B*0702) (Weekes et al., 1999), or IPS (B*3501) 
(Gavin et al., 1993) (Fig. 4.41). 
 
Consistent with previous results of this study (Fig. 4.29 and Fig. 4.34), recognition of IE-1 
epitopes on CMV-wt-infected cells was severely suppressed for all HLA allomorphs except 
C*0702 over the whole time period tested. This suppression was complete in the absence of 
IFN-γ pretreatment, and nearly so in its presence. HLA-C*0702 was the only allotype whose 
recognition was still clearly detectable in the absence of IFN-γ treatment, and was largely 
unimpaired after such treatment. With the mutant viruses, distinct patterns of allotype-specific 
interference with IE-1 presentation were detected for each of the four immunoevasins. 
Differential effects of individual immunoevasins were also observed for pp65 epitopes, despite a 
generally better presentation of pp65 epitopes even in wild-type HCMV infection.  As mentioned 
above, pp65 presentation is expected to be partially resistant to immunoevasion, due to the 
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exceptionally high abundance of this protein in infected fibroblasts and its transfer to cells by 
viral particles before the onset of any viral gene expression.   
 
The sequences of all pp65 and IE-1 epitopes included in this experiment are not expected to be 
of high hydrophobicity, because all of them contain charged side chains (except NLV, which 
contains several polar side chains). Thus, they are unlikely candidates for TAP-independent 
MHC class I presentation (Lautscham et al., 2003). Consistent with this observation, TAP-inhibi-
tion by US6 strongly affected presentation of all peptides from both antigens, IE-1 or pp65, by 
each HLA allomorph. Furthermore, effects of US6 were apparent during the whole 96 hours, 
which is in accordance with its early-late expression kinetics. Strikingly, US6-mediated impair-
ment of T cell recognition was largely or, at the earlier time points, even completely compensa-
ted by IFN-γ pretreatment of fibroblasts.   
 
For the other three immunoevasins gpUS11, gpUS2, and gpUS3, clear patterns of allele-spe-
cific effects were detected. Among the HLA allomorphs tested, only A*0301 and C*0702 were 
completely resistent to US3. Consistent with its expression at IE times post infection, US3 im-
paired peptide presentation by the other allomorphs mainly at the earlier time-points tested. 
HLA-B*0702 and B*0801 were particularly susceptible to US3, which suppressed T cell recogni-
tion by these allomorphs almost to CMV-wt level at 24 hours post infection. Strikingly, recogni-
tion of CMV-US3-infected fibroblasts was fully restored for all HLA allomorphs after IFN-γ 
pretreatment. 
 
The HLA-B*0801 and B*0702 epitopes largely escaped both US2 and US11, whereas all other 
HLA allomorphs included in the experiment were affected by these immunoevasins to a various 
extent. The US2/11-sensitive HLA allomorphs differed in their susceptibility to individual 
immunoevasins US2 and US11: for each of the allomorphs HLA-A*0201, C*0702, and B*3501,  
the effect of US2 was similar in size to the effect of US11, although A*0201-dependent 
presentation was much more strongly suppressed than presentation by HLA-C*0702 or B*3501. 
Other allotypes showed a different behavior: HLA-A*6801 and B*1801 were more susceptible to 
US2, and A*0301 more to US11. Impairment of T cell recognition by US2 or US11 was apparent 
during the whole 96 hours analyzed and decreased with time for many T cell clones tested, 
which is in accordance with the reported US2/11 expression peaking at early times post infec-
tion. In contrast to US6 and US3, the effects of US2 and US11 on T cell recognition were fully 
reversed by IFN-γ pretreatment only for those allomorphs that were not highly US2/US11-
sensitive in the absence of IFN-γ. 
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Fig. 4.40: Time course of HCMV immunoevasion of IE-1 T cell recognition by US2, 3, 6, and 11. 
MRC-5 (A*0201, C*0702), WI-38 (A*6801, B*0801), BFF2 (A*0301) or CZF (B*1801) fibroblasts were 
pretreated with IFN-γ (B) or not pretreated (A) and infected at moi = 5 with CMV-wt (wt) or recombinant 
HCMV strains expressing no immunoevasin (CMV-∆all) or only one of US11, US2, US3, or US6. At 24, 
48, 72 and 96 hours post infection (hpi), IE-1 presentation was detected by specific T cell clones and 
analyzed in IFN-γ ELISAs (10 000 fibroblasts and 10 000 T cells per well in triplicates). Data were 
normalized to recognition of CMV-∆all-infected cells set to 100%. One representative T cell clone is 
shown for each epitope specificity from one out of 1–3 independent experiments. 
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Fig. 4.41: Time course of HCMV immunoevasion of pp65 T cell recognition by US2, 3, 6, and 11. 
MRC-5 (A*0201, B*0702) or BFF2 (B*3501) fibroblasts were pretreated with IFN-γ (B) or not pretreated 
(A) and infected with CMV-wt (wt) or recombinant HCMV strains expressing no immunoevasin (CMV-∆all) 
or only one of US11, US2, US3, or US6 at moi = 5. Not infected (n.i.) and peptide-loaded (pep) fibroblasts 
served as controls. At 24, 48, 72 and 96 hours post infection (hpi), pp65 presentation was detected by 
specific T cell clones and analyzed in IFN-γ ELISAs (10 000 fibroblasts and 10 000 T cells per well in 
triplicates). Data were normalized to recognition of CMV-∆all-infected cells set to 100%. One representa-
tive T cell clone is shown for each epitope specificity from one out of 1–3 independent experiments. 
 
The observed effects of individual immunoevasins on T cell recognition over time were com-
pared to their effects on HLA surface expression, analyzed by flow cytometry. Again, fibroblasts 
were infected with wild-type HCMV or the single-immunoevasin HCMV strains (Fig. 4.42) after 
cultivation with or without IFN-γ for 72 hours. Specific antibodies were available for total HLA-
A/B/C, A2 and B7. Relative HLA expression levels were calculated in relation to CMV-∆all-in-
fected cells set to 100%. Specific MFIs of IFN-γ-pretreated cells were generally higher than spe-
cific MFIs of not pretreated cells (data not shown). As already shown before (Fig. 4.33), infec-
tion with CMV-wt downregulated HLA-A2 and -B7 expression to low residual levels in both 
pretreatment conditions, less so total HLA-A/B/C. Downregulation of HLA-A2 could be detected 
for all four immunoevasins, which is in accordance with the T cell recognition data. However, 
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US3 effects appeared more pronounced on the HLA expression level (compared to the T cell 
level) and could not be fully compensated by IFN-γ. Consistent with the abolishment of TPR and 
RPH epitope recognition without IFN-γ pretreatment, US6 and US3 had strong effects on HLA-
B7 expression. However, whereas T cell recognition could be fully restored by IFN-γ, the 
relative B7 downregulation was similar in both pretreatment conditions. This suggests that the 
absolute number of B*0702/antigen complexes, and not their relative downregulation, was 
decisive for T cell recognition. More unexpected was the observation that US2 and US11 re-
duced HLA-B7 surface expression as efficiently as US3 and US6, but did not significantly impair 
B7-dependent T cell recognition, in contrast to US3 and US6. Total HLA-A/B/C expression was 
affected by all four immunoevasins but to lesser extent than HLA-A2 and B7, indicating the 
presence of HLA allomorphs on MRC-5 cells which are more resistent to individual 
immunoevasins than A2 and B7. In summary, this result suggests that a reduction of the relative 
HLA expression levels does not necessarily impact on T cell recognition. T cell recognition 
might be largely intact as long as sufficient HLA molecules are still available for antigen 
presentation, which is especially the case after IFN-γ pretreatment. Furthermore, T cell recogni-
tion may also depend on the availability of target peptides as well as the avidity of the T cells. 
This result also indicates that biochemical analyses of immunoevasins' relative effects on HLA 
expression do not allow to predict their impact on T cell recognition with certainty. 
 
 
Fig. 4.42: Impact US2, 3, 6, and 11 on HLA class I surface expression of infected fibroblasts.  MRC-
5 cells that had (B) or had not (A) been pretreated with IFN-γ were infected at moi = 5 with CMV-wt or 
recombinant HCMV strains expressing no immunoevasin (CMV-∆all) or only one of US11, US2, US3, or 
US6. At 24, 48, 72 and 96 hpi, HLA-A/B/C, A2 and B7 surface expression was analyzed by flow cytome-
try. The specific MFIs were calculated by subtracting the MFIs of isotype controls from the MFIs of spe-
cific stainings. Values were normalized to specific MFIs of CMV-∆all-infected cells set to 100%. Means 
and standard deviations of two (HLA-B7, A2) or three (HLA-A/B/C) independent experiments are shown. 
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4.5.4 Immunoevasion of T cell recognition under immediate-early conditions 
The immediate-early phase is a critical time during the lytic cycle of HCMV, as both exoge-
nously introduced structural proteins and regulatory IE proteins are present in abundance, thus 
sensitizing infected cells to CD8+ T cell recognition. US3 is the only member of the group of 
MHC class I-specific immunoevasin genes that has been described as an IE gene, with its 
transcription initiated following infection in the absence of de novo protein synthesis (Weston, 
1988). US3 transcripts appear as early as 1 hour post infection, with their accumulation peaking 
at 3–4 hours post infection, followed by a decline in transcript levels by 5 hours post infection 
(Biegalke, 1995; Liu et al., 2002). As shown before in the T cell recognition experiments (Fig. 
4.40 A and Fig. 4.41 A), US3 suppresses T cell recognition in an allele-specific manner, most 
strongly so at the earliest time point analyzed (24 hours post infection). Interestingly, the other 
three immunoevasins also showed strong effects already at this early time. However, the T cell 
recognition assays performed in Fig. 4.40 and Fig. 4.41 did not address immunoevasion in the 
IE phase. Therefore, T cell recognition of infected fibroblasts was investigated under stringent 
IE conditions that allowed expression only of the first wave of viral genes, the IE genes (opti-
mized conditions according to Hesse et al., unpublished). MRC-5 fibroblasts (not pretreated with 
IFN-γ) were infected with wild-type HCMV or HCMV immunoevasion-defective strains CMV-∆all, 
CMV-US11, CMV-US2, CMV-US6 or CMV-US3. During the first 8 hours post infection, fibro-
blasts were treated with an inhibitor of protein translation, cycloheximide (CHX), in order to 
accumulate IE mRNAs while preventing their translation. Then, CHX was removed, and transla-
tion of mRNA was allowed for 13.5 hours. During this time, expression of early and late proteins 
was blocked by the transcriptional inhibitor actinomycin D (ActD). The cells were fixed with 
formaldehyde to prevent any further change in viral gene expression or antigen processing, and 
were subjected to recognition by pp65 (NLV/A*0201, TPR and RPH/B*0702) and IE-1 
(VLE/A*0201, CRV/C*0702) specific T cell clones, measured in IFN-γ ELISA assays (Fig. 4.43 
B). For comparison, the same experiment was performed in parallel without CHX/ActD treat-
ment of fibroblasts, thus allowing the expression of early and late genes (Fig. 4.43 A). The data 
were again normalized to CMV-∆all controls set to 100% recognition.  
Without CHX/ActD treatment, the patterns of US3-mediated suppression of antigen presentation 
by the three HLA class I allomorphs tested was in accordance with previous results of this work: 
strong impact of US3 on HLA-A*0201 and B*0702-mediated presentation, but no significant 
suppression of HLA-C*0702-mediated presentation (Fig. 4.43 A). Contrary to expectation, under 
stringent IE conditions (CHX/ActD treatment) US3 expression in infected cells had no significant 
impact on HLA-A*0201 and B*0702-mediated peptide presentation (Fig. 4.43 B). Expression of 
US6 affected T cell recognition only under non-IE conditions, which is in accordance with its 
expression at early and late time-points post infection. Under IE conditions, IE-1 peptide 
presentation, especially of VLE, was even enhanced in CMV-US6-infected cells, an observation 
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that cannot currently be explained. Consistent with the data above (Fig. 4.40 A and Fig. 4.41 A), 
US2 and US11 impaired the presentation of peptides on either HLA allomorph tested, most 
strongly HLA-A*0201, under non-IE conditions. Surprisingly, effects of US2 and US11 on NLV, 
VLE and CRV presentation were also seen under IE conditions. In particular, VLE presentation 
was completely abolished by each of US2 or US11. This observation suggests that both pro-
teins, gpUS2 and gpUS11, are already expressed and functional at IE times, and contribute to 
enhanced protection of infected cells from CD8+ T cell recognition at this time. 
  
 
Fig. 4.43: Effects of HCMV immunoevasins on T cell recognition under IE conditions. MRC-5 fibro-
blasts were infected at moi = 5 with CMV-wt (wt) or recombinant HCMV strains expressing no 
immunoevasin (CMV-∆all) or only one of US11, US2, US3, or US6. After infection, cells were kept under 
cycloheximide (CHX)/actinomycin D (ActD) blocking conditions to solely allow IE gene expression (B) or 
without CHX/ActD (A). Not infected (ni) cells served as controls. IE-1 and pp65 epitope presentation was 
detected by specific T cell clones in IFN-γ ELISAs (20 000 fibroblasts and 40 000 T cells per well in 
triplicates). Data were normalized to recognition of CMV-∆all-infected cells set to 100%. One representa-
tive T cell clone is shown for each epitope specificity from one out of 3 independent experiments. 
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4.6 The role of HLA-C*0702 in context of NK cell recognition of HCMV infection 
The selective preservation of HLA-C*0702 on infected cells by HCMV-encoded immunoevasins 
is unexpected, because it should be deleterious to the virus due to facilitated T cell attack in 
vivo. Therefore, it has to be considered that the maintenance of HLA-C*0702 might confer an 
independent advantage to HCMV. Another important function of a subset of HLA class I mole-
cules, including HLA-C allotypes, is the inhibition of NK cell-mediated killing of intact body cells 
via inhibitory killer-cell immunoglobulin-like receptors (KIRs) (Lanier, 2005). As a component of 
the innate immune system, NK cells are part of the first-line defense against viruses like HCMV, 
capable to act before adaptive immunity has risen to sufficient levels. Downregulation of MHC 
class I molecules during HCMV immunoevasion should render infected cells susceptible to lysis 
by NK cells. However, several in vitro studies described that AD169-infected human fibroblasts 
were not highly permissive to NK cell killing (Cerboni et al., 2000; Wang et al., 2002). The 
following experiments tested the hypothesis that preservation of HLA-C*0702 expression by 
HCMV is sufficient to prevent NK cell-mediated killing of infected cells. 
 
4.6.1 Generation and analysis of HLA-C*0702-specific NK cell lines  
The HLA-C/KIR system represents one of the most general mechanisms of human NK cell con-
trol. Every HLA-C allotype can provide an inhibitory signal through at least one KIR: group 2 
HLA-C allotypes through KIR2DL1, group 1 HLA-C allotypes including HLA-C*0702 through 
KIR2DL2 or 3 (Lanier, 2005). However, an individual NK cell typically expresses only a subset 
of KIRs and other MHC class I-binding inhibitory receptors, such as NKG2A that is specific for 
HLA-E, and the reactivity of the NK cell depends on its particular repertoire of receptors 
(Valiante et al., 1997). Furthermore, human fibroblasts coexpress several HLA class I allotypes 
that are ligands for NK cell inhibitory receptors and might potentially hamper the detection of 
HLA-C*0702-specific effects on NK cells expressing several HLA class I-specific inhibitory 
receptors. To circumvent this problem, NK cell lines were established that uniformly expressed 
KIR2DL3, the receptor for HLA-C*0702, and were largely devoid of any other relevant MHC 
class I-specific inhibitory receptors.  
  
Donor AJU was chosen for the isolation of KIR2DL3-expressing NK cells for two reasons: this 
donor is homozygous for KIR haplotype A and therefore lacks several activating KIR genes that 
might diversify the patterns of NK cell reactivity; furthermore, AJU is carrier of two HLA-C group 
1 alleles, which ensures an increased functional competence of KIR2DL3 in this donor's NK 
cells (Kim et al., 2008). To minimize any potential functional "re-education" in culture, the NK 
cells were cultivated in the continuous presence of allogeneic feeder cells that were biallelic for 
HLA-C group 1. 
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KIR2DL3-positive primary NK cells were enriched from PBMCs of donor AJU by immunomag-
netic separation (CD3+ depletion followed by KIR2DL3 positive isolation). These receptor-se-
lected NK cells were cultivated in bulk as polyclonal T cell lines. After five weeks of cultivation, 
the polyclonal NK cells contained 96.4% CD56-positive/KIR2DL3-positive cells, which were 
mostly negative for several other relevant NK receptors like KIR2DL1 (1.1% positive cells, lig-
ands: HLA-C 2 group), KIR3DL1 (3.9% positive cells, ligands: HLA-Bw4 group) and NKG2A 
(1.7% positive cells, ligand: HLA-E) (Fig. 4.44). In parallel, the primary KIR2DL3-enriched NK 
cells were plated under limiting dilution, and NK cell clones were established from these cul-
tures and were screened by flow cytometry for expression of KIR2DL1, KIR3DL1 and NKG2A. 
Among the 23 NK cell clones analyzed, all were positive for KIR2DL3. One additional receptor 
was expressed by eight clones, two additional receptors by three clones, and three additional 
receptors by one clone. FACS analyses are shown for two NK cell clones, a KIR2DL3 single-
positive clone (Fig. 4.44 B) and a clone expressing four NK cell receptors (Fig. 4.44 C). 
 
 
Fig. 4.44: Analysis of KIR expression by NK cell lines. NK cell lines were established from donor AJU 
and analyzed for expression of KIR2DL1, KIR2DL2/3, KIR3DL1 and NKG2A by flow cytometry. At the 
time of FACS analysis, the NK cell lines were approximately 5–6 weeks in culture. Dot plots are shown 
for the polyclonal NK cell line (A) and two NK cell clones, #29 (B) and #7 (C), which differ in their KIR 
expression patterns. 
 
Next, the NK cell lines were evaluated for their potential to kill MHC class I-deficient (K562, 
Daudi, L721.221) and various MHC class I-expressing target cells. These included L721.221 
cells transgenic for HLA-C*0702, which is a KIR2DL3 ligand, or for HLA-C*0602, which is a 
ligand of KIR2DL1 but not KIR2DL3, and MRC-5 fibroblasts that express a natural configuration 
of HLA class I molecules, including HLA-C*0702 as their only KIR2DL3 ligand (Fig. 4.45). For 
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MRC-5 cells, the influence of an IFN-γ pretreatment on their susceptibility to NK cells was also 
evaluated. Direct target cell lysis is a major effector function of NK cells and was measured by 
calcein-release asssay. Polyclonal and clonal NK cells killed MHC class I-deficient cell lines 
K562, Daudi and L721.221, but not L721.221 cells expressing HLA-C*0702. As expected, 
KIR2DL1-positive clone #7 was also inhibited from killing L721.221 cells expressing HLA-
C*0602. KIR2DL1-negative NK cell clone #29 and the polyclonal NK cell line, which contained 
only a small fraction of KIR2DL1-positive cells, were largely insensitive to HLA-C*0602. Hence, 
these two cell lines were suitable tools to detect specific effects of HLA-C*0702 even on target 
cells that coexpress HLA-C group 2 KIR ligands, such as MRC-5 fibroblasts (C*0501).   
 
 
Fig. 4.45: Sensitivity of polyclonal and clonal NK cell lines for HLA-C*0702. Polyclonal and clonal 
(clone #29 and #7) NK cell lines of donor AJU were analyzed by calcein-release assay for killing of 
C*0702-transfected L721.221 cells and uninfected C*0702-positive MRC-5 fibroblasts that were or were 
not pretreated with IFN-γ. MHC class I-deficient cell lines K562, Daudi and LCL L721.221 served as 
positive controls for HLA class I-inhibited cell lysis. Killing of L721.221 cells stably transfected with HLA-
C*0602, an HLA-C allotype belonging to the HLA-C group 2 of KIR2DL1 ligands, was assessed in 
parallel. The effector/target ratios were 8/1 (A) and 2/1 (B). Means and standard deviations of four 
replicates from one representative experiment out of four independent experiments are shown. 
 
4.6.2 Analysis of NK cell recognition of HCMV-infected fibroblasts 
In the T cell experiments, HLA-C*0702-mediated antigen presentation in context of a wild-type 
HCMV infection was somewhat reduced (Fig. 4.40), indicating that HLA-C*0702 is affected by 
HCMV immunoevasion to some extent. To test whether remaining HLA-C*0702 at the cell sur-
face of infected cells is sufficient to inhibit NK cell killing, wild-type HCMV-infected MRC-5 cells 
were used as targets of polyclonal and clonal NK cells in a calcein-release assay (Fig. 4.46). NK 
cell cytotoxicity towards infected cells was assessed under both pretreatment conditions (with or 
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without IFN-γ) and at 24, 48, 72, and 96 hours post infection. Killing of uninfected cells was as-
sessed in parallel. MHC class I-deficient K562 cells were used as positive control for HLA class 
I-dependent cell lysis. Compared to K562, killing of HCMV-infected MRC-5 fibroblasts was low 
during the whole time period tested, independent of pretreatment with IFN-γ. This suggests that 
sufficient inhibitory ligands for KIR2DL3 were present on these target cells. A slight decrease of 
NK cell killing over time, particularly at higher effector/target ratios, might reflect an accumula-
tion of HCMV-encoded NK cell evasion mechanisms. 
 
 
Fig. 4.46: Kinetics of NK cell killing of HCMV-infected fibroblasts. Polyclonal (A) and clonal (clone 
#29, B) NK cell lines of donor AJU were analyzed for killing of wild-type HCMV-infected MRC-5 
fibroblasts (C*0702-positive), pretreated with IFN-γ for 72 hours or not pretreated prior to infection. NK 
cell killing of infected cells was measured at 24, 48, 72 and 96 hours post infection by calcein-release 
assay with effector/target ratios of 8/1 (left panel) and 2/1 (right panel). Killing of uninfected fibroblasts 
(n.i.) was detected in parallel at each time point as negative control. Killing of MHC class I-deficient cell 
line K562 served as positive control (ctrl) for HLA class I-dependent cell lysis and was detected at the 24 
hours time point. Means and standard deviations of four replicates are shown. 
 
The following calcein-release experiment (Fig. 4.47) was performed to assess the NK cell 
susceptibility of MRC-5 cells infected with wild-type HCMV or immunoevasion-defective HCMV 
strains deleted in all four immunoevasins (CMV-∆all) or expressing only US11 (CMV-US11) or 
US2 (CMV-US2). Again, MRC-5 cells were treated or not treated with IFN-γ for 72 hours before 
infection. MHC class I-deficient K562 cells served as positive control for HLA class I-dependent 
NK cell killing. In general, and in particular at the lower effector/target ratio, killing of wild-type 
HCMV-infected cells was low compared to killing of K562 cells. There was no lysis of CMV-∆all-
infected or uninfected fibroblasts. Thus, wild-type HCMV was capable to partially downregulate 
HLA-C*0702, thereby inducing low levels of NK lysis. Infection with either mutant strain, CMV-
US2 or CMV-US11, also rendered fibroblasts slightly susceptible to NK cell lysis, in accordance 
with the finding that US2 and US11 partially interfered with IE-1 recognition by HLA-C*0702-
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specific T cell clones, especially in IFN-γ-untreated cells (Fig. 4.40). Lysis of CMV-US2 and -
US11-infected cells tended to be lower than lysis of CMV-wt-infected cells, in particular at the 
higher effector/target ratio, indicating cumulative effects of US2, US11 and other immunoeva-
sins (presumably US6, see Fig. 4.40) on HLA-C*0702 during wild-type HCMV infection. In this 
experiment, lysis of IFN-γ-pretreated cells was marginally lower than lysis of cells not pretreated 
with IFN-γ, reflecting the enhancement of overall HLA class I expression by this proinflamma-
tory cytokine. 
 
 
Fig. 4.47: Impact of HCMV immunoevasins on the susceptibility of infected fibroblasts to NK cell-
mediated lysis. HLA-C*0702-sensitive polyclonal NK cells of donor AJU were analyzed for killing of IFN-
γ pretreated or not pretreated MRC-5 fibroblasts (C*0702-positive) infected with wild-type HCMV (wt) or 
immunoevasion-defective HCMV strains deleted in all four immunoevasins (∆all) or only expressing US11 
or US2. NK cell killing of infected cells was measured at 48 hours post infection by calcein-release assay 
with effector/target ratios of 8/1 (A) and 2/1 (B). Killing of uninfected fibroblasts (n.i.) was detected in 
parallel as negative control. Killing of MHC class I-deficient cell line K562 served as positive control (ctrl) 
for HLA class I-dependent cell lysis. Means and standard deviations of three replicates from one 
representative experiment out of two are shown. 
 
4.6.3 Analysis of the capability of HLA-C*0702 to interfere with NK cell killing 
The previous experiments showed that HCMV-infected cells were only poorly targeted by NK 
cells compared to MHC class I-deficient cells. To confirm a role for HLA-C*0702 and its specific 
KIR, KIR2DL3, in this inhibition of NK cell-mediated killing, HLA-A/B/C on wild-type HCMV-in-
fected MRC-5 cells, or KIR2DL3 on NK cells, were blocked using specific antibodies (Fig. 4.48). 
Uninfected fibroblasts and L721.221 cells expressing HLA-C*0702 as their only HLA class I 
molecule were assessed in parallel. 
 
For each NK cell line, polyclonal or clonal, blocking of HLA-C*0702 with anti-HLA-A/B/C anti-
body on L721.221 cells expressing only this HLA class I allotype induced NK cell-mediated ly-
sis. A similar increase in NK cell cytotoxicity occurred when blocking total HLA-A/B/C on MRC-5 
cells, infected with wild-type HCMV for 48 hours or not infected. As expected, an antibody 
against HLA-A2, which is not a KIR ligand, and isotype controls did not induce target cell lysis. 
Blocking of the KIR2DL3 receptor on NK cells led to a similar increase in NK cell lysis as HLA-
A/B/C blocking for all three target cells tested, confirming that this lysis was due to an abolish-
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ment of the C*0702/KIR2DL3 interaction. These results indicate that HLA-C*0702, as the only 
ligand of KIR2DL3 present in this system, prevented an attack on HCMV-infected fibroblasts by 
NK cells expressing this inhibitory receptor. To conclude, HCMV potentially preserves HLA-
C*0702 on infected cells in order to evade killing by NK cells. 
 
 
 
Fig. 4.48: HLA-mediated inhibition of NK cell recognition of HCMV infection. HLA-C*0702-sensitive 
polyclonal and clonal (clone #29) NK cells of donor AJU were analyzed for killing of C*0702-expressing 
L721.221 cells (A) and C*0702-positive MRC-5 fibroblasts, infected (C) or not infected (B) with CMV-wt 
for 48 hours (moi = 5), by calcein-release assay at an effector/target ratio of 2. Total HLA-A/B/C on target 
cells or KIR2DL2/3 on NK cells were blocked by preincubation with specific monoclonal antibodies for 1 
hour prior to combining effectors and targets. Blockade of the non-KIR ligand HLA-A2, addition of isotype 
controls (shown for anti-HLA-A/B/C and -A2 antibodies) and samples without antibodies served as nega-
tive controls. Means and standard deviations of triplicate samples of one out of two independent experi-
ments are shown. 
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5 Discussion 
This study presents a refined analysis of the diversity and the effector functions of the T cell 
repertoire specific for the IE-1 antigen of HCMV. The IE-1 transcription activator is among the 
first endogenously expressed proteins in HCMV-infected cells (Stinski et al., 1983) and drives 
viral and cellular gene expression during the lytic replication cycle. Furthermore, reactivation of 
IE-1 expression in latently infected cells upon cell differentiation initiates productive HCMV 
replication with release of infectious virions (Sinclair and Sissons, 2006). Consequently, IE-1-
specific T cells potentially control lytic HCMV infection but also viral reactivation from latency 
with particular efficiency, because they can act before progeny virus is released and spreads 
within the body (Simon et al., 2006; Besold and Plachter, 2008). 
 
Both major arms of the IE-1-specific T cell response, CD4+ and CD8+ T cells, were readressed 
in this study, but with different focal points: key aspects of the CD4+ T cell part were the defini-
tion of IE-1 T cell epitopes and the analysis of T cell effector functions, in particular in the con-
text of HCMV infection of DCs; the CD8+ T cell part mainly focused on the elucidation of the 
mechanism underlying the immunodominance of HLA-C-restricted T cells by analyzing IE-1 T 
cell recognition in context of HCMV immunoevasion. One intention behind these detailed anal-
yses was the evaluation of the IE-1 protein as a target for HCMV immunotherapy to reduce the 
risk of HCMV disease in immunocompromised patients or of an intrauterine infection during 
pregnancy. For example, for the design of an effective peptide vaccine the identification of 
immunodominant regions within this HCMV T cell antigen is a prerequisite. The IE-1 protein is 
also considered as a particular attractive target for adoptive T cell transfer, because IE-1 spe-
cific T cells, especially CD8+ T cells, are found in the majority of healthy virus carriers (Syl-
wester et al., 2005). However, for patient studies it would be beneficial to know which of the 
various T cell specificities directed against IE-1 are particularly efficient in eradicating HCMV-
infected cells, thus providing improved protection against HCMV disease. 
  
In this work, IE-1-specific T cells were reactivated and expanded in bulk from PBMCs of healthy 
HCMV carriers by repeated stimulation with autologous mLCL expressing IE-1. IE-1-mLCLs 
were generated by infection of primary B cells with an IE-1-encoding mini-EBV vector, which 
provides the B cells with two constitutive properties, thus allowing specific T cell stimulation: 
endogenous expression of a foreign antigen of interest, here IE-1, and induction of costimula-
tory molecules (Wiesner et al., 2005). According to the classical picture of MHC presentation, 
cytosolic proteins are mainly fed into the MHC class I pathway of antigen processing and 
presentation, thereby stimulating CD8+ T cells. The MHC class II pathway was originally belie-
ved to encounter only exogenous antigens that have been endocytosed by the APC. However, 
it has been shown for EBV-immortalized B cells that cytosolic antigens like EBNA1 (Paludan et 
al., 2005) or a model antigen (Nimmerjahn et al., 2003) can also access the MHC class II 
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compartment via autophagy, resulting in their presentation on HLA class II to CD4+ T cells. The 
same is true for mLCLs, which is shown by their potential to present HCMV structural protein 
pp65 to CD4+ T cells and to expand both CD8+ and CD4+ T cells specific for pp65 (Moosmann 
et al., 2002; Wiesner et al., 2005). In this study, the same restimulation protocol has proven its 
worth for the enrichment of IE-1-specific T cells of both classes, CD8+ and CD4+. For all twelve 
donors studied except one, the resulting polyclonal T cell lines were dominated by CD8+ T 
cells. A likely reason for this are the much higher precursor frequencies of IE-1-specific CD8+ 
memory T cells in the donors' PBMCs compared to IE-1-specific CD4+ T cells.  
  
Eight of the blood donors chosen for this study were known to be healthy carriers of both EBV 
and HCMV. Consequently, a coexpansion of T cells directed against EBV latent antigens 
coexpressed in the mLCLs (EBNA1, -2, -3A, -3B, -3C, -LP and LMP1, -2), most of them known 
to be recognized by more or less immunodominant CD8+ T cell populations in EBV-seropositive 
individuals (Rickinson and Moss, 1997), was expected for these donors. However, IE-1-specific 
T cells largely dominated the cultures from most EBV-seropositive donors. This went so far that 
T cells recognizing the ctrl-mLCL were completely absent in the cell lines of six donors. For one 
donor (ALT), it was confirmed by HLA/peptide multimer staining that T cells directed against 
epitopes from EBV latent antigens were expanded in the ctrl-mLCL-stimulated culture, but were 
lost in the IE-1- and pp65-stimulated cultures. As the ctrl-mLCL-stimulated T cell populations of 
all donors equally recognized both types of mLCLs, with and without IE-1, it can be assumed 
that EBV antigen expression and presentation by mLCLs was intact. Preferential expansion of 
HCMV-specific T cells was probably favored by their higher memory T cell frequencies in the 
peripheral blood. Expression of HCMV antigens in mLCLs is under control of the constitutive 
Simian Virus 40 (SV40) promoter; while this promoter is of lower activity in B cells than other 
heterologous viral promoters, its activity is similar to the one of the V-lambda promoter (Zarrin et 
al., 1999) and therefore should suffice for reliable antigen expression. Expression of IE-1 and 
pp65 might even be higher than expression of EBV latent antigens, contributing to a certain 
degree of competition for HLA molecules and the preferential expansion of T cells specific for 
the HCMV antigens. This hypothesis is supported by the observation that some EBV latent 
antigen-specific CD8+ T cells generated from seropositive individuals fail to lyse the autologous 
LCL unless antigen dose is artificially raised (Hill et al., 1995).  
  
Detailed analyses of T cell attributes like minimal epitope, memory phenotype, TCR usage or 
cross-reactivity, were often only described for T cell specificities that are quite frequent in the 
peripheral blood of HCMV-seropositive donors, such as CD8+ pp65- and IE-1-specific T cells 
(Wills et al., 2002; Rist et al., 2009) or CD4+ T cells targeting structural proteins pp65 (Casazza 
et al., 2006; Crompton et al., 2008), and gB/gH (Elkington et al., 2004). Using the example of 
CD4+ IE-1-specific T cells, this study provides evidence that rare antigen-specific T cells can be 
expanded to significant numbers by mLCL-stimulation, thus being now available for further anal-
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yses. Mini-EBV plasmids can be easily modified in E. coli to accommodate additional genetic 
information and their capacity for foreign DNA is extraordinary large: up to 80 kilobase pairs can 
theoretically be added without impairing the efficient packaging of mini-EBV DNA into virions 
(Bloss and Sugden, 1994). In this way, one could think about inserting HCMV genes encoding 
subdominant T cell antigens, such as the transcription factor IE-2 or immunoevasin US3, in or-
der to characterize the less frequent T cell responses to these proteins (Sylwester et al., 2005). 
 
5.1 The CD4+ T cell repertoire against the IE-1 antigen 
There is growing interest in characterizing the CD4+ T cell response to HCMV. This is justified 
by HCMV's latency and lytic replication in vivo in cells of hematopoietic origin like macrophages 
and DCs (Sinzger et al., 2008) in which the HLA class II pathway of antigen presentation is 
constitutively active. Progenitor cells of the myeloid lineage are considered to be the main reser-
voir for latent HCMV and support virus reactivation upon differentiation into monocytes, macro-
phages and DCs (Reeves et al., 2005; Sinclair and Sissons, 2006). This makes it likely that vi-
rus-specific CD4+ T cells directly recognize lytically-infected or virus-reactivating cells, so that 
they can immediately provide T cell help for CD8+ T cells or, if they possess cytotoxic potential, 
can act as effectors in their own right. Adoptive T cell transfer studies have suggested a crucial 
helper role of HCMV-specific CD4+ T cells for the virus-specific CD8+ T cell response in control 
of HCMV or protection from viral disease (Einsele et al., 2008). Allogeneic SCT patients who 
failed to reconstitute endogenous CD4+ T cell responses to HCMV showed a progressive 
decline in the magnitude of adoptively transferred virus-specific CD8+ T cells (Walter et al., 
1995), although it may be difficult to distinguish association from causation in such studies. 
Conversely, infusions of predominantly CD4+ T cell lines specific for HCMV into allogeneic SCT 
patients lacking a virus-specific CD4+ T cell response led to an efficient control of viremia by the 
preexisting endogenous HCMV-specific CD8+ T cell immunity (Einsele et al., 2002). Additional 
evidence for the pivotal role of HCMV-specific CD4+ T cells in virus control comes from studies 
on patients coinfected with HIV-1, which progressively depletes the host from CD4+ T cells. In 
such patients, diminished CD4+ T cell responses to HCMV were associated with an inability to 
sustain high levels of HCMV-specific CD8+ T cells and an increased risk of HCMV-associated 
end-organ disease (Komanduri et al., 2001). CD4+ T cells provide T cell help for cytotoxic CD8+ 
T cells by mechanisms that include secretion of cytokines, such as the T cell growth factor IL-2, 
and strengthening the antigen-presenting and costimulatory capacity of APCs through CD40-
CD40L interaction (Schoenberger et al., 1998).  
 
HCMV-specific CD4+ T cells have been described to target various functionally distinct viral 
antigens including virion proteins but also non-structural proteins such as IE-1 (Sylwester et al., 
2005). However, dominant CD4+ T cell responses are largely directed against HCMV structural 
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proteins such as gB and pp65 (Beninga et al., 1995; Sylwester et al., 2005). Similar observa-
tions were also made for other herpesviruses, for example EBV-specific CD4+ T cells, which 
primarily target late-lytic structural proteins of the virus (Adhikary et al., 2007). These abundant 
virion proteins can efficiently access the MHC class II pathway of antigen presentation during 
direct infection of APCs involving endocytotic compartments or after engulfment and lysosomal 
degradation of material from infected cells by APCs. Efforts to isolate and characterize IE-1-
specific CD4+ T cells started already more than two decades ago (Alp et al., 1991), quickly 
following the description of IE-1 as one of the first HCMV CD8+ T cell antigens (Rodgers et al., 
1987; Borysiewicz et al., 1988). However, a more detailed analysis of IE-1-specific CD4+ T cells 
was apparently hampered by their low numbers in the peripheral blood of HCMV carriers. For 
example, Khan and collegues, who used IFN-γ ELISpot assays, detected IE-1-specific T cells 
only infrequently in young and elderly seropositive donors, and if they were detected, their 
proportion of the CD4+ T cell memory was low (<0.1%), in contrast to pp65-specific CD4+ T cell 
responses that were found to be quite strong (>1% of the CD4+ memory) (Khan et al., 2007). 
During evaluation of T cell reconstitution after solid organ transplantation by cytokine flow cyto-
metry, Bunde and coworkers found IE-1-specific CD4+ T cells in 41% of the patients but not at 
all time points tested and again only at much lower numbers (0.05–0.19% of all CD4+ T cells) 
than pp65-specific CD4+ T cells (0.03–16.89% of all CD4+ T cells) (Bunde et al., 2005). Using 
the same technique, Slezak et al. could not detect IE-1-specific CD4+ T cells in any of 20 
seropositive donors tested (Slezak et al., 2007). Controversially, Sylwester and collegues re-
ported IE-1 peptide-specific CD4+ T cells in 11 out of 33 donors analyzed, with an average of 
approximately 0.7% of the total CD4+ memory T cell compartment, which was half of the fre-
quency of pp65- and gB-specific CD4+ T cells (also analyzed by cytokine flow cytometry) 
(Sylwester et al., 2005). The data obtained in the present study for IE-1-specific CD4+ T cell 
frequencies in total PBMCs of HCMV carriers are in agreement with the majority of above 
mentioned studies, which report low numbers of these T cells. However, the experiments perfor-
med here were not primarily focused on the detection of IE-1-specific CD4+ T cells in PBMCs. 
To gain more exact information, it would be worth reanalyzing CD8+ T cell-depleted PBMCs 
from a variety of donors. Low numbers of IE-1-specific CD4+ T cells may be connected to the 
fact that IE-1, a nuclear protein, can reach the MHC class II pathway in infected cells only via 
autophagy and not, like abundant structural proteins, by the standard lysosomal pathway after 
uptake from extracellular material. Furthermore, as a regulatory protein expressed very early 
during the replicative cycle, IE-1 is less abundant in infected cells than late expressed structural 
proteins, whose amounts increase in molar ratios with the accumulation of newly synthesized 
viral DNA (Stinski, 1978). This together could result in smaller levels of IE-1 peptides presented 
on MHC class II and, consequently, less efficient stimulation of specific CD4+ T cells in vivo.  
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Despite their low precursor frequencies in PBMCs, IE-1-specific CD4+ T cells could be effi-
ciently expanded by antigen-specific stimulation of PBMCs using individual peptides (as shown 
for EFF-specific T cells) or mLCLs expressing IE-1, making these T cells available for further 
analysis. Attempts to selectively enrich IE-1-specific CD4+ T cells have been made before by 
two groups: Alp and coworkers expanded IE-1-specific CD4+ T cell lines from five donors by 
stimulation of PBMCs for 12 days with recombinant baculovirus IE-1 protein or synthetic IE-1 
peptides (Alp et al., 1991); Davignon et al. could enrich IE-1-specific CD4+ T cells from the 
PBMCs of 7 out of 23 seropositive donors by 7 day-stimulation with lysate of IE-1-transfected 
astrocytoma cells (U373MG) (Davignon et al., 1995). Both mentioned approaches have in com-
mon that they use exogenous antigen or peptides for specific stimulation of PBMCs. The profes-
sional APCs within PBMCs preferentially process these exogenously added antigens/peptides 
via endocytotic pathways thus favoring presentation on MHC class II over presentation on class 
I. In contrast to these approaches, this study used whole mLCLs endogenously expressing IE-1 
for stimulation, which necessarily led to the coexpansion of IE-1-specific CD8+ and CD4+ T 
cells. Nevertheless, IE-1 epitope-specific CD4+ T cells could be enriched and isolated from all 
donors analyzed, indicating that MHC class II presentation of cytosolic proteins by APCs via 
autophagy is efficient enough to obtain antigen-specific CD4+ T cells. This process might also 
work in vivo for MHC class II presentation of IE-1-derived peptides by HCMV-infected APCs like 
DCs or macrophages, and might be of importance for early interference with reactivation of la-
tent virus which takes place in these cell types. 
   
In this study, IE-1-specific CD4+ polyclonal T cell lines and T cell clones were generated from 
eight healthy HCMV carriers with a broad panel of HLA class II types. IE-1 CD4+ epitopes were 
determined for each donor using a library of peptides covering the entire AD169 IE-1 sequence 
and also containing nine peptides with a selection of sequence variants found in HCMV strains 
TB40E, Toledo and other strains. A high diversity of 3 to 7 different T cell specificities was found 
per donor and was restricted through a manifold set of HLA-DR, -DQ and -DP allotypes 
suggesting that IE-1-specific CD4+ T cells can be generated for adoptive T cell therapy from 
most donors with divergent HLA types. With one exception, T cell clones recognized different 
strain-specific IE-1 sequence variants, allowing to target different HCMV strains with these T 
cells. Two CD4+ T cell epitopes, EFFTKNSAFPKTT (DRB5*0101 or DRB1*1501-restricted) and 
VKSEPVSEIEEVAPE (DQA1*0201/DQB1*0202-restricted), were found in different donors shar-
ing the presenting HLA class II allotypes, thus being of particular interest for adoptive T cell 
therapy. Nevertheless, despite the identification of individual epitopes in more than one donor, 
the strongest CD4+ T cell responses in the donors analyzed did not consistently map to a 
particular subset of epitopes. This is in contrast to the IE-1-specific CD8+ T cell response, which 
targeted only 1 or 2 epitopes per donor and these were regularly found to elicit dominant 
responses in donors overlapping in the relevant HLA class I molecules (discussed in 5.2). This 
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discrepancy between the structures of virus-specific CD4+ and CD8+ T cell repertoires has 
been documented before. For example, for pp65-specific CD4+ T cells an average of 4 different 
epitopes (range 2–5) was recognized by each of the donors tested with responses to particular 
epitopes found in more than one donor but at variable intensity (Harcourt et al., 2006). By con-
trast, pp65-specific CD8+ T cell responses focused on few immunodominant epitopes that were 
recurrently identified in the donors tested (Khan et al., 2007). Similar reports came from the 
EBV field: CD4+ T cell responses to EBV latent-cycle antigens EBNA1, -2, -3A, and -3C, were 
diverse, and epitopes that were found in the highest number of donors were not necessarily 
immunodominant in terms of T cell numbers (Long et al., 2005). By contrast, the EBV-specific 
CD8+ T cell response to the same proteins is less diverse and focused preferentially on 1 or 2 
immunodominant epitopes per donor (Khanna and Burrows, 2000).  
  
Mapping of all identified IE-1 epitopes in the IE-1 sequence revealed that, with exception of the 
first 80 amino acids, the whole IE-1 sequence is well accessible for recognition by CD4+ T cells. 
Some epitopes were overlapping, thus creating hotspots of immunogenicity; for example, 6 
different epitopes were covered by aa 85–107 and 8 different epitopes by aa 197–235. These 
regions might be particularly interesting for the generation of peptide vaccines. Besides the 
present work, the only major study attempting to map CD4+ T cell epitopes in IE-1 was publis-
hed in 1991 (Alp et al., 1991). Alp and coworkers used polyclonal IE-1-specific CD4+ T cell lines 
of five donors to map IE-1 CD4+ T cell epitopes using 15–20-meric peptides with 6 amino acids 
overlap. They identified eight candidate epitopes, which were equally distributed over the IE-1 
sequence thereby sparing the first 80 amino acids and overlapping in the first half of the protein 
as found in this study. One peptide recognized by clones of F63 and F65 in this study (RRKM-
MYMCYRNIEFFTKNS) was precisely matching a peptide defined as T cell epitope in the Alp 
study. Two other epitopes targeted in this study by clones from donors ARZ (ARAKKDEL-
RRKMMYMCYRN) and F63 (CLQNALDILDKVHEPFEEM) were partially overlapping with 
peptides of the older study. Unfortunately, Alp et al. did not establish T cell clones for more 
detailed analyses, such as minimal epitope definition. Putative HLA restrictions cannot be de-
duced for the candidate epitopes as only HLA-DR types are given and each epitope was identi-
fied only in one donor. Apart from the present work, IE-1-specific CD4+ T cell clones were only 
reported by Davrinche, Davignon and coworkers. They used clones of four different specificities, 
restricted through HLA-DR3, -DR7, -DR8 or -DR13, for studying T cell effector functions (see 
below) (Davrinche et al., 1993; Davignon et al., 1996; Le Roy et al., 2002). The HLA-DR8 
epitope (DKREMWMACIKELH) (Gautier et al., 1996) may be identical to a T cell epitope identi-
fied in this work for DRB1*08-positive donor F63 (EDKREMWMACIKELHDVSK). 
 
A couple of IE-1 CD4+ T cell epitopes identified in this work were presented in different donors 
in the context of different HLA class II allotypes, suggesting some degree of promiscuity in 
peptide binding. For example, the HLA-DP-restricted epitope SVMKRRIEEICMKVFAQYI was 
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found in donors ARZ, AJU, and F61, who share only the DP α chain allele DPA1*0301, but no 
DPB allele encoding the DP β chain. It is tempting to speculate that class II molecules 
presenting the same peptides also recognize common peptide motifs. Unfortunately, the 
identification of binding motifs for MHC class II molecules is complicated by heterogeneity in 
peptide length due to an open-ended peptide binding cleft and a relatively degenerate amino 
acid usage at potential anchor positions in MHC class II peptide ligands (Rammensee, 1995). 
The specificity of peptide binding to MHC class II may be mediated by multiple weak interac-
tions between residues inside the α and β chain pockets and residues of the bound peptide. 
Consequently, two or three obligatory anchor residues, as found in peptides binding to MHC 
class I, cannot be determined for MHC class II-presented peptides. The weak contacts leading 
to peptide binding might be mediated by different residues in different HLA class II molecules. 
The same peptide, when binding to different HLA class II allotypes, could adopt a different 
position on each HLA molecule. According to the literature, promiscuous peptide binding 
appears to be a common feature of HLA class II molecules. Using a pp65 peptide library, Li Pira 
and collegues screened 20 HCMV carriers for pp65 CD4+ epitopes and found six peptides that 
seemed to be recognized in different individuals in the context of more than one HLA-DR allele 
(Li Pira et al., 2004), although this is not definitive because donors were typed only for HLA-
DRB1. HIV-1-derived peptides that were most frequently recognized by CD4+ T cells of the 
donors tested showed broad promiscuous binding capacity to a minimum of four out of eight 
HLA-DR alleles tested (Kaufmann et al., 2004). In addition to virus-derived CD4+ T cell 
epitopes, several MAGE-3 epitopes (Consogno et al., 2003) and one Her2/neu epitope 
(Kobayashi et al., 2000) were reported to promiscuously bind to a panel of different HLA-DR 
allotypes. The identification of broadly promiscuous epitopes can strongly increase the number 
of patients eligible for immunotherapy and offers the potential to induce CD4+ T cell responses 
in a genetically diverse population using only a limited number of peptides. 
   
One aim of this work was to elucidate the role of IE-1-specific CD4+ T cells during HCMV infec-
tion by analyzing the effector functions of these cells. Only 5 out of 25 T cell clones tested 
showed significant cytolysis of IE-1 peptide-presenting target cells, suggesting that IE-1-specific 
CD4+ T cells tend to exert helper or indirect effector functions, by secretion of immunomodula-
tory cytokines, rather than mediating direct cytotoxicity. The cytokine profiles of all T cell clones 
tested contained the Th1 cytokines IL-2, IFN-γ and TNF-α. CD4+ T cells of the Th1 type appear 
to be the most abundant subtype of CD4+ T cells involved in antiviral immune responses and 
have been described for several herpesviruses including HCMV (Rentenaar et al., 2000), EBV 
(Bickham et al., 2001), HSV (Bettahi et al., 2006) and VZV (Zhang et al., 1994). Th1 cytokines 
stimulate the cellular arm of the immune response, which is crucial for elimination of virus-in-
fected cells. The pleiotropic effects of IFN-γ on target cells include mechanisms that facilitate 
the recognition of infected cells by CD8+ cytotoxic T cells, for example upregulation of TAP 
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components and MHC class I molecules, as well as induction of the immunoproteasome 
(Schroder et al., 2004). The proliferation, differentiation and survival of antigen-selected CD8+ T 
cells are stimulated by the T cell growth factor IL-2 (Stern and Smith, 1986; Beadling and Smith, 
2002). A helper cell function of IE-1-specific CD4+ T cells for CD8+ T cells would be in accord-
ance with frequent reports about T helper cell dependence of HCMV-specific CD8+ T cell re-
sponses in vitro and in vivo (Walter et al., 1995; Li Pira et al., 2004; Salkowitz et al., 2004). IE-1-
specific CD8+ T cells are found to be very abundant in HCMV carriers and might be particularly 
important for early control of HCMV infection or reactivation due to the immediate-early expres-
sion kinetics of their target antigen. However, during an early phase of infection, immune cells 
such as NK cells, macrophages and DCs may not suffice to create a supportive cytokine milieu 
for CD8+ T cells. Hence, IE-1-specific CD8+ T cells might especially rely on help by CD4+ T 
cells, which, for their own activation, have to see their target antigen simultaneously. Conse-
quently, only IE-1-specific CD4+ T cells have the ability to fulfill this function during the early 
immune response. In addition to stimulation of CD8+ T cells, Th1 cytokines like IFN-γ exhibit 
direct antiviral activity (Gamadia et al., 2003) via induction of growth-inhibitory and pro-apoptotic 
signaling pathways in virus-infected cells (Schroder et al., 2004). Such growth-inhibitory effects 
were also detected in this study: cocultivation of IE-1/EFF-specific CD4+ T cells and mLCLs 
resulted in regression of mLCL outgrowth, which was largely dependent on specific stimulation 
by IE-1. Th1-like cytokine profiles have been reported by Davignon and collegues for HLA-DR3, 
-DR13 and -DR8-restricted IE-1-specific T cell clones (Davignon et al., 1996). These authors 
further showed that supernatants from these clones, activated with soluble antigen, inhibited 
HCMV replication in astrocytoma (U373MG) cells, and that this effect was mostly due to IFN-γ 
(Davignon et al., 1996). In line with the work of Davignon et al., the present study detected 
secretion of the Th2 cytokine IL-4 by some of the IE-1-specific CD4+ T cell clones in addition to 
the Th1 cytokines. Such T cells with broadened cytokine profiles have been designated Th0 
cells, and have also been described for other viruses including HSV (Yasukawa et al., 1991) or 
Hepatitis B virus (Barnaba et al., 1994). IE-1-specific CD4+ T cells producing Th2 cytokines 
may contribute to anti-HCMV immunity by stimulating B cells to produce neutralizing antibodies, 
which are abundantly detected in the serum of HCMV carriers (Jackson et al., 2011), while the 
simultaneous production of Th1 cytokines may favor switching to appropriate antibody isotypes 
(Deenick et al., 2005). 
 
A minority of the IE-1-specific CD4+ T cell clones tested displayed direct cytotoxic potential 
towards mLCLs expressing IE-1 or peptide-loaded mo-DCs. This emerging novel role of CD4+ 
T cells as direct antiviral effectors has been reported for several human viruses including influ-
enza, poliovirus, measles virus, HIV, HSV, VZV, EBV and HCMV (Brown, 2010). Among these, 
CD4+ CTLs may be especially important for herpesviruses, which encode various mechanisms 
to suppress MHC class I antigen presentation in order to impede elimination of infected cells by 
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HLA class I-restricted CD8+ cytotoxic T lymphocytes (Hansen and Bouvier, 2009). CD4+ CTLs 
may remove infected cells that escape elimination through CD8+ T cells in an HLA class II-
dependent fashion, thus expanding the capacity of the immune system to control such virus 
infections. The rare IE-1-specific CD4+ CTLs may be uniquely important in the control of HCMV 
reactivation and disease by directly targeting the reservoirs of latent virus, DCs and macro-
phages, which constitutively express MHC class II molecules. Evaluation of the cytotoxic poten-
tial of these T cells towards infected cells exceeded the scope of this study and remains to be 
done in the future. For HCMV, CD4+ T cells with cytolytic function are primarily described 
against structural proteins such as pp65 (Weekes et al., 2004), gB (Hopkins et al., 1996), and 
gH (Elkington et al., 2004), which are the quantitatively dominant target of HCMV-specific CD4+ 
T cells (Sylwester et al., 2005). This observation suggests a functional diversification of CD4+ T 
cell responses towards structural and non-structural proteins of HCMV, with the first ones being 
predominantly cytotoxic and the latter ones providing mainly T cell help or APC-activating func-
tion. This might reflect the biological need for different effector functions at different phases of 
the replication cycle: T cell help might be particularly important to initiate a successful immune 
response immediately after infection or reactivation from latency, when the lytic replication cycle 
is initiated by expression of regulatory proteins; later during infection, when HCMV virion pro-
teins are abundantly expressed and presented, CD4+ CTLs contribute to the direct elimination 
of infected cells to restrict infection. 
  
Assessment of the actual role of CD4+ IE-1-specific T cells in the HCMV immune response re-
quires to study their ability to recognize IE-1 in context of an HCMV infection, because infection 
could dampen IE-1 presentation by virus-encoded immunomodulatory functions. Unfortunately, 
the in vitro analysis of CD4+ T cell recognition in context of HCMV infection is hampered by the 
limited availability of cell systems that are susceptible to HCMV infection and express MHC 
class II. MHC class II presentation can be triggered in many cell types of non-hematopoietic 
origin by IFN-γ, which induces the molecules HLA class II, invariant chain and HLA-DM via 
expression of the class II transactivator (CIITA) (Pieters, 1997). In this study, MHC class II 
expression was induced in primary fibroblast cell lines, a commonly used cell system to study T 
cell recognition of HCMV infection; however, the achievable MHC class II level was not high 
enough to demonstrate significant CD4+ T cell recognition of infected cells. This might be due 
to the capability of HCMV to repress IFN-γ-mediated MHC class II induction at the level of CIITA 
in order to escape CD4+ T cell recognition (Miller et al., 2001). To achieve permanent MHC 
class II expression, Le Roy et al. have transfected the HCMV-permissive astrocytoma cell line 
U373MG with CIITA (Le Roy et al., 2002). IE1-specific CD4+ T cell clones (HLA-DR3 and DR7-
restricted) were efficiently activated by infected U373MG-CIITA cells through endogenous IE-1 
presentation (Le Roy et al., 2002). By contrast, this study used mature mo-DCs with natural 
constitutive HLA class II expression to investigate IE-1-specific CD4+ T cell recognition of in-
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fected cells. DCs were considered to be a more adequate cell system for this purpose as they 
are naturally targeted by HCMV in vivo and are known as cell reservoirs for reactivating virus 
(Sinclair and Sissons, 2006). Previous studies showed that mature mo-DCs permit low-level 
infection (≤20%) with fibroblast-adapted HCMV strain AD169 (Odeberg et al., 2003), and sup-
port all phases of viral gene expression, but do not release infectious progeny virus (Senechal 
et al., 2004). Strikingly, all CD4+ IE-1-specific T cell clones tested in the present study showed 
good recognition of HCMV-infected mo-DCs. This potent effector function of IE1-specific CD4+ 
T cells across various studied HLA class II allotypes is in contrast to IE1-specific CD8+ T cells, 
whose action in vitro is counteracted by viral functions that suppress most class I allotypes (dis-
cussed in 5.3). Interestingly, there is also some allotype-specific diversification among IE1-spe-
cific CD4+ T cells: only the HLA-DP-restricted T cell clones (SVM-specific) secreted similarly 
high IFN-γ amounts in response to infected cells and peptide-loaded cells; for HLA-DR and DQ-
restricted T cells the response to infection was somewhat lower than to peptide-loaded cells. 
This could be due to intrinsic differences in the availability of the different target peptides or of 
HLA-DP versus DQ or DR, or due to differences in the avidities of the T cell clones. Further-
more, there is evidence that HCMV downregulates constitutive MHC class II expression in in-
fected macrophages (endotheliotropic strains) (Miller et al., 2001; Sinzger et al., 2006) and DCs 
(strain AD169) (Odeberg et al., 2003). Inhibition of the MHC class II pathway may be particularly 
important during HCMV infection of APCs due to the accumulation of endogenously expressed 
structural proteins in the trans-Golgi network (TGN) for virion assembly (Tooze et al., 1993; 
Sanchez et al., 2000), thus delivering large quantities of viral antigens to endosomes and the 
MHC class II compartment (MIIC) (Hegde et al., 2002). To date, three HCMV-encoded proteins, 
pp65, US2 and US3, are described to interfere with the MHC class II pathway of antigen 
presentation. The tegument protein pp65 down-regulates cell surface expression of HLA-DR by 
accumulation of HLA-DR in lysosomes and destruction of the DR α chain (Odeberg et al., 
2003). US2 causes rapid retro-translocation of DR α and DM α chains from the ER, followed by 
proteasomal degradation (Tomazin et al., 1999). US3 binds newly synthesized class II heterodi-
mers and reduces their association with the invariant chain, thus preventing efficient sorting to 
MIIC (Hegde et al., 2002). However, while these studies described that such mechanisms inhibit 
the presentation of an irrelevant model antigen to CD4+ T cells (Tomazin et al., 1999; Hegde et 
al., 2002), it was shown later that genuine HCMV gB-specific CD4+ T cells recognize infected 
cells very well (Hegde et al., 2005). Potential immunoevasive effects of the virus on IE-1 
presentation to CD4+ T cells remain to be investigated. To date, studies on MHC class II 
downregulation have focused on total HLA class II or HLA-DR, whereas HLA-DQ and -DP have 
not been investigated. As reported for class I immunoevasins, it is possible that the effects of 
class II immunoevasins are allele-specific. Experiments using defined HCMV immunoevasin 
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deletion mutants will clarify if HLA-DP-dependent presentation of IE-1 is less affected by viral 
immunoevasion than HLA-DR-dependent presentation.  
  
In summary, the potent effector functions of IE-1-specific CD4+ T cells shown in this study sug-
gest an important role of these cells during the immune response to HCMV. It is hypothesized 
that these T cells can efficiently control viral reactivation. To test this hypothesis it will be 
interesting to study the function of IE-1-specific CD4+ T cells in a cell culture model for HCMV 
reactivation from latency. The establishment of such a cell culture model should be feasible, 
because critical steps that promote the transition from HCMV latency to reactivation during mye-
loid progenitor differentiation have been described (Sinclair and Sissons, 2006; Reeves and 
Compton, 2011). On this basis, several experimental cell culture models for HCMV reactivation 
have been designed and evaluated. For example, CD14+ monocytes from peripheral blood of 
HCMV carriers were infected with clinical HCMV isolates and maintained in an undifferentiated 
state, in order to establish HCMV latency (Hargett and Shenk, 2010). When treated with cyto-
kine mixtures to stimulate differentiation to macrophages or DCs, infected monocytes reac-
tivated virus replication and produced infectious progeny. Such a cellular system will likely be a 
useful tool to study the function of IE-1-specific CD4+ T cells in greater detail. 
 
5.2 The CD8+ T cell repertoire against the IE-1 antigen 
Among HCMV-specific T cells, IE-1-specific CD8+ T cells might be of vital importance for 
preventing opportunistic HCMV disease in immunosuppressed patients, because these T cells 
could potentially eradicate cells at the onset of viral reactivation, before progeny virions are pro-
duced (Simon et al., 2006). In early studies in the mouse system, it was established that IE-1-
specific CD8+ T cells protect against lethal MCMV infection (Reddehase et al., 1987; Jonjic et 
al., 1988). For HCMV, CD8+ T cells specific for IE-1, but not pp65, were associated with protec-
tion from viral disease in heart and lung transplant patients (Bunde et al., 2005) and with protec-
tion from early reactivation after stem cell transplantation (Sacre et al., 2008). In a comprehen-
sive study covering all known 213 open reading frames of HCMV, IE-1 was one of only three 
HCMV proteins able to stimulate CD8+ T cells in PBMCs of more than half of healthy HCMV 
carriers tested; IE-1-specific CD8+ T cells were found in 55% (18/33) of donors (Sylwester et 
al., 2005). In contrast, the present study showed, by IFN-γ ELISpot assay of IE-1 mLCL-stimula-
ted cultures, that IE-1-specific CD8+ T cells were present in all (11 of 11) seropositive donors 
tested (Fig. 4.23). Without prior stimulation, IE-1-specific T cells were detected in 75% of donors 
(Fig. 4.28). Furthermore, with up to 2% (donor LT12) of cells in  the total CD8+ memory T cell 
compartment secreting IFN-γ in response to HCMV peptides in ELISpot, IE-1-specific CD8+ T 
cells appeared to be rather frequent. As only a fraction of antigen-specific T cells secrete suffi-
cient amounts of IFN-γ within the time frame of an ELISpot assay to form a spot, the actual 
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proportion of IE-1-specific T cells is expected to be higher (see multimer staining for CRV-spe-
cific T cells, Fig. 4.27), presumably by a factor in the range of 4 (Tan et al., 1999). In their 
evaluation of HCMV ORFs for CD8+ T cell recognition, Sylwester and collegues detected IE-1 
recognition by an average of ~2.9% of the total CD8+ T cell compartment (Sylwester et al., 
2005), which largely agrees with the data of this study. Interestingly, the authors found that IE-1 
stimulated the highest proportion of CD8+ T cells among the 213 ORFs tested (Sylwester et al., 
2005). These extraordinary high numbers of CD8+ T cells specific for IE-1 could be explained 
with IE-1 being among the first proteins endogenously expressed in infected cells (Stinski et al., 
1983). Consequently, IE-1-specific T cells are the first to be activated, and are therefore at an 
advantage in the competition with other T cells, for example for access to APCs (Kedl et al., 
2003). This competition may be intensified by HCMV's progressive interference with MHC class 
I-dependent peptide presentation during the viral replication cycle. Furthermore, in the post-
acute phase of infection, IE-1-specific CD8+ T cells may experience continuous stimulation by 
subclinical virus reactivation, leading to their sustained expansion (Khan et al., 2007). As IE-1-
specific CTLs eliminate cells with reactivating virus at the early stage, they may limit the expan-
sion of T cells recognizing antigens expressed later in the replication cycle such as pp65 (Khan 
et al., 2007). 
  
In this study, 11 HCMV-seropositive blood donors were analyzed for IE-1 epitopes. Although 
these donors covered a broad panel of HLA class I types, only 1 or 2 epitopes restricted through 
HLA-A, -B or -C allotypes could be identified for each donor, and these epitopes were frequently 
found to be immunodominant in different donors sharing the respective class I alleles. For exa-
mple, in HLA-A*0201 and/or C*0702-positive donors, the A*0201 epitope VLE and/or the 
C*0702-restricted epitope generally ranked first or second in frequency, irrespective of other 
HLA allotypes carried by the donor. This is in contrast to the IE-1-specific CD4+ T cell repertoire 
found to comprise 3–7 different specificities per donor with the same epitopes not always elicit-
ing strongest responses in different donors. Such pronounced CD8+ T cell immunodominance 
hierarchies have previously been reported for other HCMV proteins like pp65 (Khan et al., 2007) 
and also other viruses such as EBV (Khanna and Burrows, 2000) and vaccinia (Kastenmuller et 
al., 2007). Several mechanisms which could lead to epitope selectivity and differential pro-
minence of T cell specificities have been proposed. First of all, among the thousands of pep-
tides that can be formed by degradation of a medium-sized protein like IE-1, few will bind with 
high affinity to a given HLA class I allotype, because there is a strict requirement for particular 
"anchor" residues in defined positions of the sequence, as well as a strict requirement of correct 
peptide length, often 9 amino acids (Yewdell and Bennink, 1999). The number of available pep-
tides is further reduced by the substrate specificity of the proteasome: only a peptide carrying a 
preferred proteasomal cut site at its C-terminus, but not inside its sequence, will be produced 
with high efficiency. By contrast, HLA class II molecules appear to possess less stringently de-
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fined peptide binding motifs, and there are much less stringent length requirements, which ena-
bles the engagement of a larger number of different peptides. Promiscuous binding of the same 
peptide to several different class II molecules may further enhance the spectrum of available 
HLA class II/peptide complexes (discussed in 5.1). If the restrictions mentioned above lead to 
unequal levels of different HLA class I/peptide complexes on the surface of infected cells or 
APCs, this might impact on the magnitude of epitope-specific T cell responses (Khan et al., 
2007). Ultimately, the HLA/peptide complex density at the cell surface will depend on the pro-
cessing efficiency of the target peptide and its MHC class I binding affinity (Yewdell and Ben-
nink, 1999), but also on allele-specific effects of HCMV immunoevasins (discussed later in 5.3). 
Features of the T cells, the other side of the coin, participate in shaping the immunodominance 
structure, for example CD8+ T cell precursor frequencies (Thomas et al., 2007) and TCR affinity 
(Kedl et al., 2003). Selection of high affinity T cell clones from an initially more diverse T cell 
pool available during early primary response to virus infection was observed at the level of sin-
gle epitopes such as pp65 NLV and TPR (Day et al., 2007). The rapid expansion of dominant T 
cell populations further restricts the diversity of the immune response through competition-ba-
sed suppression of subdominant responses, a process called ‘immunodomination’ (Stock et al., 
2006). In this process, dominant T cell specificities limit the access of low-frequency T cells to 
APCs and cytokines (Kedl et al., 2003; Oh et al., 2004) and deprive them of their target antigens 
by direct killing of infected cells or APCs (Stock et al., 2006). For example, during symptomatic 
primary infection, Khan and collegues detected a number of weaker subdominant T cell re-
sponses in addition to the dominant responses to pp65 and IE-1, however, these were 
undetectable after transition to the latent phase of virus carriage (Khan et al., 2007). When an 
immunodominant T cell epitope is lost from the antigen, an expansion of T cells targeting alter-
nate epitopes may take place as shown for HSV (Stock et al., 2006) and influenza (Andreansky 
et al., 2005), demonstrating the importance of immunodomination.  
  
Due to the restriction of the IE-1-specific CD8+ T cell repertoire to a limited number of targeted 
epitopes, the characterization of a large panel of 11 blood donors with various HLA class I types 
was necessary to allow the identification of novel T cell epitopes within the present study. Three 
new epitopes were characterized in more detail. The subdominant T cell epitope identified in 
donor F46 was restricted through HLA-A*03(01), which is, after A*0201 (~29% gene frequency), 
the second most common HLA allele in the German population (~16%) (Schmidt et al., 2009), 
thus making it an interesting candidate for immunotherapy. These A*0301-restricted T cell 
clones showed HLA-A*29(02)-dependent alloreactivity, which should be considered if these T 
cells are to be used for adoptive transfer in HLA-mismatched transplant patients (Amir et al., 
2011). Based on common amino acid residues of well-described HLA-A*03(01)-restricted 
epitopes (Hill et al., 1995; Pepperl et al., 1998), the 10-mer RHRIKEHMLK was postulated as 
the minimal epitope of these T cells, but this remains to be confirmed in the future by peptide 
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titration studies. The other two new IE-1 epitopes evaluated in more detail in this study were 
identified as the first IE-1 epitopes restricted through HLA-C allotypes: an epitope uniquely 
found in donor ARZ was presented on HLA-C*0602, and an epitope found in donors ALT, AJJ, 
AJU, F46, and F60 was HLA-C*0702-restricted. The minimal epitope sequence was determined 
for the HLA-C*0702-restricted epitope. The sequence of this nonameric peptide was CRV-
LCCYVL (IE-1, aa 309-317). A variant of this sequence, CRVLCCYIL, that is found in some 
HCMV strains such as Toledo, Davis and TB40E, was equally well recognized by specific T cell 
clones. The high prevalence of HLA-C*0702 in the population, e.g. in 28% of Germans (Schmidt 
et al., 2009) and 37% of southern Chinese (Trachtenberg et al., 2007), renders this T cell 
epitope a particularly attractive candidate for immunotherapy. Analyses of the frequency of such 
responses across donors showed that, strikingly, CRV-reactive T cells were present in all 15 
HLA-C*0702-positive donors analyzed, and sometimes reached very high numbers (up to 4.5% 
of total lymphocytes, detected by multimer staining). In the majority (~73%) of HLA-C*0702-
positive donors analyzed, the response to the CRV epitope dominated the response to the total 
IE-1 protein, even in HLA-A*0201 carriers that also had T cells specific for the known, strongly 
immunogenic epitope VLE (Khan et al., 2002). Furthermore, HLA-C*0702-positive donors were 
generally found to harbor higher numbers of total IE-1-specific T cells compared to HLA-
C*0702-negative donors, thus confirming the importance of this particular epitope. A possible 
mechanism underlying the immunodominance of CRV-specific T cells was identified in this work 
and involves selective preservation of HLA-C surface expression despite HCMV immunoeva-
sion, leading to escape from NK cell recognition (discussed in 5.4). 
  
Interestingly, dominant CD8+ T cell responses to the CRV peptide have been reported earlier 
(Kern et al., 1999). Since that time, such responses were described to be restricted through 
HLA-B7, and this notion has been accepted in the literature (Wills et al., 2002; Khan et al., 
2007), but was not experimentally verified. Data of the present work clearly demonstrate that 
this view is erroneous: experiments using recombinant HLA-B*0702 and -C*0702 in transfection 
studies showed that the CRV peptide-presenting HLA molecule was undoubtedly HLA-C*0702; 
moreover, the CRV peptide could be incorporated into MHC-peptide multimers of HLA-C*0702 
(this study), but not of HLA-B*0702 (Khan et al., 2004), and CRV-specific T cells were well stai-
ned with C*0702/peptide multimers. It can easily be reconstructed how the original study mista-
kenly defined the CRV epitope as HLA-B7-restricted: Kern and collegues investigated ex vivo 
CD8+ T cell responses in donors of presumable European descent who were HLA-typed at low 
resolution, and responses to the CRV peptide were only found in HLA-B7+ Cw7+ donors, 
whereas B7– Cw7+ donors never responded, thus leading to the conclusion that CRV was B7-
restricted (Kern et al., 1999). However, HLA-B and -C alleles are in strong linkage disequilib-
rium, their genes being positioned close to each other in the MHC locus. In European populati-
ons, HLA-C*0702 is almost always linked with HLA-B*07, whereas the equally frequent HLA-
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C*0701 is usually linked with HLA-B*08 (Schmidt et al., 2009). Of note, such linkages may differ 
between worldwide populations; for example, in Southern Chinese HLA-C*0702 most frequently 
segregates with B*4001 and B*3802 (Trachtenberg et al., 2007).  
 
Compared to HLA-A and -B molecules, the role of HLA-C in antigen presentation was long ne-
glected. One historical reason for this is a technical limitation, as HLA-C alleles of blood donors 
are difficult to determine by human alloantisera that were routinely used for HLA typing before 
PCR-based techniques arose (McCutcheon et al., 1995). In addition, HLA-C was considered to 
be less effective in antigen presentation owing to its observed 10-fold lower surface expression 
compared to HLA-A and -B allotypes in some cell types (Snary et al., 1977; McCutcheon et al., 
1995). Several mechanisms of HLA-C downregulation are discussed in the literature: rapid 
turnover of heavy chain mRNA due to miRNA targeting; inefficient association of HLA-C heavy 
chains with β2-microglobulin; higher restricted peptide binding properties of HLA-C compared to 
HLA-A and -B molecules leading to accumulation of immature HLA-C molecules in the ER and 
eventually to subsequent degradation; promotion of internalization and lysosomal degradation 
by a di-hydrophobic signal in the HLA-C cytoplasmic tail (reviewed in (Kulpa and Collins, 2011)). 
However, low cell surface expression of HLA allotypes does not necessarily prevent T cell 
recognition, as it was shown that fewer than 10 MHC-peptide complexes per target cell can be 
sufficient to trigger T cell activation (Kageyama et al., 1995). Furthermore, phosphorylation of a 
serine residue in the cytoplasmic tail of HLA-C was reported to upregulate HLA-C surface 
expression upon macrophage differentiation suggesting a unique role for HLA-C in APCs 
(Schaefer et al., 2008). Today, the importance of HLA-C for antigen presentation to T cells is 
beyond question, since epitopes restricted through HLA-C allotypes have been identified in se-
veral viruses including HCMV (mainly for pp65) (Kondo et al., 2004; Slezak et al., 2007), EBV 
(Khanna and Burrows, 2000) and HIV (Adnan et al., 2006). As shown for an HCMV HLA-
C*0602-restricted pp65 epitope (Rist et al., 2009) and for the CRV epitope from IE-1 (this 
study), HLA-C-restricted T cells can show similar or even higher memory T cell frequencies than 
dominant HLA-A and B-restricted epitopes. Precise information on conserved T cell epitope 
motifs for HLA binding would be useful to identify additional targets for monitoring and immuno-
therapy of HCMV and other viruses, but is still not available for several HLA-C allotypes. 
Accordingly, it is still difficult to predict HLA-C*0702-restricted epitopes. Although tyrosine (Y) 
and proline were defined to be anchors in position two, arginine (R) was similarly enriched in 
this position in pool-sequenced endogenous C*0702-bound peptides (Falk et al., 1993). Well-
characterized C*0702-restricted T cell epitopes such as VRIGHLYIL from MAGE-A12 (Bettinotti 
et al., 2003) and FRCPRRFCF from HCMV UL28 (Kim et al., 2011) share with the CRV peptide 
an arginine at position two and a bulky hydrophobic residue at the C-terminus. Therefore, it can 
be hypothesized that these might be preferred anchors of HLA-C*0702-restricted T cell epito-
pes.  
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5.3 Differential resistance of CD8+ T cells to HCMV immunoevasion 
Ultimately, the control of HCMV infection is achieved by CD8+ T cells (Riddell et al., 1992). 
Hence, it is not surprising that a substantial number of viral genes is devoted to counteracting T 
cell recognition of infected cells by interfering with the MHC class I pathway of antigen presenta-
tion (Manley et al., 2004). Immunoevasins encoded in the US2-11 region of the HCMV genome 
downmodulate MHC class I surface expression by preventing peptide transport (US6), retaining 
MHC molecules in the ER (US3), or targeting them for cytoplasmic degradation (US2, US11) 
(Jones et al., 1996; Wiertz et al., 1996a; Wiertz et al., 1996b; Ahn et al., 1997). The broad range 
of immunoevasins with overlapping function is astonishing, however, it may be necessary for 
cell-type-specific adaptation (Rehm et al., 2002) and, particularly, to cope with the high number 
of existing class I allotypes due to MHC polymorphism (Reddehase, 2002). A large body of 
research has been dedicated to allele-specific effects of HCMV immunoevasins (Miller-Kittrell 
and Sparer, 2009). However, most of these studies have been limited to molecular or phenoty-
pic investigations of transfected or transduced cells, and the impact of the observed effects on 
genuine CD8+ T cell recognition of HCMV-infected cells has remained largely unexplored. Such 
studies are warranted because CD8+ T cells might well be sensitive enough to recognize their 
antigen even when the presenting peptide/MHC class I complex is partially downregulated by 
the virus. For developing T cell therapies and vaccines, the identification of HCMV peptide/MHC 
complexes that are functionally recognized in spite of viral immunoevasion would be important. 
 
The IE-1 protein is a prime example for strong impact of HCMV immunoevasion. However, the 
studies investigating recognition of IE-1 in context of HCMV infection did not produce consistent 
results. The majority of groups have observed that the recognition of HCMV-infected cells by IE-
1-specific CD8+ T cells is severely suppressed (Gilbert et al., 1993; Mutimer et al., 2002; Man-
ley et al., 2004; Khan et al., 2005; Besold et al., 2007). By contrast, a minority of reports descri-
bed that IE-1-specific CD8+ T cells recognize and control HCMV infection in vitro (Borysiewicz 
et al., 1988). This controversy in the literature has remained unresolved until today. In the previ-
ous studies, T cell recognition of IE-1 in the context of HCMV infection was investigated using T 
cell clones directed against A2 epitopes VLE (Khan et al., 2005) and TMY (Besold et al., 2007) 
or with T cells of undefined HLA restriction (Borysiewicz et al., 1988; Mutimer et al., 2002; Man-
ley et al., 2004). Hence, the conflicting data might reflect the analysis of T cell clones that were 
restricted through HLA allotypes differentially affected by viral immunoevasion. This study used 
an extended set of CD8+ T cell clones restricted through a variety of different HLA-A, -B and -C 
allotypes to analyze the recognition of IE-1-derived peptides in context of HCMV infection. Stri-
kingly, only T cell clones directed against the IE-1 epitope CRV (HLA-C*0702-restricted) identi-
fied in this study recognized wild-type HCMV-infected cells in spite of the presence of viral 
immunoevasins, whereas T cell clones restricted through HLA-A and -B allotypes did not. As 
shown by peptide titration studies, this differential T cell recognition was not due to different 
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avidities of the T cell clones. By contrast, in the absence of class I immunoevasins US2, 3, 6, 
and 11, recognition of infected cells by HLA-A and B-restricted T cell clones was restored. As 
expected, pp65 recognition by specific T cell clones used for comparison was less affected by 
viral immunoevasion. As structural protein, pp65 is introduced into host cells with the virion and 
therefore processed and presented before the onset of full viral immunoevasive activity (Riddell 
et al., 1991; McLaughlin-Taylor et al., 1994). Cells infected with the US2/3/6/11-deleted virus 
stimulated every CD8+ T cell clone similarly strongly as uninfected cells that had been exoge-
nously loaded with the antigenic peptide, indicating that HCMV antigens were very efficiently 
processed and presented in the absence of US2, 3, 6, and 11, and that other immunoevasins 
such as US10 (Park et al., 2010) did not interfere with antigen presentation by the HLA-A, -B or 
-C allotypes tested. To conclude, HLA-C*0702-restricted T cells largely resist HCMV class I 
imunoevasion. This may provide an explanation for the extraordinarily high frequency of these T 
cells in healthy carriers due to better stimulation by infected cells. 
 
Employing a broad panel of IE-1- and pp65-specific T cell clones, this study provides, for the 
first time, a systematic dissection of HLA class I allotype-specific effects of individual HCMV 
immunoevasins on CD8+ T cell recognition of infected cells. The major focus was on IE-1: 
CD8+ T cell clones restricted through seven different HLA class I allotypes of all major classes 
were available (three different HLA-A allotypes, three HLA-B allotypes, and one HLA-C allo-
type), all of them generated in this study, and the interaction of these clones with HCMV-infec-
ted cells was studied side by side at different stages of infection (days 1, 2, 3, and 4). CD8+ cell 
clones specific for pp65 epitopes with three different HLA-A/B restrictions were studied in paral-
lel. T cell reactivity to wild-type HCMV and to a set of HCMV gene deletion mutants that carried 
no or only one of the immunoevasin genes US2, US3, US6, and US11 were compared under all 
these conditions. Therefore, the results comprehensively inform on the following aspects: (1) 
allotype specificity of HCMV immunevasion for epitopes from the same HCMV antigen; (2) 
temporal pattern of immunoevasion after infection; (3) differential regulation of immunoevasion 
for representative antigens of different functional classes; (4) the individual role of each HCMV 
immunoevasin. The results of these analyses show that there is an unexpectedly large degree 
of diversification of HCMV immunoevasion on all these investigated levels: allotype, antigen, 
infection phase, and immunoevasin.  
An influence of US6 was detected for all specificities tested as expected. The US6 protein pre-
vents the translocation step of peptide ligands for HLA class I across the ER membrane and is 
found associated with the peptide loading complex including TAP1, TAP2, and tapasin (Hengel 
et al., 1997). Effects of US6 were largely revertable by IFN-γ, due to this cytokine's ability to 
induce TAP1, TAP2, tapasin and subunits of the immunoproteasome, which will increase the 
generation and supply of viral peptides for MHC class I assembly (Schroder et al., 2004). 
Furthermore, IFN-γ strongly impairs gpUS6 synthesis in HCMV-infected cells (Benz and 
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Hengel, 2000), which may have further contributed to the observed reversion of US6 effects by 
IFN-γ. 
Analysis of US3-mediated impact on T cell recognition revealed that only IE-1 presentation in 
context of HLA-C*0702 and A*0301 was completely unimpaired by this immunoevasin. As US3 
inhibits the ER-resident chaperone tapasin, the susceptibility of HLA class I allotypes to US3 is 
related to their grade of tapasin-dependence for peptide loading and surface expression (Park 
et al., 2004). The amino acid at position 114 of class I heavy chains was described to be deci-
sive for the degree of tapasin-dependence: high for acidic residues (D, E), moderate for neutral 
residues (N, Q), and low for basic residues (H, R) (Park et al., 2003). This rule was only partially 
confirmed by the data of this study. Concordant with Park et al., peptide presentation on HLA-
A*0301 (114R) was completely unaffected by US3, whereas presentation on HLA-B*0801 
(114N), B*1801 (114D), B*0702 (114D) and B*3501 (114D) was affected to a greater or lesser 
extent. However, in discordance with the rule of Park et al., HLA-A*0201 (114H) and A*6801 
(114R)-dependent T cell recognition was affected by US3, and HLA-C*0702 (114D)-dependent 
peptide presentation was fully resistant to US3, even under IE conditions (after accumulation of 
US3 mRNA). Hence, other residues of the MHC class I heavy chain, in addition to position 114, 
must be involved in interaction with tapasin. This hypothesis is supported by more recent stu-
dies on HLA allotypes which differ from each other only in one amino acid (position 116 or 156) 
that is determining for tapasin dependence (Sieker et al., 2007; Badrinath et al., 2012). In the 
present study, effects of US3 were fully compensated by IFN-γ, probably because the capability 
of US3 to retain HLA molecules is exhausted under these conditions. 
For US2 and US11, more complex T cell recognition patterns arose: US2 and US11, both 
strongly and equally suppressed recognition of IE-1 peptides presented by HLA-A*0201, 
B*1801 and B*3501, weakly affected C*0702-dependent (only without IFN-γ pretreatment) and 
largely spared B*0801- and B*0702-dependent presentation; among the allotypes with different 
susceptibility to US2 and US11, HLA-A*6801 was more strongly affected by US2 and A*0301 by 
US11; HLA-B*4001-mediated presentation was only influenced by US2. These data partly con-
firm and partly challenge the conclusions drawn from earlier studies. Using CTL clones gener-
ated from HLA-A2 transgenic mice, strong effects of either immunoevasin, US2 and US11, were 
observed for HLA-A*0201-dependent presentation of IE-1TMY (Besold et al., 2009) and weaker 
effects for pp65NLV (Besold et al., 2009) which is in good accordance with this work detecting 
generally less impact of immunoevasins on pp65 presentation. The binding of US2 to recombi-
nant MHC/peptide complexes containing HLA-A2 and -A68 (Gewurz et al., 2001) is precisely 
mirrored by the observation of this study that CD8+ T cell recognition of IE-1 peptides presented 
by HLA-A2 and -A68 was fully inhibited after infection with a HCMV recombinant expressing 
only US2. Discordant with the HLA staining data of this study and of Besold et al. (2009), others 
reported that gpUS2 failed to interact with HLA-B7 in the ER and was insufficient to downregu-
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late HLA-B7 on the cell surface (Gewurz et al., 2001; Llano et al., 2003; Barel et al., 2006). A 
potential reason for this discrepancy could be a higher baseline HLA class I expression in the 
lymphoid cells studied by these authors, which is more difficult to overcome by immunoevasins 
that have only a limited affinity for the relevant HLA allele, such as US2 for HLA-B7. By contrast, 
downregulation of HLA-B*0702 surface expression by US11 detected in this study, was also 
found by other groups (Llano et al., 2003; Barel et al., 2006). Interestingly, in the present work, 
partial downregulation of HLA-B*0702 permitted unimpaired peptide presentation to T cells, 
which is a good example that biochemical studies of immunoevasins' effects cannot reliably 
predict their impact on T cell recognition, because (I) they only study total levels of HLA but not 
levels of particular HLA/peptide complexes, and (II) they neglect that reductions in HLA levels 
will not be relevant for T cell recognition if they occur in dimensions that are far above the 
sensitivity thresholds of T cells. After coinfection of J26 cells with VV-US2 and VV-HLA-B8, cell 
surface expression of HLA-B8 was unaffected (Thilo et al., 2006), thus confirming the unim-
pared HLA-B*0801-dependent T cell recognition in presence of US2 observed in this study. In 
accordance with this study, HLA-C alleles generally do not seem to be retained by US2 (Schust 
et al., 1998; Gewurz et al., 2001; Barel et al., 2003a). By contrast, US11 appears to affect some 
HLA-C allotypes (Llano et al., 2003; Barel et al., 2006) but not others (Schust et al., 1998). Of 
note, previous studies reported partial downregulation of endogenous Cw7 in a B lymphoma cell 
line (RPMI 8866) by overexpression of either immunoevasin, US2 or US11 (Llano et al., 2003), 
which conforms the weak effects of both immunoevasins on HLA-C*0702-dependent presenta-
tion observed in this study, however, only without IFN-γ pretreatment of the infected cells. IFN-γ 
could fully compensate only for modest influences of US2 and US11 as detected for HLA-
C*0702, but not for strong effects as in case of HLA-A*0201 or A*6801. 
Studies that showed reduced surface expression of HLA-A2 and -G, but not of HLA-B7, -Cw3, 
or -E, by retrovirally expressed US2 in astrocytoma cells and murine fibroblasts (Barel et al., 
2003b; Barel et al., 2006) indicate that amino acids 180–183, positioned at the junction of the 
α2/α3 domains of the MHC class I heavy chain, have a dominant role for US2-mediated 
downregulation. This agrees well with the observation of this study that US2 sensitivity of T cell 
recognition (but not MHC–T cell interaction) is conferred by amino acids that are C-terminal to 
residue 176. However, the variations in this region are complex and do currently not allow to 
predict the degree of US2-mediated downregulation for every allotype (Barel et al., 2006). With 
regard to US11, the data of this work confirm those of Barel et al. (2006) who described that 
HLA-A2 was the allotype most strongly affected by US11. These authors further showed that 
the presence of a lysine-valine (KV) motif at the C-terminus of the MHC class I cytoplasmic tail 
was associated with US11-mediated downregulation (Barel et al., 2003a), but their data were 
not fully consistent with this rule for every allotype and chimeric MHC class I chain tested (Barel 
et al., 2006). This is also the case for the functional data obtained in the present study: T cell 
Discussion 
 
138 
recognition in context of all HLA-A alleles (which carry the KV motif) was partially or completely 
sensitive to US11; the situation for the tested HLA-B and -C alleles (which all lack this motif) 
was more complex: most allotypes were resistant, but the allotypes B*1801 and B*3501 were 
not. This may indicate that other residues than KV may also sensitize to US11. In case of HLA-
C*0702 and A*0201, US11 sensitivity was fully reverted by exchange of amino acids C-terminal 
of position 176, suggesting that residues in the α1/α2 domain might not be decisive for US11 
sensitivity as supposed in a previous study (Barel et al., 2003a). 
 
For most class I allotypes, a single immunoevasin was not able to reduce antigen presentation 
to levels detected for wild-type HCMV. Thus, gpUS2, 3, 6, and 11 cooperate to mediate efficient 
protection of infected cells from T cell recognition through most allotypes. This may be espe-
cially important after enhancement of total HLA class I expression by IFN-γ, which is abundantly 
released by NK cells and T cells during HCMV infection. Such cooperation has been studied by 
others in biochemical analyses showing that the turnover of class I molecules is increased in 
cells expressing both US2 and US3 than either immunoevasin alone (Noriega and Tortorella, 
2009). Possibly, the ability of US3 to retain class I molecules in the ER creates a target-rich 
environment for US2 to mediate the destruction of class I heavy chains (Noriega and Tortorella, 
2009). A recent report by the same group described that there is also some cooperation be-
tween US11 and US3 (Noriega et al., 2012). A prerequisite for an interplay amongst US2, 3, 
and 11 is a temporal overlap in their expression kinetics. However, so far US3 was the only 
immunoevasin of the US2/3/6/11 group shown to be expressed at immediate-early times post 
infection (Weston, 1988). Data of the present work and Hesse et al. (unpublished data) now 
clearly demonstrate that US2 and US11 are already active in the IE phase in which exoge-
nously introduced structural proteins and regulatory IE proteins are present and available for 
presentation to CD8+ T cells. To attack the vast majority of HLA allotypes already at this critical 
phase, it appears to be required that several immunoevasins, US2, US3 and US11, are already 
present. In accordance with its reported expression at early/late times post infection (Jones and 
Muzithras, 1991), US6 effects could not be detected under IE conditions. TAP inhibition by US6 
may be particularly important at later time points post infection to cope with the additional supply 
of antigenic peptides derived from abundantly expressed structural proteins. 
  
Efficient recognition of wild-type HCMV infection by IE-1-specific T cells was only detected for 
HLA-C-restricted T cells, whereas HLA-A and B-dependent IE-1 presentation was severely sup-
pressed. In spite of this suppression, a broad IE-1-specific CD8+ CTL response including T 
cells of HLA-A and -B restrictions is maintained in healthy carriers, often at high frequencies 
(Manley et al., 2004). How is this possible? Supposedly, HCMV immunoevasins targeting HLA 
class I presentation are not equally effective in inhibiting T cell activation in vivo due to the 
action of proinflammatory cytokines such as type I interferons (IFN-α/β), IFN-γ and TNF-α, 
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which might partially restore antigen presentation in HCMV-infected cells (Benz and Hengel, 
2000). Second, reactivation from latency may differ from de novo infection/replication (as stud-
ied here) in its degree of immunoevasion. Third, besides direct priming through infected cells, T 
cell proliferation can also be induced by cross-priming via DCs that process exogenously ac-
quired antigen but are not subjected to HCMV immunoevasion as they are not infected them-
selves. However, many of the so primed T cells may be biologically ineffective, since their cog-
nate epitope is not presented by HCMV-infected cells when immunoevasion is active. Such a 
mechanism could be seen as a viral tactic of misleading the immune system to sustain an 
ineffective response (Khan et al., 2005) and has already be demonstrated vor MCMV 
(Holtappels et al., 2004). Hence, the critical question is: which of the various specificities have a 
protective role in vivo? Based on this work, it can be assumed that HLA-C*0702-restricted CTLs 
might be more effective in eliminating infected cells than HLA-A and B-restricted T cells and will 
therefore be particularly important for adoptive T cell therapy. 
 
5.4 The relationship between HLA-C, CD8+ T cells and NK cells 
Besides antigen presentation to CD8+ T cells, a subset of HLA class I molecules, including the 
HLA-C allotypes, functions in regulating NK cell activity through interaction with NK cell inhibi-
tory receptors like NKG2A and KIRs (Lanier, 2005). The lack of such inhibitory signals ("missing 
self") due to downregulation of HLA expression, in combination with activating signals, would 
stimulate NK cells to attack infected cells (Lanier, 2005). These circumstances motivated the 
hypothesis, presented here, that HCMV may selectively preserve HLA-C at the cell surface in 
order to protect infected cells from NK cell lysis. HLA-C allotypes provide inhibitory signals eit-
her through KIR2DL1 (C2 group allotypes) or KIR2DL2/3 (C1 group allotypes), and every hu-
man KIR haplotype encodes KIRs specific for either group of HLA-C (Uhrberg et al., 1997). An 
individual NK cell typically expresses a subset of activating and inhibitory KIRs and other NK 
cell receptors like NKG2A, and in aggregate these receptors guide its reactivity (Valiante et al., 
1997). To be able to analyze the role of HLA-C*0702 during NK cell recognition of HCMV-infec-
ted cells in primary NK cells (to obtain biologically relevant results) while minimizing the comple-
xity of the system (to obtain mechanistic information), particular donors and techniques were 
chosen. Primary NK cells were isolated from a donor homozygous for KIR haplotype A, which is 
devoid of several activating KIR genes that might diversify the patterns of NK cell reactivity. 
Furthermore, the NK cell donor was carrier of two C1 group alleles, as it has recently become 
clear that the presence of class I allotypes matched to NK inhibitory receptors is required to 
license KIR-expressing NK cells for recognition of cells that lack those MHC class I allotypes 
(Orr and Lanier, 2010). As a result of such education, both the functional competence and the 
frequency of NK cells with self-specific KIRs is enhanced (Yu et al., 2007; Kim et al., 2008). 
However, such a licensing state of NK cells may change upon transfer into an environment with 
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altered KIR ligands, for example after stem cell transplantation (Yu et al., 2009). In an effort to 
minimize any potential functional "re-education" in culture, isolated KIR2DL3-positive NK cells 
were cultivated in the continuous presence of feeder cells that were biallelic for HLA-C group 1. 
 
During HCMV infection, NK cell reactivity is modulated by interactions with additional inhibitory 
and activating NK receptors (Leong et al., 1998; Carr et al., 2002), and a multitude of HCMV 
proteins target such interactions (Wilkinson et al., 2008). Nontheless, using HLA-C*0702-spe-
cific NK cell lines, the present experiments indicate that the classical mechanism of inhibitory 
signaling through HLA-C and an inhibitory KIR (KIR2DL3) largely protects infected fibroblasts 
from NK cell recognition: compared to lysis of MHC-deficient cell lines, lysis of wild-type HCMV-
infected cells was low during the whole replicative cycle (analyzed during 96 hours). The NK cell 
lines were even sensitive enough to confirm partial downregulation of HLA-C*0702 by wild-type 
HCMV compared to immunoevasion-defective HCMV strains, as detected in the T cell assays in 
absence of IFN-γ. Interestingly, in the NK cell assays, IFN-γ treatment of fibroblasts prior to 
infection to enhance total MHC expression reduced NK cell cytotoxicity only marginally, 
suggesting that lower numbers of HLA-C*0702 molecules might be already sufficient to inhibit 
NK cells. By contrast, complete downregulation of HLA-C*0702, as simulated in the antibody-
blocking studies, would render infected cells much more susceptible to NK cell lysis. 
  
Surprisingly, the idea that the downregulation of classical MHC class I molecules is causally 
connected to NK cell recognition of HCMV-infected cells is controversial, being supported by 
some (Huard and Fruh, 2000; Falk et al., 2002; Llano et al., 2003) but contested by other stud-
ies (Leong et al., 1998; Cerboni et al., 2000; Carr et al., 2002). Allotype-specific downregulation 
of MHC class I could explain some of these contradictions. For example, Falk and collegues 
demonstrated that NK cell lysis was induced after fibroblast infection with wild-type but not 
US2–11-deleted HCMV (Falk et al., 2002). Because the relevant receptor-ligand pair in this 
study was KIR2DL2 and (likely) HLA-C*0701, this rises the interesting possibility that the two 
major HLA-C*07 allotypes are differentially regulated by HCMV infection. Others suggested that 
KIRs and MHC class I do not play a role in NK recognition of HCMV-infected fibroblasts (Leong 
et al., 1998), but because the role of individual KIR-HLA pairings in the context of infection was 
not addressed, their data are consistent with the results of this work. The absence of a 
differential reactivity to non-infected and infected autologous fibroblasts observed in a majority 
of NK cell clones from two HLA-C*0702 carriers (Carr et al., 2002) is perfectly compatible with 
an HLA-C*0702-mediated inhibition via KIR2DL3, as demonstrated in this study. 
  
The NK cell experiments of this study are restricted to the role of HLA-C*0702/KIR2DL3 interac-
tion in NK cell defense of HCMV. Hence, it is unknown whether other HLA/KIR combinations 
similarly protect infected cells from NK cell recognition, but it is entirely possible that particular 
HLA/KIR pairings play uniquely favourable or unfavourable roles. For example, such a unique 
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role has been shown for resolution of hepatitis C virus infection, where superior protection is 
mediated by KIR2DL3 and group 1 HLA-C (Khakoo et al., 2004). In this line, experimental data 
of this work predict that NK cells whose specificity is determined by KIR3DL2 should be less 
inhibited from recognizing HCMV-infected cells, because HLA-A3, a ligand of this KIR, is fully 
downregulated after HCMV infection. 
 
Taken together, the immunodominance of HLA-C*0702-restricted T cells observed in this study 
may be the consequence of a viral strategy that strives to minimize NK cell recognition of HCMV 
infection by selective preservation of NK cell inhibitory ligands on the surface of infected cells. 
NK cells are part of the innate immune response, the earliest host defense mechanism capable 
to immediately interfere with virus infection, before adaptive immunity takes effect. Therefore, 
NK cell evasion might be essential for HCMV to establish infection in the host. Later on, T cells 
(especially CRV-specific ones) may efficiently control productive HCMV replication but are not 
able to completely eliminate the virus due to its persistence in a latent state. This mechanism to 
escape NK cell attack may also be operative for other viruses. Indeed it has already been 
reported that the HIV Nef protein downregulates HLA-A and -B molecules on the cell surface 
but spares HLA-C (Cohen et al., 1999), implying that HLA-C-restricted T cells could potentially 
control HIV infection with particular efficiency (Kulpa and Collins, 2011).  
 
According to the previous hypothesis, HLA-C*0702 carriers might have less efficient NK cells 
but very efficient T cells for HCMV control. Further studies will be required to assess if these 
persons are especially protected from HCMV disease and, conversely, if HLA-C*0702-negative 
individuals are more susceptible to HCMV or to a more severe manifestation of viral disease. 
Notably, in carriers of other C1 group HLA alleles such as C*0701, inhibition of KIR2DL2/3-posi-
tive NK cells would be operative as well, but might not be complemented by an IE-1-specific 
CD8+ T cell response that is as abundant and efficient as CRV-specific T cells. (It is worth not-
ing that the CRV epitope is not recognized on C*0701 by T cells, although the differences by the 
two C*07 allotyes are rather minor.) Potentially, HLA-C*0702-negative donors carry unidentified 
specific T cells directed against other HCMV proteins than IE-1 and restricted through other 
HLA-C allotypes, that are similarly resistant to HCMV-mediated suppression. Such investiga-
tions might be particularly interesting in context of congenital HCMV infection as HLA-C, but not 
HLA-A and -B, is expressed on trophoblast cells (Apps et al., 2009) and might therefore be 
involved in protection of the fetus from HCMV infection. To think one step further, it is obvious 
that certain HLA alleles including HLA-C*0702 appear to be particularly frequent in the human 
population. It might well be that such alleles or also certain HLA/KIR combinations have been 
selected for during human evolution due to superior control of ubiquitous pathogens including 
HCMV and other human herpesviruses which have accompanied the human species since its 
existence. 
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Abbreviations 
β2m   beta 2-microglobulin 
ActD   actinomycin D 
AIDS   acquired immunodeficiency syndrome 
ALP   alkaline phosphatase 
APC   antigen-presenting cell  
APC   Allophycocyanin 
bp   base pairs 
BMT   bone marrow transplantation 
cam   chloramphenicol acetyltransferase 
cAMP   cyclic AMP 
CD   cluster of differentiation (cell surface marker) 
CD40L   CD40 ligand 
CHX   cycloheximide 
CMV   cytomegalovirus 
C-terminal  carboxy terminal 
ctrl   control 
DC   dendritic cell 
(D)MEM  Dulbecco's Modified Eagle Medium 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
E. coli   Escherichia coli 
e.g.   exempli gratia (lat., for example) 
EBV   Epstein-Barr virus 
EDTA   ethylenediaminetetraacetic acid 
EGFP   enhanced green fluorescent protein 
ELISA   Enzyme-Linked Immunosorbent Assay 
ELISpot  Enzyme-Linked ImmunoSpot 
ER   endoplasmic reticulum 
ERAP   ER-aminopeptidase  
et al.   et alii 
FACS   fluorescence-activated cell sorting 
FCS   fetal calf serum 
Fig.   figure 
FITC   fluoresceinisothiocyanate 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
gB/H   glycoprotein B/H 
gp   glycoprotein 
GVHD   graft-versus-host disease 
hpi   hours post infection 
HAART   highly active anti-retroviral therapy   
HCMV   human cytomegalovirus 
HHV   human herpesvirus 
HIV   human immunodeficiency virus 
HLA   human leukocyte antigen 
HSCT   hematopoietic stem cell transplantation 
HSV   herpes simplex virus 
i.e.   id est 
IE   immediate-early 
IE-1   immediate-early 1 protein 
IFN   interferon 
Ig   immune globuline 
Abbreviations 
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IL   Interleukin 
ISG   interferon-stimulated gene 
kb   kilobases/kilo base pairs 
kDa   kilodalton 
KIR   killer-cell immunoglobulin-like receptor 
KSHV   Kaposi's sarcoma-associated herpesvirus 
LB   Luria Bertani (bacteria culture medium) 
MIIC   MHC class II compartment 
MACS   magnetic cell sorting 
Mb   megabases 
MCMV   murine cytomegalovirus 
MFI   mean fluorescence intensity 
MHC   major histocompatibility complex 
miRNA   microRNA 
mRNA   messenger RNA 
mLCL   mini-lymphoblastoid cell line 
mo-DCs  monocyte-derived dendritic cells 
moi   multiplicity of infection 
MVA   modified vaccinia virus Ankara 
NK cell   natural killer cell 
n.d.   not determined 
N-terminal  amino terminal 
ORF   open reading frame 
PBMCs   peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PE   phycoerythrin 
PE-Cy5   phycoerythrin-cyanine 5 
PEI   polyethyleneimine 
p-NPP   para-nitrophenyl-phosphate   
pp65   phosphoprotein 65 
P/S   penicillin/streptomycin 
rhu   recombinant human 
RNA   ribonucleic acid 
SDS   sodium dodecyl sulphate 
SOT   solid organ transplantation 
SV40   simian virus 40 
rpm   revolutions per minute 
RPMI   "Roswell Park Memorial Institute" (cell culture medium) 
TAP   transporter associated with antigen processing 
TCID50   50% infectious tissue culture dose 
TCR   T cell receptor 
TLR   Toll-like receptor 
TNF-α   Tumor Necrosis Factor alpha 
TPA   tetradecanoylphorbol acetate 
U   units 
US   unique short 
UL   unique long 
vol/vol   volume per volume 
VZV   varicella-zoster virus 
w/o   without 
wt   wild-type
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